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ABSTRACT 
 
Congenital Muscular Dystrophies (CMDs) are a heterogeneous group of conditions that 
usually present in the first months of life with weakness and hypotonia. Extramuscular 
manifestations are common and may include brain, skin and eye abnormalities. CMDs 
are relatively rare disorders and despite the major progress made over the last 2 
decades in identifying, mapping and investigating these conditions, there remains a lot 
to be learned. Little is known about the relative frequency of the various forms of CMD 
in the UK population. Experience had shown that founder mutations are common in 
different ethnic populations and epidemiological studies performed in other countries 
are of limited value in this regard. Since 2001, the Dubowitz Neuromuscular Centre 
(DNC) has been the National Commissioning Group UK Centre for CMD. As such we 
are in the privileged position to have access to a large number of UK patients with 
CMD. I analysed a cohort of 214 CMD referrals to the DNC between 2001 and 2008 
with a view to reporting the diagnostic outcome and the frequency of the various forms 
of CMD encountered in our patient population. 
 
The second part of the thesis is concerned with the dystroglycanopathies, a recently 
described group of CMDs associated with aberrant glycosylation of alpha dystroglycan. 
To date, 7 genes have been identified, some of which give rise to multiple 
dystroglycanopathy phenotypes. I studied the genotype-phenotype relationship in a 
large group of dystroglycanopathy patients, reporting new clinical phenotypes and 
establishing the mutation frequency in this group. I also report in detail the spectrum of 
MRI brain changes seen in 27 dystroglycanopathy patients. 
 
In summary, this work reports the diagnostic outcome in the largest cohort of UK CMD 
cases studied and refines the genotype-phenotype correlation in patients with 
dystroglycanopathies. 
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AIMS OF THIS THESIS 
 
 
Despite the progress made over the last two decades and the increasing number of 
investigative options available, congenital muscular dystrophies (CMD) are still an 
emerging group of disorders and much remains to be learnt about the phenotypic 
heterogeneity and molecular basis of these conditions  
 
The aims of this thesis are: 
 
1. To review the general activity of the CMD National Commissioning Group 
service from 2001 to 2008. To establish the relative frequency of the various 
forms of CMD seen within our population group and the common differential 
diagnoses.  
2. To review our cohort of dystroglycanopathy patients. 
a. To report phenotypic and genetic heterogeneity 
b. To establish the extent and variability of brain involvement. 
 
This thesis is divided in to 3 sections, chapters 2, 3 and 4, reflecting the main areas 
described above. Chapter 1 is a general introduction to CMD and relevant topics are 
expanded further in specific chapter introductions. Chapter 5 serves as a concluding 
discussion. 
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CHAPTER 1. INTRODUCTION  
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1. INTRODUCTION 
 
1.1 CONGENITAL MUSCULAR DYSTROPHY IN 2010 
 
 
Congenital muscular dystrophies (CMDs) are a heterogeneous group of mainly 
autosomal recessive disorders associated with dystrophic changes on muscle biopsy. 
These conditions present at birth or within the first few months with muscular 
weakness, hypotonia, delayed motor milestones and variable joint contractures. In 
addition, a significant proportion of affected individuals exhibit mental retardation, often 
with structural changes visible on Magnetic Resonance (MRI) brain imaging. Other 
features found in specific types include spinal rigidity, joint laxity, muscle hypertrophy, 
respiratory involvement and structural eye defects. Approximately a dozen different 
CMD phenotypes have been described to date with an associated spectrum of severity 
and distinct clinical features (1, 2).  
 
CMD was first described as a disease entity over a century ago by Batten (3), however, 
scientific progress in this field was relatively modest until the 1990’s. This decade 
marked a turning point during which rapid advances in understanding the clinical and 
molecular aspects of CMD were made in large part aided by the establishment of 
European Neuromuscular Centre Consortium workshops (2, 4-8). 
 
The classification of CMDs has historically been problematic. The original phenotypic 
descriptions were largely based on clinical features and geographical origin of the 
various conditions. The first attempt to formally classify the CMDs divided them into 
‘classical’ CMD, without intellectual impairment or overt CNS changes and those cases 
with clear CNS involvement (5). The discovery of abnormal merosin staining in skeletal 
muscle in 1994 and the subsequent reports of mutations in LAMA2 in patients with 
MDC1A in 1995 paved the way for a new classification of CMD based on biochemical 
and molecular abnormalities. The renewed interest in this area resulted in the 
identification of a number of new CMD phenotypes and associated genes and also an 
understanding of the molecular basis of these conditions (9, 10).  
 
The Dubowitz Neuromuscular Centre (DNC) is the designated National Commissioning 
Group (NCG) UK centre for CMD (previously known as NSCAG, National Specialist 
20 
 
Committee Advisory Group) and has a long standing clinical and academic interest in 
this field. As such, we are in an excellent position to collect and study genetic, clinical 
and pathological data from patients with CMD. In addition we have an ethically 
approved project covering research into this area and have recently established a 
biobank facility for obtaining and storing pathological specimens from disease and 
control patients. 
 
 
1.2 SKELETAL MUSCLE STRUCTURE AND FUNCTION 
 
Skeletal muscle varies in shape and size according to function. Each muscle is 
surrounded by a connective sheath known as the epimysium that is continuous with the 
tendon and subdivided into fascicles by the perimysium. Within each fascicle individual 
muscle fibres are found tightly packed and are separated by endomysium, comprised 
of a collagen network and extracellular matrix proteins. Individual muscle fibres 
(myofibres) are multinucleated and formed by the fusion of immature myoblasts (Figure 
1) (4) . 
 
Myofibres are seen in two major physiologically and histologically distinct forms. Type 1 
fibres are slow twitch fibres and contain a higher quantity of mitochondria and lipid. 
They are suited for sustained low grade activity. Type 2 fibres are fast twitch fibres and 
are smaller, with more glycogen but less mitochondria and lipid. Their function is to 
support brief duration high intensity activity. Type 1 and 2 fibres are found randomly 
distributed in muscle and are seen as a chequer board pattern on cross section. 
 
Myofibres contain sarcoplasm, enclosed by the sarcolemma. The sarcoplasm contains 
the sarcomeres, the contractile elements of the cell. Sarcomeres comprise actinin, 
which forms the Z band, and actin and myosin which are major constituents of the thin 
and thick filaments respectively. Surrounding the sarcomeres is the myofibrillar 
network, made up of several components including mitochondria, lipid, glycogen and 
sarcoplasmic reticulum. Surrounding the sarcolemma is the basement membrane 
which abuts the extracellular matrix (Figure 1). 
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SR. As shown in the figure, the SR forms a network around the myofibrils, storing and 
providing the Ca2+ that is required for muscle contraction. 
Myofibrils are contractile units that consist of an ordered arrangement of longitudinal 
myofilaments. Myofilaments can be either thick filaments (comprised of myosin) or thin 
filaments (comprised of actin). Together they produce movement by contraction 
through the sliding filament model.  
Protein assemblies known as costameres, located on the peripheral myofibrils of the 
myofibre, line up with the Z-disk. Costameres physically link the sarcomeres, which 
produce force through contraction, with the sarcolemma and, are proposed to transmit 
this force across the sarcolemma to the extracellular matrix and on to neighbouring 
muscle cells. So, during both contraction and relaxation, sarcomere length remains 
consistent between muscle cells within skeletal muscle. 
 
Adapted with permission from Davies et al.(11) Macmillan Publishers Ltd: Nat Rev Mol 
Cell Biol  copyright (2006). 
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Many proteins known to be defective in the CMDs are components of the basement 
membrane or extracellular matrix. The basement membrane is comprised of the outer 
reticular layer and inner basal lamina. The outer reticular layer is fibrillar and contains 
collagen 6 myofibrils embedded in a proteoglycan rich substance. The inner basal 
lamina is linked directly to the sarcolemma and is comprised of networks of non fibrillar 
collagen VI and laminin linked by non-collagenous glycoproteins (4, 12). The basement 
membrane has a number of important functions. It has long been known that it offers 
the cells structural support but more recently it has been shown to have a role in 
developmental and regenerative processes including myogenesis and synaptogenesis. 
In addition it is now appreciated that it has a critical role in cell signalling through its 
complex network interactions with other proteins and receptors including the 
dystrophin-glycoprotein complex (DGC)(13, 14). The DGC is a multimeric 
transmembrane protein complex comprised of 3 subcomplexes; the central 
dystroglycan complex, the intracellular dystrophin complex and the sarcoglycan-
sarcospan complex. The DGC provides a structural link between the cytoskeleton and 
the proteins of the basement membrane through interaction with extracellular ligands 
including perlecan and laminin. It is thought to protect the sarcolemma from mechanical 
stress during muscle contraction (Figure 2) (14) . 
 
The nuclear envelope consists of an inner nuclear membrane (INM) and an outer 
nuclear membrane (ONM) separated by a perinuclear space. Nuclear pore complexes 
span the 2 membranes providing a link between the cytoplasm and nucleus (15, 16). 
The ONM is continuous with the endoplasmic reticulum. At the nuclear face of the INM 
lies the nuclear lamina, comprised largely of A-type and B-type lamins that form 
intermediate filaments providing major structural and mechanical support to the 
nucleus(17). In mammalian somatic cells, the predominant A-type lamins are lamin A 
and lamin C encoded by LMNA (18).  Nesprin-1 is an actin binding protein and integral 
part of the ONM. It forms part of the LINC (linker of nucleoskeleton and cytoskeleton) 
complex that connects the actin cytoskeleton via nesprin proteins to the nuclear lamins 
and other components of the nuclear interior (19). 
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T. Lisi, Ronald D. Cohn, Congenital muscular dystrophies: New aspects of an 
expanding group of disorders, copyright (2007), with permission (21). 
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1.3  CLASSIFICATION OF CMD 
 
CMDs may be grouped according to those that occur as a result of 
abnormalities in external membrane, basal lamina and extracellular matrix 
proteins (including integrins, Laminin α2, and Collagen VI) and those CMDs 
resulting from abnormal glycosylation of alpha dystroglycan (ADG) secondary to 
mutations in known/ putative enzymes involved in this pathway (Protein-O-
mannosyl transferase 1, Protein-O-mannosyl transferase 2, Protein-O-mannose 
1,2-N-acetylglucosaminyltransferase 1, Fukutin,  Fukutin-related protein, 
LARGE and Dolichyl-phosphate mannosyltransferase polypeptide 3). In 
addition, CMD may result from mutations in SEPN1, a gene that encodes an 
endoplasmic reticulum protein of unknown function or, more rarely, by 
mutations in the nuclear envelope proteins Lamin A/C and Nesprin(12) (22). 
The cellular location of a number of these proteins is represented in Figure 2. 
 
The known genetic variants of CMD are summarised in table 1 and table 2 (2) 
(23, 24). 
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Functional 
Classification 
Protein Gene Gene ID≠ Chromosomal
Location 
Disease OMIM 
Number± 
Structural protein of 
basement 
membrane, 
extracellular matrix 
or external 
membrane protein 
Laminin α 2 LAMA2 156225 6q2 MDC1A 607855 
Collagen VI Col6A1 
Col6A2 
Col6A3 
120220 
120240 
120250 
21q2 
21q2 
2q3 
UCMD 
BM 
254090 
158810 
Integrin α 7 ITGA7 600536 12q Integrin α 7 
deficiency 
600536 
Dystroglycanopathy Protein-O-
mannosyltransferase 1 
POMT1 607423 9q34 WWS* 236670 
Protein-O-
mannosyltransferase 2 
POMT2 607439 14q24 WWS* 236670 
Protein-O-linked mannose 
beta 1,2-N-
acetylglucosaminyltransferase 
POMGNT1 606822 1p34 MEB* 253280 
Fukutin FKTN 607440 9q31 FCMD* 253800 
Fukutin Related Protein FKRP 606596 19q13 MDC1C* 606612 
Like-Glycosyltransferase LARGE 603590 22q12 MDC1D* 608840 
Dolichyl-phosphate 
mannosyltransferase 
polypeptide 3 
DPM3 605951 1q22 CDG1o¥ 612937 
Endoplasmic 
reticulum protein 
Selenoprotein N,1 SEPN1 606210 1p35-36 RSMD1† 606210 
Nuclear envelope 
protein 
Lamin A/C LMNA 150330 1q21 EDMD2‡ 181350 
Nesprin SYNE1 608441 6q25 CMD with adducted 
thumbs(25)  
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Table 1. Congenital Muscular Dystrophy Variants with known gene defects. 
 
≠ Entrez Gene Identifier from the NCBI database (http://www.ncbi.nlm.nih.gov/).± Online Mendelian Inheritance in Man reference 
(http://www.ncbi.nlm.nih.gov/OMIM). *Denotes original phenotype described in association with gene, the dystroglycanopathies show considerable 
genetic heterogeneity.†SEPN1 mutations may also be associated with other myopathy phenotypes (see section 1.6.3). ‡LMNA mutations are 
associated with a number of other non-CMD phenotypes (see section 1.6.4). ¥ To date mutations in DPM3 have only been detected in a single 
patient.  
 
MDC1A; Congenital Muscular Dystrophy type 1A, UCMD; Ullrich Congenital Muscular Dystrophy, BM; Bethlem Myopathy, WWS; Walker Warburg 
Syndrome, MEB; Muscle Eye Brain Disease, FCMD; Fukuyama CMD, MDC1C; Congenital Muscular Dystrophy type 1C, MDC1D; Congenital 
Muscular Dystrophy type 1D, CGD1o; Congenital Disorder of Glycosylation type 1o, RSMD1; Rigid Spine Muscular Dystrophy, EDMD2; Autosomal 
Dominant Emery Dreifuss Muscular Dystrophy.
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Disease OMIM Number± Chromosomal Location Phenotype Reference 
 
Congenital Muscular 
Dystrophy with Joint 
Hyperlaxity (CMDH) 
 
- 3p23† CMD with joint hyperlaxity Tetreault et al.(26) 
Congenital Muscular 
Dystrophy associated with 
4p16.3 
 
609456 4p16.3 Merosin positive CMD* Sellick et al.(27) 
Congenital Muscular 
Dystrophy type 1B 
(MDC1B) 
604801 1q42 CMD with early respiratory 
failure 
Brockington et al.(28) 
 
 
 
Table 2. Congenital Muscular Dystrophy loci, gene defect unknown in 2006. 
 
*subsequently shown to be a congenital myasthenia resulting from mutations in DOK7. (Francesco Muntoni personal communication)  
†subsequently shown to be due to mutations in integrin α9(29)  
.± Online Mendelian Inheritance in Man reference (http://www.ncbi.nlm.nih.gov/OMIM). 
 
 
 
30 
 
1.4 CLINICAL FEATURES OF CMD 
 
By definition, the muscular system is always affected in CMD although the degree to 
which it is affected is very variable. To a large degree it is dependent on the type of 
CMD a patient has, although variability within phenotypic groups may also be seen. 
The main musculoskeletal features are weakness, hypotonia, muscle wasting or 
hypertrophy. Some patients are severely affected and may be recognised prenatally 
with decreased foetal movement. This is typical in cases of WWS. Others are clearly 
hypotonic and weak at birth with minimal or reduced movement, commonly seen in 
cases of MDC1A, MDC1C and MEB. Others may appear relatively normal from a 
musculoskeletal perspective in the first few weeks, with weakness and failure to 
achieve motor milestones recognised outside the neonatal period. This would be 
expected in milder cases of UCMD, BM and also in the some dystroglycanopathy 
phenotypes.  
 
Maximal motor achievement is equally variable. In some forms of CMD, for example 
WWS, motor progress may be virtually absent. Others progress to sitting with or 
without support but would not be expected to achieve independent ambulation. This 
would be typical of MDC1A or MDC1C. At the milder end of the spectrum patients with 
milder UCMD, BM and SEPN1 related myopathy would be expected to achieve 
ambulation and in the case of BM and SEPN1 related myopathy would anticipate 
remaining ambulant into the third decade and maybe beyond. The progression of 
weakness in CMD is usually relatively static with increasing disability often the result of 
contractures and scoliosis. 
 
Individuals with CMD may also have other musculoskeletal manifestations including 
contractures, congenital dislocation of the hips, torticollis, spinal rigidity and scoliosis. 
The presence of such features may be important diagnostically; patients with UCMD for 
example frequently have one or more of these features present at birth. Weakness can 
also extend to respiratory musculature. In RSMD1 and MDC1B diaphragmatic 
weakness causes respiratory insufficiency early in the disease course. Respiratory 
involvement is also invariable in UCMD and MDC1A, whilst in other forms of CMD it 
does not appear to cause significant early morbidity.  
 
Cardiac involvement in CMD is unusual with a few exceptions. Patients with congenital 
onset EDMD2 may have conduction defects including paroxysmal atrial tachycardia 
and ventricular tachycardia. Sudden death has also been reported.(30) Cardiac 
involvement is also seen in dystroglycanopathy patients with FKTN and FKRP 
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mutations and may take the form of dilated cardiomyopathy or left ventricular systolic 
dysfunction(31, 32) (33). Patients with MDC1A have also been reported with cardiac 
abnormalities with one study suggesting subclinical cardiac involvement in 3-35% of 
cases (34, 35). 
 
Eye involvement is a feature of some CMDs. This is particularly evident in the 
dystroglycanopathies where structural abnormalities such as anterior chamber defects, 
retinal abnormalities, cataracts and severe myopia are typical, particularly among the 
more severely affected individuals. In MDC1A, external ophthalmoplegia is also a 
recognised feature and whilst visual function is usually normal, visual evoked 
responses are usually abnormal (36). 
 
Structural and functional brain involvement is common in the CMDs. This may exhibit 
as white matter changes on MRI brain scan associated with normal intelligence, as 
often seen in MDC1A, through to dramatic structural changes including agyria 
inevitably associated with profound mental retardation, as seen in WWS. Other 
features include seizures, often seen in MDC1A and learning difficulties in the absence 
of abnormal features on MRI brain scan. Conversely, intelligence and MRI brain 
imaging may be normal, as in the case of UCMD and BM. 
 
 
1.5 INVESTIGATION AND DIAGNOSIS OF CMD 
 
The investigation of CMD requires a detailed patient history and clinical assessment 
combined with directed pathological, biochemical and genetic testing and in many 
cases is supported by imaging techniques. 
 
 
PATIENT HISTORY AND EXAMINATION 
The baseline assessment for patients with CMD includes a detailed medical and family 
history and clinical examination. Features particularly relevant for CMD include age of 
onset, pattern of weakness and contractures, muscle wasting and hypertrophy, eye 
and brain involvement, presence of skin changes, feeding difficulties and respiratory 
and cardiac abnormality. Family information is important, in particular a history of 
consanguinity given the autosomal recessive nature of the majority of CMDs. 
 
 
 
32 
 
 
SKELETAL MUSCLE BIOPSY 
Skeletal muscle biopsy forms a key role in the diagnostic assessment of patients with 
CMD. Skeletal muscle samples may be obtained by open or by closed (needle) biopsy 
procedure. In theory any muscle can be sampled but in practice it is usually the 
quadriceps muscle and historically in our department needle biopsy has been the most 
commonly used method of obtaining samples.  
 
Biopsy samples can be assessed using a variety of immunohistochemical techniques 
depending on the diagnosis in question(4). Few findings are pathognomonic of a 
condition and it is therefore imperative that muscle biopsy findings are interpreted in 
conjunction with clinical patient review. The morphology of frozen transverse sections 
of skeletal muscle is routinely assessed using haematoxylin and eosin (H&E) staining. 
This allows assessment of, among others, the general structure of the muscle, the fibre 
size, presence of adipose tissue, inflammation, nerves and blood vessels. Other 
routine histochemical analysis allows the identification of enzyme abnormalities, 
substrate excess and other structural changes. Immunochemical labelling for specific 
proteins is increasingly used in the investigation of CMD and may provide a definitive 
diagnosis in some cases (for instance the absence of laminin α2 seen in MDC1A). 
 
Although termed congenital muscular dystrophies, a dystrophic appearance on skeletal 
muscle biopsy is not universal and not a prerequisite for diagnosis of CMD. There are 
numerous reports of patients with CMD with minimal change or myopathic features on 
muscle biopsy. The cardinal features of dystrophy on skeletal muscle biopsy are 
fibrosis and necrosis. If necrosis is not seen then features of regeneration should be 
sought (CA Sewry, personal communication). A number of other features are frequently 
observed and may include variability in muscle fibre size, perimysial and endomysial 
proliferation, phagocytosis and increase in adipose tissue. Changes may be marked or 
mild and are not a reliable indicator of disease severity. In addition, muscle involvement 
may be selective and change with disease progression, hence biopsy findings are 
dependent on the individual muscle sampled as well as the age of the patient at time of 
biopsy (Figure 3)(4).  
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SKIN BIOPSY 
 
In some patients a muscle sample may not be available and in such cases pathological 
analysis of skin biopsy may help. In MDC1A, for example, laminin α2 may be reduced 
or absent in the epidermal-dermal junction. Secondary reduction can also occur 
however, so results should be interpreted with caution (4). 
 
FIBROBLAST ANALYSIS 
The use of fibroblasts cultured from skin biopsy is increasingly used in investigating 
CMD. They are of particular value in the investigation of Collagen VI related 
myopathies. Sometimes fibroblasts are used purely to extract RNA for protein 
expression studies. In other cases collagen VI expression may be analysed in cultured 
fibroblasts and although technically difficult has been shown to be a sensitive indicator 
of abnormal collagen VI expression (38, 39). 
 
MOLECULAR GENETIC TESTING 
The gold standard diagnostic test in the investigation of CMD is the identification of a 
pathogenic genetic mutation. All genetic testing has limitations and in the diagnostic 
setting screening of genomic DNA may miss deletions, duplications and inversions. 
Despite these general limitations, for some of the known CMD genes, genetic testing is 
straightforward. Screening of SEPN1, FKRP and LAMA2 for example, is well 
established and the interpretation of results is usually uncomplicated.  In other genes, 
genetic investigations are more difficult to interpret. In Collagen VI in particular, 
assessing which changes are pathogenic and which are polymorphisms is complicated. 
This is due to the size and complexity of the collagen VI genes, the variable clinical 
phenotype and mode of inheritance of the disorder. Many changes identified are 
currently classified as unknown variants. In such cases, alternative supportive evidence 
of pathogenicity is required and this may include RNA studies and family segregation 
studies in conjunction with consistent pathological and clinical investigations.  
 
CREATINE KINASE 
This is one of the most basic but most useful investigations in supporting a diagnosis of 
CMD.  Serum Creatine Kinase (CK) is elevated in a number of CMDs and reflects 
muscle damage.  The extent to which it is elevated may provide a clue to the diagnosis. 
For instance, in the dystroglycanopathies CK would be expected to be very elevated, 
sometimes up to 50X the upper limit of normal whilst in Collagen VI myopathies and 
RSMD1 the CK is usually only mildly elevated and may be normal. 
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MUSCLE IMAGING 
On a basic level, the use of muscle ultrasound in the clinic setting may help by 
confirming the presence of increased echogenicity in muscles, indicative of muscle 
atrophy in patients with CMD.  In recent years, our department and others have 
investigated and promoted the use of muscle magnetic resonance imaging (MRI) in the 
investigation of muscle disorders. The underlying principal is that abnormal increased 
signal intensity in muscle on T1 weighted images denotes fatty infiltration or atrophy. 
Different subtypes of CMD and congenital myopathy often have a specific pattern of 
muscle involvement (Figure 4). MRI Images taken through the transverse plain of the 
thigh and upper arm may reveal a characteristic pattern of abnormality and help direct 
molecular testing. Although not covered in detail within this thesis, myself and others 
have recently reported the sensitivity and specificity of muscle MRI changes found in 
83 muscular dystrophy patients associated with rigid spine and also reported the 
muscle MRI appearance in FHL1 linked reducing body myopathy (40, 41).  
 
BRAIN IMAGING 
Several of the CMDs have associated brain abnormalities. These can have dramatic 
appearances on MRI brain scans and can be pathognomonic for a particular condition. 
Patients with MDC1A universally have diffuse white matter involvement seen after 6 
months of life, often in conjunction with other abnormalities. Patients with 
dystroglycanopathies may have a variety of changes, the most striking of which is 
cobblestone lissencephaly. Some changes, in particular ventricular dilatation, may be 
apparent on foetal scans and in this regard can serve as a useful tool for prenatal 
assessment of a potentially affected baby (42). 
 
ELECTROPHYSIOLOGY 
In some variants of CMD, particularly MDC1A, abnormalities may be observed on 
electrophysiological testing. These patients have a motor demyelinating neuropathy 
and reduced nerve conduction velocity. In addition visual and somatosensory evoked 
responses are usually abnormal (36, 43). 
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1.6 CONGENITAL MUSCULAR DYSTROPHY VARIANTS 
 
In order to place my work in context, in 2006 when this project started, 16 CMD genes 
and 3 CMD loci had been reported (Table 1 and 2). There were also a number of CMD 
variants reported in the literature for which no gene or loci had been identified. Over the 
last 4 years, one new gene, Dolichyl-phosphate mannosyltransferase polypeptide 3 
(DPM3), has been reported that is mutated in CDG1o, a condition with features 
overlapping CMD and a congenital disorder of glycosylation (CDG)(44). In addition, the 
3p23 loci causing CMD with joint hyperlaxity (26) has been refined to reveal mutations 
in Integrin α9 (ITGA9) and the CMD associated with 4p16.3 (27) has been shown to 
not be a CMD at all, but a congenital myasthenia resulting from mutations in DOK7 
(Francesco Muntoni, personal communication). Mutations in Nesprin-1 are now known 
to be the cause of CMD with adducted thumbs, a phenotype initially reported by Voit et 
al (25, 45). Mutations in the same gene also cause a form of autosomal recessive 
arthrogryposis with features overlapping CMD and congenital myopathy (46). 
 
In 2006, CMD variants were broadly be grouped according to those that occur as a 
result of abnormalities in external membrane, basal lamina and extracellular matrix 
proteins (MDC1A, CMD due to integrin alpha-7 deficiency and collagen VI related 
myopathies) and dystroglycanopathies resulting from abnormal glycosylation of alpha 
dystroglycan (ADG). Other CMD phenotypes include RSMD1 resulting from mutations 
in SEPN1, a gene that encodes an endoplasmic reticulum protein of unknown function 
and EDMD2 resulting from severe mutations in the nuclear envelope protein Lamin A/C 
(12) (22). Each of these variants is detailed below, to provide a background to the work 
in this thesis. 
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1.6.1 Merosin Deficient Congenital Muscular Dystrophy Type 1A 
 
Merosin (or laminin 2) deficient congenital muscular dystrophy type 1A (MDC1A, MIM 
#607855) was the earliest CMD pathologically defined due to a characteristic 
deficiency of merosin on skeletal muscle biopsy; this also became the first CMD variant 
for which the genetic defect, mutations in Laminin α2 (LAMA2, MIM #156225), was 
found.  Initially called classical or occidental CMD, it was previously thought to account 
for up to 50% of all cases of CMD. The availability of a straightforward pathological 
diagnosis and genetic testing, led to the rapid proliferation of manuscripts reporting the 
clinical features and relative frequency of this condition in several populations (47) (10) 
(9). 
 
Laminin structure and function 
 
Laminins are situated in the cell basement membrane and act as barriers to cell 
penetration and filtration, enabling the tissue to compartmentalise. Laminins are 
heterotrimers, formed from combinations of different α, β and γ chains. At least 15 
different combinations are known to exist. The predominant form of laminin found in 
skeletal muscle basal lamina is laminin-2 (merosin) which is composed of α2, β1 and 
γ1 chains. The chains bind together via their coiled domains and through multiple 
interactions with other proteins play an essential role in maintaining basement 
membrane integrity during development and adult life. Merosin is necessary for 
myogenesis as well as for the survival and stability of myotubes in vitro. Muscle fibre 
degeneration and  apoptosis occurs in the very early stages of MDC1A(48).  
 
The laminin α2 chain consists of 6 domains: I and II are part of the long arm, IIIa, IIIb 
and V contain cysteine rich EGF like repeats, IVa, IVb and VI are predicted to form 
globular structures. The G domain, C-terminal region comprises internal homologous 
repeats and contains the interaction sites for membrane receptors that are, in muscle, 
α dystroglycan and integrin α7, an interaction necessary for the polymerisation of 
laminin (49).  In skeletal muscle, laminin α2 is found around the muscle fibre, the 
Schwann cell basal lamina and at the neuromuscular and myotendinous junction (50) 
Although not expressed in the skeletal muscle blood vessels it is expressed in the 
basement membrane of brain blood vessels, epithelial cells lining the choroid plexus, 
oligodendrocytes tracts and glia limitans (51). The α2 chain is involved in cellular 
attachment, neurite growth and the migration of Schwann cells.  
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Clinical Features 
 
The variant MDC1A is due to mutations in the LAMA2 gene at 6q22, which encodes 
the laminin-α2 chain which forms part of merosin (Laminin-2) and also laminin-4. Most 
mutations result in complete absence of laminin α2 protein, with a small minority 
causing a partial deficiency. MDC1A with complete absence of merosin is a severe 
CMD, with CK levels typically exceeding 1000 U/l.  It presents in the neonatal period or 
first few months of life with profound proximal and axial weakness, hypotonia and 
delayed motor milestones.  Affected individuals rarely acquire independent ambulation 
and although most are able to sit unsupported, mobility is further compromised by the 
development of contractures and scoliosis. Most patients  go on to need ventilatory 
support and enteral feeding and respiratory insufficiency, if left untreated, frequently 
leads to death in the first decade of life. Other features reported in MDC1A include 
partial external ophthalmoplegia and occasional cardiac abnormalities in the form of 
cardiomyopathy, hypokinesis or subclinical cardiac involvement. 
 
Intelligence is usually normal in MDC1A although some have mental retardation and 
seizures. MRI brain imaging invariably reveals diffuse white matter changes after 6 
months of life (9, 52, 53), thought to be dysmyelination, a change not seen in the dy 
(laminin deficient) mice. Structural brain abnormalities may include hypoplasia of the 
cerebellum (up to 1/3) and occasionally neuronal migration abnormalities, usually of the 
occipital lobes (54).  
 
Laminin α2 is expressed in the Schwann cell basal lamina and both MDC1A patients 
and laminin α2 deficient mice have reduced nerve conduction velocity. In dy mice this 
may be due to disrupted Schwann cell basal lamina and defective myelination, but in 
humans Schwann cell basement membranes appear to be well preserved(55). 
 
 
Genotype Phenotype Correlations 
 
Mutations in LAMA2 have been reported throughout the gene. Complete absence of 
Laminin α2 causes a severe predictable phenotype and may be caused by 
substitutions, deletions, or insertions in LAMA2. Some mutations have been seen 
repeatedly such as the 703X (2098delAC) and the C967X. The phenotypic spectrum 
seen in patients with partial deficiency is wide. Some patients display a milder clinical 
picture, whilst others, such as those with missense mutations in the conserved cysteine 
residues involved in trimer assembly, result in partial deficiency with a severe 
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phenotype. Mutations involving the G domain often result in a severe MDC1A 
phenotype because they interfere with the interactions with ADG and/or integrin α7/ 
β1D (48, 56-59).  
 
 
 
Pathology and Diagnosis 
 
Diagnosis in MDC1A is usually made by a combination of clinical features, muscle 
biopsy examination and genetic studies (either sequencing or linkage studies). Muscle 
biopsies in MDC1A patients show a variable degree of fibre necrosis and regeneration, 
increased connective tissue and inflammatory infiltrate. Immunocytochemically, laminin 
α2 chain is deficient with over expression of a4 and a5 chains in the basal lamina 
surrounding myofibres. In analysing the biopsies for MDC1A, antibodies must be used 
that recognise both the 80kDa C terminal and 300kDa N terminal fragments of laminin 
α2 or a reduction in labelling can be missed (60). Western blotting can also be used to 
detect laminin α2 defects. To complicate matters, in Laminin α2 deficiency, ADG and 
integrin a7b1 (both functional laminin receptors) show secondary reduction in labelling 
(61). When laminin α2 is absent from muscle basal lamina, it is also absent from the 
epidermal-dermal junction. Quantitatively, lamininα2 expression may be different in the 
muscle and skin from the same patient. Although expression of laminin α2 levels in the 
skin may be useful, a secondary reduction in the skin may also occur in conditions 
such as dystroglycanopathies secondary to FKRP mutations. The main differential in 
cases with reduction in Laminin α2 are the dystroglycanopathies where secondary 
reduction can occur with brain changes on MRI scan that are often similar to those 
seen in MDC1A. 
 
Prenatal testing by CVS is also available in families with complete merosin deficiency 
due to abnormal laminin α2 expression in the trophoblast of affected individuals (62, 
63). It is important in such cases to verify complete absence or dramatic reduction of 
merosin in the proband to avoid ambiguity in interpreting the results. 
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1.6.2 Collagen VI Related Disorders 
 
The collagen VI related disorders, Ullrich Congenital Muscular Dystrophy (UCMD, MIM 
#254090) and its milder allelic variant Bethlem Myopathy (BM, MIM #158810),  
represent another significant proportion of CMD cases and are caused by mutations in 
Collagen 6A1 (MIM  #120220), 6A2 (MIM  #120240) and 6A3 (MIM #120250). UCMD 
was first described in 1930 but the genetic defect was not reported until 2001 (64, 65).  
 
Collagen VI Structure and Function 
 
Collagen VI is a ubiquitously expressed extracellular matrix protein that forms a link 
between the cytoskeleton and extracellular matrix in skeletal muscle (66-68). Collagen 
VI is composed of 3 chains; α1 and α2 encoded by COL6A1 and COL6A2 on 
chromosome 21q2 and α3 encoded by the larger COL6A3 on chromosome 2q3. All 
three chains contain a short triple helical domain with repeating Gly-Xaa-Yaa 
sequences flanked by globular domains (69, 70). 
 
The collagen chains undergo a complex assembly process, initially forming triple 
helical monomers which then assemble into antiparallel dimers and then tetramers 
stabilised by disulphide bonds. These tetramers are secreted and associate 
extracellularly via N terminal globular domains to form a microfibrillar network in the 
reticular layer of basement membranes, collagen VI is also found in the endomysium 
and perimysium (71, 72). The myofibrillar network encircles interstitial collagen fibres 
and is in contact with the basement membrane surrounding muscle fibres (73-75).  Co 
localisation experiments have suggested that one of the main functions of collagen VI 
is a structural role, anchoring the basement membrane to the underlying connective 
tissue by way of association with collagen IV (73). Collagen VI has also been shown to 
interact with cells directly via binding to transmembrane proteins such as integrins and 
NG2 proteoglycan and indirectly via basal lamina components including collagen IV, 
perlecan and decorin (76-79). In addition, in vitro experiments have shown a possible 
role for collagen VI in cell signalling (80-82).  
 
Clinical Features 
 
UCMD was originally described as an autosomal recessive condition, although 
autosomal dominant cases are increasingly recognised. It is characterised by neonatal 
onset proximal muscle weakness and contractures with distal joint laxityPresenting 
features may also include hypotonia, congenital dislocation of the hip, torticollis and 
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kyphosis. Motor achievement is variable; some patients achieve independent 
ambulation but this is usually lost and functional motor ability is further compromised by 
the development of contractures, scoliosis and spinal rigidity. Respiratory insufficiency 
requiring ventilatory support is almost invariable by the second decade of life but 
cardiac abnormality is not a feature. Intelligence is normal. The development of 
characteristic skin changes including hyperkeratosis and abnormal scarring may 
facilitate a diagnosis.  CK is usually normal or mildly increased (39, 64, 83-85). Muscle 
MRI changes are characteristic and include diffuse involvement of the thigh muscles 
with relative sparing of the anteromedial muscles (Figure 4) (86). 
 
Bethlem myopathy, usually an autosomal dominant entity, is a much milder disorder. It 
is reported as a slowly progressive proximal myopathy with the development of 
contractures particularly of the wrist, elbows, ankles and long finger flexors. 
Hypermobility of the distal interphalangeal joints is also a feature. In some cases BM 
may only be recognised in a parent after the diagnosis of the condition in a more 
severely affected child.  Although the phenotype is milder than that of UCMD, patients 
may present in first years of life, usually with hypotonia, torticollis or congenital 
dislocation of the hip. Cardiac involvement is not a feature but patients may rarely 
develop respiratory insufficiency in later life (87, 88). Skin changes may be similar to 
those seen in UCMD. CK is normal or only mildly elevated (85). 
 
Muscle MRI is often helpful in differentiating BM from other muscular dystrophies. 
Although changes are not always seen, especially in milder cases, a classical BM scan 
would show concentric muscle atrophy with peripheral involvement most evident in the 
vasti and gastrocnemii. There is often a characteristic ‘central shadow’ in the rectus 
which facilitates a diagnosis (Figure 4)(86, 89). 
 
Although many patients with mutations in collagen VI are easy to classify as BM or 
UCMD, it is increasingly apparent that patients exist whose symptoms fall at the severe 
end of BM or the milder end of UCMD and display an ‘intermediate’ phenotype. This in 
turn led to the concept that BM and UCMD, rather than being separate disease entities, 
were in fact part of a spectrum of collagen VI related disorders (2). 
 
 
Genotype Phenotype correlation 
 
Mutations in all three genes cause BM and UCMD. The complex structure of collagen 
VI, the numerous polymorphisms in the 3 genes and the high number of splice site 
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mutations make mutation detection a lengthy task (90). RNA sequencing has become a 
commonly adapted strategy to overcome some of these obstacles. 
 
A frequent group of mutations seen in BM are those that disrupt the Gly-Xaa-Yaa triple 
helical motif. It is thought that these mutations cause kinked collagen VI tetramers, 
reducing their ability to form microfibrils and resulting in BM by a dominant negative 
effect (91). Splice site mutations leading to skipping of exon 14 of COL6A1 and 
subsequent deletion of 18 amino acids from the triple helical domain of the α1 chain 
are also frequently seen in BM. These mutations result in the production of shortened 
α1 chains that are unable to undergo subsequent assembly into dimers and tetramers 
and consequently cause a reduction in the detectable level of collagen VI in the 
extracellular matrix (92-94). Numerous other missense and splice site mutations have 
been reported although in many cases the pathogenicity of the variants has not been 
definitively established. (85) 
 
In UCMD, mutations are often loss of function. These are frequently caused by the 
introduction of premature stop codons, by a variety of pathogenic mechanisms, and 
subsequent nonsense mediated RNA decay leads to loss of the mutant COLA chain 
(65, 85).  Both autosomal recessive and dominant mutations cause UCMD with 
approximately equal frequency. A large heterozygous mutation in COL6A1 has been 
shown to result in the secretion of abnormal tetramers that disrupt microfibrillar 
assembly by a dominant negative effect (94). Large inframe deletions and a number of 
missense mutations have also been reported in UCMD, the mechanism by which many 
of these mutations cause UCMD is not clear (85, 95).    
 
As more mutations were discovered it became increasingly clear that a clean line could 
not be drawn between those mutations that cause UCMD and those that result in BM. 
Although single glycine substitutions in the triple helical domain usually result in BM, 
there are reports of UCMD patients with these as the only mutation.  This supports the 
notion of a disease continuum between BM and UCMD (90). 
 
Pathology and Diagnosis 
 
Skeletal muscle biopsy in UCMD and BM may be dystrophic or myopathic. 
Immunohistochemical studies of collagen VI in BM and UCMD are variable and may 
show anything from a subtle reduction in the basal lamina to complete absence of 
extracellular matrix collagen. In BM, collagen VI immunohistochemistry in skeletal 
muscle biopsies is usually normal and therefore not of diagnostic use (84, 96, 97). In 
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UCMD however, complete or partial depletion of collagen VI may be observed and 
hence facilitate a diagnosis. 
 
Collagen VI is also expressed in other connective tissue including skin. Immunostudies 
of collagen VI expression in skin may reveal a reduction although normal expression 
does not exclude a collagen VI defect. The analysis of fibroblasts derived from skin 
biopsies appears to be a more sensitive test of collagen 6 abnormality and has been 
used in diagnostic settings although is a complex technique and requires interpretation 
by experienced pathologists(38, 39, 71). 
 
Immunolabelling of collagen VI in CVS samples has been successfully used in prenatal 
diagnosis of UCMD, but interpretation of collagen VI expression levels requires 
knowledge of the collagen VI status of the proband and should be linked to genetic 
data (98). 
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1.6.3 Rigid Spine Muscular Dystrophy 
 
Mutations in  Selenoprotein N,1 (SEPN1; MIM #606210) give rise to 4 pathological 
phenotypes; rigid spine muscular dystrophy (RSMD1,  MIM #602771), desmin-related 
myopathy with Mallory body-like inclusions (MB-DRM, MIM  #602771) multiminicore 
disease (MmD, MIM #602771) and congenital fibre-type disproportion (CFTD  MIM 
#255310). All are autosomal recessive conditions and although RSMD1 is typically the 
only one considered a CMD they show considerable phenotypic overlap (99-103). 
 
SEPN1 Structure and Function 
 
SEPN1 was the first human selenoprotein shown to be associated with a disease 
(102). It is a membrane bound glycoprotein found in the endoplasmic reticulum, with a 
high expression in foetal tissues but found at lower expression levels in a number of 
human tissues including skeletal muscle. The specific function of SEPN1 is unknown 
but it is thought to have a role in early development and in cell proliferation and 
regeneration (104). Recent work by Arbogast et al. has suggested an important role for 
selenoprotein N in protecting cells from oxidative stress damage(105). 
 
Clinical Features 
 
RSMD1 was first reported by Dubowitz in 1973 (106). It is characterized by early onset 
hypotonia and marked spinal rigidity as a result of contractures of the spinal extensors 
leading to loss of movement of the spine and the thoracic cage. Weakness is 
classically axial with head drop a finding in some. Facial and bulbar muscle weakness 
is frequently found and palatal weakness with a nasal sounding voice is common. 
Patients often have a thin habitus.  Respiratory involvement is prominent and 
disproportionate to the muscle weakness which is often well preserved with many 
patients remaining ambulant into adult life. Assisted nocturnal ventilation is usually 
required in childhood or early adolescence. Structural or functional brain involvement is 
not a feature of RSMD1. CK is usually normal or only mildly elevated (102, 103, 107, 
108). 
 
Muscle MRI findings are characteristic with prominent involvement of the Sartorius and 
to a lesser degree adductors and biceps femoris (Figure 4) (40). 
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Genotype Phenotype Correlation 
 
The diagnostic gold standard in RSMD1 is the finding of mutations in SEPN1. 
Mutations have been found throughout the coding region with no precise genotype 
phenotype relationship reported, although familial phenotype seems to be consistent. 
In addition no conclusive correlation has been reported between the muscle pathology 
and phenotype (99-103). 
 
Pathology and Diagnosis 
 
The pathological changes in skeletal muscle biopsy of RSMD1 patients are not 
diagnostic and as illustrated above, findings may be variable. Muscle histology may 
show non-specific myopathic features, multiminicores or congenital fibre type 
disproportion (108). 
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1.6.4 Autosomal Dominant Emery-Dreifuss Muscular Dystrophy 
 
Autosomal Dominant Emery-Dreifuss Muscular Dystrophy (EDMD2, MIM #181350) is 
one of a number of disorders caused by mutations in Lamin A/C (LMNA, MIM 
#150330)(109). EDMD2 is not usually viewed as a congenital muscular dystrophy 
although early onset cases are documented.  
 
In addition to EDMD2, LMNA mutations are responsible for, among others, Autosomal 
Recessive Emery Dreifuss (MIM #604929), Autosomal Dominant Dilated 
Cardiomyopathy (MIM #115200), Autosomal Dominant Limb Girdle Muscular 
Dystrophy type 1B (MIM #159001) and Autosomal Recessive Charcot Marie Tooth 
Disease (MIM #605588). 
 
Lamin A/C Structure and Function 
 
Three types of lamins, A, B and C, have been described in mammalian cells. Lamin A 
and C are derived from alternative splicing of the LMNA gene. LMNB1 encodes lamin B 
(110).  Lamins are intermediate filaments, structural proteins that are components of 
the nuclear lamina. Through their polymerisation and association with other proteins 
including emerin and nesprin, they form a network that determines nuclear shape and 
size and also make the nuclear envelope more resistant to mechanical stress (111). 
Many of the proteins associated with Lamin A are dependent on it for correct 
organisation (15) (112).  
 
Clinical Features 
 
EDMD2 classically presents with scapulohumeroperoneal atrophy and weakness, 
contractures of elbows and Achilles tendons and spinal stiffness. The major morbidity 
associated with the condition is the propensity to cardiac conduction defects that 
usually present before the third decade and may ultimately lead to complete heart 
block.  Clinical variability is well documented with congenital presentations and slowly 
progressive adult forms reported.  CK is normal or moderately elevated (2-20 x upper 
limit of normal). 
 
Genotype Phenotype Correlation 
 
The distribution and type of LMNA mutations found in EDMD2 is variable with a large 
proportion of de novo events. Mutations are found throughout the gene and many are 
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missense leading to amino acid substitution and a deleterious effect on protein folding 
and consequently the stability of the nuclear membrane. Nonsense mutations resulting 
in haploinsufficiency have only been reported in patients with striated muscle disease 
suggesting that these 2 mechanisms are the predominant cause of the LMNA 
associated skeletal muscle phenotypes (113). Significant clinical heterogeneity may 
exist even between patients with the same mutation. The weight of evidence suggests 
that disease modifying factors may be important in the pathogenesis of this group of 
conditions (109, 112-116). The mechanisms underlying this variability are unclear 
although it has been suggested that the more severe phenotypes are the result of 
dominant negative or gain of function mutations whilst the milder patients have loss of 
function mutations (117). Other work has highlighted the clinical variability found in 
patients with mutations in the same codon on exon 11 (118).  
 
Pathology and Diagnosis 
 
Skeletal muscle biopsy is not diagnostic and shows non-specific myopathic or 
dystrophic changes. A predominance of type 1 fibres may be present and structural 
changes such as cores may also be seen. Electronic microscopy may reveal specific 
alterations in nuclear architecture including aggregation of chromatin. Immunostaining 
for lamins in EDMD2 muscle biopsies, show no detectable difference from normal 
controls, as a result of the normal allele producing a normal product (119-121). 
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1.6.5 Congenital Muscular Dystrophy due to Integrin Alpha 7 Deficiency 
 
 
Congenital muscular dystrophy due to integrin alpha-7 deficiency (MIM #613204) is a 
very rare form of congenital muscular dystrophy, with only 3 patients identified 
worldwide.  It is due to mutations in integrin alpha 7 (ITGA7, MIM #600536). 
 
Integrins are transmembrane glycoproteins comprised of an α and β chain. Integrin 
α7β1 is a laminin α2 receptor in skeletal myotubes and mature myofibres. The 3 
patients reported had motor delay with one patient also having mental retardation 
without brain MRI changes. CK was mildly elevated.  Immunostaining of the skeletal 
muscle biopsy showed myopathic features with absent integrin α7 subunit and normal 
expression of laminin α2 (122, 123). 
 
 
1.6.6 Congenital Muscular Dystrophy Type 1B 
 
Congenital Muscular Dystrophy type 1B (MDC1B, MIM#604801) is linked to 1q42. 
Brockington et al. described 2 families with proximal girdle weakness, generalised 
muscle hypertrophy, contractures, spinal rigidity and early, severe respiratory failure. 
CK was very elevated and skeletal muscle biopsy was dystrophic with a secondary 
reduction in laminin α2 expression. Despite extensive investigation the gene 
responsible remains unknown (24, 28).  
 
1.6.7 CMD with Joint Hyperlaxity 
 
Tetreault et al. described a French-Canadian cohort of 14 patients with congenital 
muscular dystrophy and features overlapping those of the collagen 6 myopathies. In 
particular they had distal join laxity, contractures, hypotonia and a slowly progressive 
myopathy. Respiratory impairment was present but not as severe as that seen in 
UCMD and Bethlem Myopathy. Intelligence was usually normal and CK was normal or 
only mildly elevated. Collagen VI involvement was excluded by linkage and the disease 
was found to link to 3p23-21 presumably as a result of a founder mutation within that 
population. The defective gene is now known to be integrin α9 (29)  (26). 
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1.6.8 Dystroglycanopathies 
 
The dystroglycanopathies are discussed in more comprehensive detail than other 
CMDs as this group forms the basis for the majority of work in this thesis. 
 
The dystroglycanopathies are a heterogeneous group of autosomal recessive disorders 
characterised by hypoglycosylation of alpha-dystroglycan (ADG) on skeletal muscle 
biopsy. They  include CMD variants with structural changes affecting the brain and 
eyes (Fukuyama CMD (FCMD),  Muscle-Eye-Brain disease (MEB), Walker-Warburg 
syndrome (WWS)), as well as relatively milder forms, characterised by subtle or absent 
brain involvement and ranging in severity from CMD (MDC1C, MDC1D) to later onset 
limb girdle muscular dystrophy (LGMD) forms (LGMD2I, LGMD2K, LGMD2L, 
LGMD2M) (2, 44, 124-126). By 2006, mutations in 6 genes (Protein-O-mannosyl 
transferase 1 (POMT1), Protein-O-mannosyl transferase 2 (POMT2), Protein-O-
mannose 1,2-N-acetylglucosaminyltransferase 1 (POMGNT1), Fukutin (FKTN), 
Fukutin-related protein (FKRP) and Like-Glycosyltransferase (LARGE)) had been 
identified as giving rise to dystroglycanopathy phenotypes (127-132). Mutations in a 
further gene, Dolichyl-phosphate mannosyltransferase polypeptide 3 (DPM3; MIM 
#605951) were reported in 2009 and give rise to condition with features overlapping 
those of the dystroglycanopathies and congenital disorders of glycosylation (44). 
 
 
Structure and Function of Alpha Dystroglycan 
 
During the 1990’s a number of papers reported the importance of the dystrophin-
associated-glycoprotein complex (DGC) in the pathogenesis of muscular dystrophies 
(133-137). The DGC is present along the sarcolemma of skeletal muscle fibres and 
contains a number of cytoplasmic, transmembrane and extracellular matrix proteins. 
Components of the DGC include: the cytoplasmic proteins dystrophin and syntrophins 
(α and β), the transmembrane protein sarcospan, the glycoproteins dystroglycan (α and 
β) and sarcoglycans (α, β, γ, and δ) (Figure 5) (138).  
 
  
Figure 5. 
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Central to the DGC are α and β dystroglycan (ADG and BDG), formed by 
posttranslational cleavage of the dystroglycan peptide. ADG is non-covalently linked to 
sarcolemmal spanning BDG that binds via its cytoplasmic domain to components of the 
cell cytoskeleton, hence forming a link between the ECM and cytoskeleton (139). The 
main function of the DGC in skeletal muscle is to confer structural stability to the 
sarcolemma during cyclical contraction and relaxation, acting as a ‘shock absorber’ 
protecting skeletal muscle from damage (140).  
 
The gene encoding dystroglycan, DAG1, was initially cloned in 1992 and subsequently 
mapped to 3p21 in 1993 (141, 142). The primary structure of dystroglycan is strongly 
conserved across mammalian species and displays a high degree of homology 
throughout lower invertebrates. No mutations in DAG1 have been identified in any 
human disorder although post-translational processing defects of dystroglycan, in 
particular abnormal glycosylation, have been associated with a number of pathological 
conditions. Dystroglycan has a wide tissue distribution and outside skeletal muscle is 
expressed in the central and peripheral nervous system, in epithelia and endothelia 
(143). Dystroglycan has diverse roles and in addition to its role in the DGC has been 
implicated in cell signalling (144, 145), structure and function of the central nervous 
system (146), myelination and nodal architecture of peripheral nerves (147), epithelial 
morphogenesis (148), synaptogenesis (149) (150) and cell adhesion (151). 
 
In the DGC, transmembrane BDG binds intracellularly via its carboxy terminal residues 
to  dystrophin via the WW (Trp-Trp) domain and Ca2+ binding motifs (152) which in turn 
bind to the actin associated cytoskeleton. In tissues other than skeletal muscle, 
dystroglycan binds to various alternative splice forms of dystrophin or utrophin (153). A 
for BDG role in cell signalling is also implied given interactions with the signalling 
adapter molecule Grb2 and components of the ERK-MAP kinase cascade including 
MEK and ERK. The precise biological significance of these interactions is unknown 
(145) (154).  
 
 
ADG is an extracellular glycoprotein that contains a central, highly O-glycosylated, 
mucin domain connecting the globular C- and N-terminal domains. ADG also contains 
3 potential N-linked glycosylation sites (155, 156). The predicted molecular mass of the 
core protein is ~40 kDa, however the size of ADG detected by immunoblot varies from 
120 kDa in brain to 156 kDa in skeletal muscle, largely due to extensive O-
glycosylation (138). ADG binds many of its extracellular matrix partners through its 
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carbohydrate modifications. Known ECM ligands include  laminin-2, agrin and perlecan 
in skeletal muscle and neurexin and pikachurin in the brain and retina respectively 
(157) (158) (141). ADG is also the cellular receptor for arenaviruses and 
Mycobacterium leprae (159, 160).  
 
Dystroglycan is expressed in high levels in developing and foetal tissues, typically in 
cell types facing basement membranes.  Disruption of DAG1 in mice is embryonically 
lethal around day 5.5 due to perturbations in Reichert’s membrane, a basement 
membrane that separates the embryo from the maternal circulation (161). It was 
subsequently shown that dystroglycan is required for the formation of the sub-
endodermal basement membrane in embryoid bodies and is also required for the 
organisation of laminin-1 on the cell surface (162). However in the LargeMyd mouse, (in 
which LARGE is mutated causing ADG hypoglycosylation), the skeletal muscle 
basement membranes are largely intact despite large disruptions of basement 
membranes in the brain (163). It is probable that the role of dystroglycan in basement 
membrane formation is dependent on numerous factors (154). Mice with skeletal 
muscle specific loss of dystroglycan showed mild muscular dystrophy with skeletal 
muscle hypertrophy. This suggested that maintenance of regeneration capacity by 
satellite cells expressing dystroglycan was likely to result in a milder muscular 
phenotype than that observed in chimeric dystroglycan null mice, implying a role for 
dystroglycan in skeletal muscle repair (164, 165).  
 
Dystroglycan also has an important function at the Neuromuscular Junction (NMJ). 
Most proteins of the DGC are expressed along the entirety of the sarcolemmal 
membrane. At the extrasynaptic regions of the myofibre a protein scaffold similar but 
not identical to the DGC exists, containing proteins that are only expressed at the NMJ. 
This includes uniquely synaptic forms of laminin, utrophin and dystrobrevin-1. The 
localisation of dystroglycan at the NMJ is dependent on its interaction with ankyrin 
(166). Synaptic forms of laminin and agrin interact with ADG, whilst BDG interacts 
intracellularly with utrophin which binds to actin filaments. BDG also binds to rapsyn, a 
postsynaptic protein involved in clustering of acetylcholine receptors implying a role in 
the formation of neuromuscular junctions (167). Further work suggests a role for 
dystroglycan in the stabilisation of post-synaptic acetylcholine receptor clusters (168). 
 
 
In the retina, distinct isoforms of ADG are localised in apposition to the basal lamina in 
the inner limiting membrane and blood vessels as well as within the parenchyma of the 
retina along the Muller glia.  It is thought that dystroglycan has a role in organising 
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synapses and basement membrane assembly in the retina (169). Recently it has 
emerged that pikachurin (a ligand of dystroglycan) plays a crucial role in the formation 
of the photoreceptor ribbon synapse and that posttranslational modification of ADG is 
necessary for correct pikachurin binding and localisation (170). 
 
The role of ADG in the developing brain and in neuronal migration has been studied in 
animal models. In adult mice ADG is expressed in the neurones of cerebral cortex, 
hippocampus, olfactory bulb, basal ganglia, thalamus, hypothalamus, brainstem and 
cerebellum. During CNS development, ADG is expressed in the ventricular zone and in 
basement membranes, and participates in neuronal proliferation, in the constitution of 
the meningeal layer and in neuronal migration (171). This is covered in more detail in 
section 4.1.1. 
  
Dystroglycan is also thought to have a role in branching morphogenesis of kidney, lung 
and salivary glands and is expressed in high levels on the basal side of most epithelial 
cells (172, 173).  
 
DGC proteins are implicated in the pathogenesis of a number of muscular dystrophies 
including dystrophinopathies and sarcoglycanopathies. Involvement of basal lamina 
proteins in the pathogenesis of dystroglycanopathies was first postulated to be 
important in patients with FCMD. Molecular work established the reduced expression of 
laminin α2 chain of merosin in the basal lamina of skeletal muscle from these patients 
and subsequently an abnormality in the glia limitans (a basal lamina complex in the 
brain) of foetuses (174, 175).  
 
In 2001, Hayashi et al demonstrated reduced immunoreactive levels of ADG in FCMD 
patients using a VIA-4 antibody, directed against glycosylated ADG. They also reported 
loss of the 156kDa band, representing glycosylated ADG in skeletal muscle, in FCMD 
patients. BDG expression was normal in both immunoreactive studies and immunoblot. 
They thought that the most likely explanation for their results was that ADG was 
selectively lost in FCMD, perhaps as a result of protein instability or altered 
glycosylation (176). Around the same time, Grewal et al. showed that the gene mutated 
in the myodystrophy mouse (LargeMyd) encoded LARGE, a glycosyltransferase (177). 
Due to the muscular dystrophy phenotype of the LargeMyd mouse, DGC proteins, in 
particular those that are glycosylated were identified as potential downstream targets of 
LARGE. They showed that whilst migration of sarcoglycans and BDG was normal in 
immunoblots of LargeMyd skeletal muscle, monoclonal antibodies to ADG (VIA-4) 
showed almost complete loss of binding. This led to the speculation that abnormal 
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glycosylation of ADG could be implicated in muscular dystrophy. Further work by the 
same group went on to refine the phenotype of the LargeMyd  mouse, revealing 
ophthalmic and CNS defects including neuronal migration abnormalities, features 
reminiscent of those seen in MEB and FCMD (178). Complementary work by Michele 
et al. used polyclonal antibodies directed against ADG to demonstrate that in MEB and 
FCMD patients, ADG was in fact expressed at the muscle membrane but was 
hypoglycosylated, accounting for the reduced levels of ADG seen when using VIA-4 
antibodies. Such hypoglycosylation would interfere with ADGs ability to interact with 
extracellular ligands providing an elegant explanation for the muscular dystrophy 
phenotype. Michele et al. expanded the phenotype of the LargeMyd mouse, 
demonstrating the similarity in brain abnormalities, including disruption of the basal 
lamina, between the mouse and the MEB/ FCMD patients studied. They concluded that 
FKTN, LARGE and POMGNT1 may participate in a similar pathway resulting in the 
glycosylation of ADG. This discovery provided a neat explanation for the phenotypic 
overlap reported in MEB, FCMD and other ‘dystroglycanopathy’ patients with mutations 
in different genes (163).  
 
Glycosylation 
 
Glycosylation is highly complex post translational process by which sugars are added 
to proteins in the endoplasmic reticulum and Golgi apparatus. Glycosylation affects 
protein stability, conformation and function which in turn affect crucial cellular 
processes such as molecular recognition, cell adhesion, growth and differentiation 
(179, 180). Glycosylation occurs in 2 main forms. N-glycans are linked to the target 
protein via an asparagine residue whilst O-glycans are linked via a serine or threonine. 
ADG is both N- and O- glycosylated, the glycosylation of ADG is tissue specific and the 
molecular mass is different in skeletal muscle (156kDa), cardiac muscle (140kDa) and 
brain (120kDa).  
 
N- glycosylation is by far the most common form of glycosylation seen in mammalian 
cells. Disorders that affect N-glycosylation and are known as congenital disorders of 
glycosylation (CDGs).They can be subdivided into type I and II. Type I CDGs are 
caused by defects in the assembly of lipid linked oligosaccharides in the endoplasmic 
reticulum resulting in the production of incomplete glycan structures. Type II CDGs are 
caused by defects in the processing of protein bound sugar chains and include 
conditions with mutations in nucleotide sugar transporters, glycosyltransferases, and 
cytoplasmic proteins that traffic into and within the Golgi apparatus (181, 182). 
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O-glycans can be divided according to the sugar that O-links with the protein. ADG is 
an O-mannosylated protein, a rare finding in mammalian cells (183). The central O-
glycan sequence in ADG is – -Sialyl-α2,3Galβ1,4GlcNAcβ1,2Manα-O-Ser/Thr-. The –
Sialyl-α2,3Galβ1,4GlcNAcβ1 portion is necessary for binding of ADG to laminin (184). 
Several other glycans have been identified that are derivatives of the O-linked 
mannose structure including the Lewis X antigen, the CT carbohydrate antigen, 
restricted to the neuromuscular junction and the HNK-1 carbohydrate antigen (185-
187).  
 
The formation of the major O-linked mannose glycan on ADG involves the action of 
specific enzymes (glycosyltransferases) that add monosaccharides in a stepwise 
manner (12, 188). The genes implicated in the dystroglycanopathies are putative or 
proven enzymes involved in the O-mannosylation of ADG (2). As such the 
hypoglycosylation observed in this group of conditions is a secondary effect as a 
consequence of abnormalities in glycosyltransferases rather than a primary 
abnormality in ADG.  POMT1 forms a complex with POMT2 (132) that catalyses the 
first step in the assembly of the O-mannosyl glycan, adding a mannose directly to the 
Ser/Thr residue. POMGNT1 is the second enzyme in the O-mannosylation process, 
adding an N- acetylglucosamine (GlcNAc) residue to the mannose group.  Interruption 
of the O-mannosylation pathway provided a clear explanation for the pathogenicity of 
mutations in these three genes however the precise function of FKTN, FKRP and 
LARGE in facilitating the glycosylation of ADG has yet to be elucidated (Figure 6) (129, 
132, 189-191). 
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Figure 6. Diagrammatic representation of the O-mannose-linked glycan attached 
to ADG.  
 
Sugar residues are added in sequential order to the ADG backbone by the catalytic 
activity of glycosyltransferases. POMT1 and POMT2 act in the endoplasmic reticulum 
and catalyse the first step, the addition of mannose (190). POMGNT1 catalyses the 
second step in the Golgi apparatus, the linkage of a N-acetylglucosamine residue to 
the mannose (129). The function of FKTN, FKRP and LARGE have yet to be fully 
characterised.  
  
58 
 
FKTN and FKRP show sequence similarity to glycosyltransferases(192, 193). FKTN is 
expressed in highest amounts in brain, heart, pancreas and skeletal muscle. Although 
FKRP is a putative glycosyltransferase, its precise subcellular localisation is 
controversial. Some studies have suggested that it localises to the rough endoplasmic 
reticulum with POMT1, whilst others report subcellular localisation of FKRP to the Golgi 
apparatus with mutations in FKRP leading to endoplasmic reticulum retention (193-
196). In one study in mammalian cells  FKRP was found to be present at the 
sarcolemma and associated with the DGC although the precise role of FKRP remains 
elusive(196). 
 
The LARGE gene encodes the N-acetylglucosaminyltransferase-like protein (LARGE), 
a homologue of mammalian β3,1-N-acetylglucosaminyltransferase. The gene is 
ubiquitously expressed with the highest levels seen in heart, brain and skeletal muscle 
(197). The LARGE protein is localised to the Golgi and contains 2 putative catalytic 
domains, both of which are necessary for correct function(177, 198). The N-terminal 
domain of ADG interacts directly with LARGE and initiates functional glycosylation of 
ADG (199, 200). The precise action of LARGE is unknown. However, forced 
expression of LARGE induces hyperglycosylation of ADG in normal cells and also 
restores the hypoglycosylation of ADG in patients with dystroglycanopathies including 
FCMD, MEB, WWS and LGMD2I, resulting in increased laminin binding. Interestingly, 
hyperglycosylation of ADG can also be restored by overexpression of a LARGE 
homologue, LARGE2 (GYLTL1B). LARGE2, although sharing sequence similarity has 
a different expression pattern to LARGE, having virtually absent expression in skeletal 
muscle and heart(198). This interesting observation has opened up the possibility 
exploiting this phenomenon for therapeutic benefit in patients with 
dystroglycanopathies (158, 201). Work published this year by Yoshida-Moriguchi et al. 
has suggested that patients with MEB and FCMD as well as the LargeMyd mouse, have 
defects in postphosphoryl modification of a phosphorylated O-linked mannose in ADG. 
This modification is mediated by LARGE and is required for laminin binding, hence 
suggesting a mechanism by which forced overexpression of LARGE may circumvent 
defects in CMD cells (202). 
 
Interestingly, aberrant glycosylation and post translational modification of ADG is 
implicated in the pathogenesis of other conditions including a number of cancers, 
probably as a result of disruption to the basal lamina and interaction with the 
extracellular matrix. Loss of ADG expression in prostate and breast cancer cells 
correlates with a higher degree of malignancy (158, 203, 204). Correct post 
translational processing is also necessary for ADG to act as a receptor for a bacteria 
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and viruses including lymphocytic choriomenigitis virus (LCMV) and Lassa Fever virus 
(LFV) (158, 159).  
 
Dystroglycanopathy Phenotypes and Associated Genes 
 
The phenotypes reported in patients with hypoglycosylation of ADG are very variable. 
The clinical classification of dystroglycanopathies has been clouded somewhat by the 
heterogeneity of this group. Initially, discreet phenotypes were described based on 
clinical findings and sometimes associated with a particular population; MEB was well 
described as a severe CMD with eye and brain abnormalities common in the Finnish 
community, FCMD was known as clinically similar to MEB but isolated to the Japanese 
population and WWS was recognisable by the devastating extent of the CNS 
phenotype. As the genetic basis for individual conditions emerged, they became 
associated with mutations in a particular gene; MEB with POMGNT1, FCMD with FKTN 
and WWS with POMT1.   
 
As more dystroglycanopathy genes were discovered, additional phenotypes attributed 
to these new genes were reported, often with features similar to those described in 
other dystroglycanopathies. The first patient found to have a LARGE gene mutation for 
instance, was designated as having MDC1D, a condition with features of CMD and 
brain abnormalities in keeping with milder aspects of the previously reported conditions  
(131). As a consequence, a number of dystroglycanopathy phenotypes, particularly in 
the intermediate severity range, have overlapping features but have historically 
emerged as separate conditions. This classification problem was confounded further by 
the realisation that particular dystroglycanopathy genes may produce several different 
phenotypes, best illustrated by mutations in FKRP which may produce anything from 
WWS through to milder late onset LGMD without CNS involvement (205). As it 
currently stands, among the dystroglycanopathies, mutations in one gene may cause 
several phenotypes and some phenotypes may be caused by mutations in a number of 
different genes. In addition the diagnostic boundaries between some of the conditions, 
particularly in the intermediate spectrum are not clear. Despite this, several key 
phenotypes have been well described and these, together with the associated genes 
involved are summarised below.   
 
 
Walker Warburg Syndrome (WWS, MIM #236670): This is a severe form of CMD with 
onset prenatally or at birth. Patients have structural brain abnormalities including 
complete agyria or severe ‘cobblestone’ lissencephaly with only rudimentary cortical 
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folding, marked hydrocephalus, severe cerebellar involvement and complete or partial 
absence of the corpus callosum.  Eye abnormalities include congenital cataracts, 
microphthalmia and buphthalmos. Motor development is minimal or absent and death 
before 1 year of age is usual (206).  
 
The first gene identified in patients with WWS was Protein O-mannosyltransferase 
(POMT1), found to be mutated in 20% of a WWS patient cohort (130). In 2005, Protein 
O-mannosyltransferase 2 (POMT2), a homologue of POMT1, was also found to be 
mutated in a number of patients with WWS. POMT2 was an obvious 
dystroglycanopathy candidate gene as it shares 36% amino acid identity with POMT1. 
POMT1 and POMT2 are expressed in most human tissues and expression of both 
proteins is required for POMT enzymatic activity (190). POMT2 was reported to be 
mutated in 3/41 patients with WWS. Mutations in FKRP and FKTN were subsequently 
identified in WWS patients. It has been estimated that mutations in POMT1, POMT2, 
FKTN and FKRP account for approximately 1/3 of patients with WWS  (130), (132, 207, 
208).  
 
Muscle Eye Brain Disease (MEB, MIM #253280): MEB is a CMD with brain abnormality 
less pronounced than that seen with WWS, originally reported in the Finnish 
population. MRI brain findings include; cortical abnormalities including pachygyria and 
polymicrogyria, cerebellar abnormalities including hypoplasia, dysplasia and cysts, and 
brain stem abnormalities. Structural eye involvement is a feature and may include 
congenital glaucoma, progressive myopia, retinal atrophy and juvenile cataracts. 
Individuals may, rarely, acquire the ability to walk although this is delayed. Significant 
learning difficulties are expected although patients occasionally manage to learn a few 
spoken words (206).  
 
The MEB locus 1p32-p34 was first identified in 1999 and was followed in 2001 by the 
report of Protein O-linked mannose β1,2-N-acetlyglucosaminyltransferase 1 
(POMGNT1) mutations in Finnish and Turkish patients with MEB(129, 209). Cormand 
et al. subsequently analysed a large cohort of MEB and WWS patients and effectively 
excluded linkage to 1p32-p34 from all but 1 patient with diagnostic criteria compatible 
with WWS. Conversely all patients except 1 Swedish girl with features consistent with 
MEB linked to the locus. Mutations in FKRP and POMT2 were subsequently found in 
MEB patients (129, 210, 211).  
 
Fukuyama Congenital Muscular Dystrophy (FCMD, MIM #253800): This is the second 
most frequent form of muscular dystrophy in Japan after Duchenne muscular 
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dystrophy, due to the presence of a FKTN founder mutation within this population. 
Reports of the disease outside of Japan are rare. FCMD was first described by Yukio 
Fukuyama in 1960 (212). Affected children have generalized muscle weakness with 
marked motor delay, most patients only achieve independent sitting or standing with 
support. Pseudohypertrophy of the tongue, calves, and quadriceps muscles is 
common. Brain involvement is reflected in structural brain malformations including 
cobblestone lissencephaly, more often described as pachygyria or polymicrogyria 
although all part of the same spectrum, dilated lateral ventricles, white matter 
abnormality seen on T2 weighted images indicative of dysmyelination, midbrain 
hypoplasia and cerebellar abnormalities including polymicrogyria and cysts (213). 
Functional brain involvement is found in the form of mental retardation and seizures. 
Respiratory failure in the mid-to-late teens is an invariable complication (127, 214). 
 
Mutations in the FKTN gene were first reported in patients with FCMD in 1998 (127, 
215). A common founder retrotransposal insertion was found in more than 80% of 
FCMD chromosomes.  
 
Congenital Muscular Dystrophy type 1C (MDC1C, MIM #606612): A bioinformatics 
approach, searching for homologues of FKTN led to the discovery of mutations in 
FKRP in a group of patients with CMD and secondary reduction in laminin α2, 
designated MDC1C (128). They were subsequently found to have hypoglycosylation of 
ADG on muscle biopsy. Patients are characterised by pronounced muscle involvement 
with sparing of functional brain abnormality in most cases. Patients typically present in 
the first few months of life with hypotonia and weakness and do not acquire 
independent ambulation. Leg and tongue muscle hypertrophy are features and 
shoulder girdle wasting is often seen. Weakness is not particularly progressive but 
disability is compounded by the development of scoliosis and respiratory decline 
usually necessitating non-invasive ventilation in the second decade.  Dilated 
cardiomyopathy is also a finding in some. FKRP mutations were subsequently reported 
in patients with MDC1C associated with mild mental retardation and cerebellar cysts 
(128, 211, 216). 
 
Limb Girdle Muscular Dystrophy type 2I (LGMD2I, MIM #607155): This is a milder 
allelic condition to MDC1C, although the range of severity within this group is itself 
varied. Patients typically present in the second or third decade with gait abnormality 
resulting from limb girdle weakness. Facial and neck flexor weakness is also common 
and calf and tongue hypertrophy is often seen. Cardiac involvement is sometimes 
observed, usually left ventricular abnormality. At the more severe end of the spectrum, 
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patients may present in the first few years of life with delayed motor milestones in 
addition to the above features and follow a motor severity course comparable to 
Duchenne muscular dystrophy. Intelligence and brain MRI imaging is normal. CK 
typically ranges between 1000-4000 IU/l. A common C826A mutation in FKRP is 
frequently observed in this phenotypic group and patients who are homozygous for this 
mutation are usually at the milder end of the phenotypic spectrum (192). 
 
Congenital Muscular Dystrophy type 1B (MDC1B, MIM #604801): This is a congenital 
muscular dystrophy reported in 2 consanguineous families characterised by weakness 
of the proximal girdle, facial muscles and sternomastoids with generalised muscle 
hypertrophy. The striking finding is of profound respiratory deficiency in the first decade 
of life resulting from diaphragmatic weakness and spinal rigidity. Conversely weakness 
elsewhere remains relatively non progressive. Intellect is normal with no evidence of 
central nervous system involvement and CK is characteristically raised (2000-7000 
IU/l). This disease has been assigned to 1q42 although despite extensive searching 
the genetic defect has not been ascertained (24, 28). 
 
Congenital Muscular Dystrophy type 1D (MDC1D, MIM #608840): This is the 
phenotype attributed to the first patient described with a LARGE mutation. LARGE was 
identified as a candidate gene for dystroglycanopathy because of the evocative 
phenotype in the LargeMyd mouse in which LARGE is mutated. This patient presented 
at 5 months of age with developmental delay and hypotonia. She progressed to 
independent walking at the age of 4 years and at the age of 17 years was able only to 
manage a few steps. She had moderate calf, arm and quadriceps hypertrophy and mild 
facial weakness. She had profound mental retardation with use of a few words without 
meaning. Brain MRI was abnormal with high signal intensity in the white matter, 
abnormal neuronal migration with pachygyria and a hypoplastic brainstem. 
Echocardiography was normal. Fundoscopy was normal although electroretinographic 
examination revealed reduced amplitude of the evoked response (131). 
 
Limb Girdle Muscular Dystrophy type 2K (LGMD2K, MIM #609308): This phenotype 
describes patients, originally identified in the Turkish population, with a limb girdle 
muscular dystrophy presenting in the first decade of life, mental retardation and 
microcephaly without any structural brain abnormality detectable on MRI. This group of 
patients were subsequently found to harbour A200P mutations in POMT1 (125, 217).  
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Congenital Disorder of Glycosylation type Io (CDG1O, MIM #612937): In 2009 Lefeber 
et al. reported a patient presenting with mild muscular dystrophy, dilated 
cardiomyopathy and stroke like episodes with no associated brain or eye involvement. 
IIH6 immunoreactivity was reduced on skeletal muscle biopsy, consistent with a 
dystroglycanopathy, but transferrin isoelectric focusing studies in blood also revealed 
an abnormal transferrin profile. This was in keeping with a CDG type I pattern 
consistent with a disorder in N-glycosylation and an ER defect. A reduction in Dol-P-
Man synthase activity was found in the patients fibroblasts. Mutation analysis 
subsequently revealed a homozygous mutation in DPM3, one of 3 subunits in the Dol-
P-Man synthase complex, required for anchoring the catalytic subunit to the ER. The 
Dol-P-Man synthase complex is required for N-glycosylation, C-mannosylation, O-
mannosylation and GPI-anchor formation and a mutation would be expected to affect 
all 4 processes. It is speculated that O-mannosylation is more sensitive to the reduced 
binding capacity of DPM3 resulting from the reported mutation and consequently 
produces a phenotype that overlaps with that seen in dystroglycanopathy (44).  
 
Prior to this report, CDGs and dystroglycanopathies, although both disorders of 
glycosylation, were regarded as two separate disease entities (44). This report reveals 
for the first time a patient with clinical features consistent with a dystroglycanopathy, 
supported by reduced ADG glycosylation in skeletal muscle, but with a biochemical 
profile in keeping with a CDG.  
 
 
Genotype Phenotype Correlation 
 
Initially a genotype-phenotype correlation was reported between the individual 
dystroglycanopathy genes and various phenotypes. However, subsequent work has 
shown that each of the genes is responsible for a wide range of clinically overlapping 
conditions as illustrated by the phenotypic descriptions above.  Despite this, certain 
genes are classically associated with particular conditions; for instance, mutations in 
FKTN give rise to Fukuyama CMD in the Japanese population, almost invariably as a 
result of founder mutations. This is expanded further in section 3.1. 
 
Pathology and Diagnosis 
 
Skeletal muscle biopsy in patients with dystroglycanopathy is usually dystrophic in 
appearance with a large proportion of fibres expressing neonatal myosin. A reduction in 
ADG on immunoblot and immunohistochemistry is apparent with normal expression of 
BDG (12). The commonly used monoclonal antibodies (IIH6 and VIA-4) are directed 
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against the glycosylated epitope of ADG, and show variable reduction in labelling that 
does not consistently correlate with disease severity (12, 218). Other features include a 
reduction in labelling of laminin α2, although this is never absent as often seen in 
MDC1A (Figure 7)(128). 
 
In order to investigate the specific involvement of POMGNT1, POMT1 and POMT2, 
enzymatic activity can be studied in muscle biopsy samples, fibroblasts or EBV- 
transformed lymphoblasts. These enzymatic assays are not routinely used in our 
department for diagnostic studies, but have been used to investigate cases where 
pathogenicity of a mutation is disputed (190, 219, 220). 
 
 
  
 
 
 
Figure 7.
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dystroglycan and GT20ADG. B) Immunoblot analysis of WGA-enriched total muscle 
from control normal muscle (C) and a dystroglycanopathy patient (P). The molecular 
weight of β-dystroglycan is unchanged on western blot analysis yet a dramatic 
reduction in molecular weight of α-dystroglycan is seen using the GT20ADG antibody 
due to hypoglycosylation. Primary sequence analysis of α-dystroglycan predicts a 
molecular mass of 72 kDa however α-dystroglycan in skeletal muscle migrates to 156 
kDa.  
 
Adapted with permission from Macmillan Publishers Ltd: Michele et al. Nature 
2002;418:417-422 copyright Nature 2002(163). 
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1.7 PERSPECTIVE 
 
Despite the major progress made over the last 2 decades in identifying and mapping 
various forms of CMD, there are large gaps in our cumulative knowledge. The CMDs 
are clearly a very heterogeneous group and it is apparent that a large proportion of 
patients remain for whom no definitive diagnosis can be made. Some of these will have 
phenotypes that evolve allowing a diagnosis to be made in later years. Other patients 
fall within a pathological subgroup (for instance dystroglycanopathy) but have no 
identifiable gene defect. Others appear to fulfil the general clinical and pathological 
criteria for CMD but remain a diagnostic mystery. This suggests that some genes 
involved in congenital muscular dystrophy are yet to be discovered. 
 
Establishing a correct diagnosis has never been so important. On a basic level, giving 
a name to a condition is often helpful to family and carers especially when negotiating 
complex medical and social arrangements. A diagnosis also allows accurate genetic 
counselling and in relevant cases may be necessary for prenatal testing. Although 
historically muscular dystrophies have been untreatable, supportive therapies are 
increasingly available and an accurate diagnosis ensures that disease complications 
can be anticipated and appropriate intervention established. In the last few years, 
advances in our understanding of the CMDs have also facilitated the pathway to 
therapeutic trials for these rare disorders. A confirmed genetic diagnosis is a 
prerequisite for enrolment in many clinical trials. 
 
Although a proportion of CMD cases are easily diagnosed and run a predictable 
course, for many the path to diagnosis and then onward disease progression is less 
straightforward. For these families, the use of alternative investigative strategies such 
as muscle or brain MRI is often helpful and may allow insight where traditional 
diagnostic methods have failed. Even in those cases where the diagnosis is known, 
accurate documentation of complications and disease progression helps establish 
natural history data, which in turn is useful when monitoring the effect of therapeutic 
interventions. 
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CHAPTER 2:  DIAGNOSTIC OUTCOMES OF 
REFERRALS TO UK CONGENITAL MUSCULAR 
DYSTROPHY SERVICE 2001-2008. 
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2.1 INTRODUCTION 
 
The Dubowitz Neuromuscular Centre (DNC) was commissioned in 2001 by the UK 
Department of Health National Commissioning Group (NCG) to provide a national 
comprehensive service for Congenital Muscular Dystrophy (CMD) including the 
assessment, investigation and management of children with these rare disorders. 
The NCG service can be accessed by the referring clinical team at various levels, 
including clinical review of patient, assessment of muscle biopsy or molecular 
genetic analysis.  The centre is freely available to any UK patient. The centre moved 
to its current location in Great Ormond Street Hospital in 2008.  
 
2.1.1 Heterogeneity And Differential Diagnosis Of Congenital Muscular 
Dystrophy 
 
Congenital muscular dystrophies are a heterogeneous group of disorders. They 
present in a number of ways although most commonly with muscle weakness and 
hypotonia in the first months of life; contractures are common and serum creatine 
kinase (CK) frequently elevated. Other clinical features include contractures, muscle 
wasting or hypertrophy and abnormalities of eye, skin and brain. Respiratory and 
cardiac abnormalities are also common.  
 
There are at least 13 genetically distinct forms of CMD reported (table 1 and 2). In 
addition there is a further group of as yet undefined patients in whom all known 
forms can be excluded. A proportion of these cases are affected by CMD variants 
that are clinically and pathologically undistinguishable from genetically defined 
forms, while others, despite their clinical and/ or pathological similarities to CMD, 
clearly belong to a different group of conditions. Typical examples of the latter are 
myotonic dystrophy, some congenital myopathy variants and congenital myasthenic 
syndromes (2, 221). The diagnostic challenge presented by CMD and the frequently 
occurring differential diagnoses seen in our department has been reported by Dr A 
Klein and myself (222).  
 
Skeletal muscle biopsy is an important part of the diagnostic workup of children with 
suspected CMD.  Muscle biopsy findings in affected individuals range from mild to 
overtly dystrophic, depending on the muscle biopsied and the age at biopsy.  What 
constitutes dystrophic changes in skeletal muscle is also subject to debate.  For the 
purpose of this report, dystrophic change is defined as muscle with fibrosis and 
necrosis. If necrosis is not observed then muscle fibre regeneration must be present  
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(CA Sewry, personal communication)(4).  Immunohistochemical studies of muscle 
are sometimes in themselves diagnostic, particularly in the case of MDC1A 
associated with complete merosin deficiency. In other conditions, notably collagen 
VI related myopathy and dystroglycanopathy, a proportion of patients will have clear 
cut diagnostic immunohistochemical abnormality whilst in others the findings may 
be subtle and inconclusive.  
 
2.1.2 Incidence of Congenital Muscular Dystrophy 
 
Few studies have looked at the incidence of CMD but from the reports available the 
incidence has been estimated at between 4.7 x 10-5 live births in the north of Italy 
and a point prevalence of 2.5 x10-5 in Western Sweden (1, 223).  It is clear that the 
prevalence of different subtypes of CMD varies in different populations, often due to 
founder mutations. MDC1A has historically been thought of as the most common 
form of CMD with estimates suggesting that it accounts for between 30 and 50% of 
cases (2, 221). The relatively high number of reports of MDC1A is probably in part a 
reflection of its historically early identification, its homogenous, usually early 
presentation and the relative ease of pathological and genetic diagnosis. In Japan 
however, Fukuyama CMD (FCMD) is the most common form of CMD with an 
incidence estimated at 1.92-3.68/100000 births (224). This is largely due to a 
founder retroposon insertion mutation in the FKTN gene, present in the majority of 
Japanese FCMD patients. A number of reports have documented the frequency of 
this founder mutation in Japan with one study revealing its presence in 87% of 
FCMD chromosomes and suggesting a carrier frequency in the Japanese 
population of 1/88.  FCMD is rarely reported outside of Japan although similar 
disorders with mutations in FKTN are increasingly being identified (127, 225-227). 
Okada et al have subsequently reported collagen VI deficiency as the second most 
common cause of CMD in the Japanese population(228). A recent Australian report 
of 101 CMD biopsies identified dystroglycanopathies as the most prevalent form in 
that population (25% of cohort) followed by collagen VI related myopathies (12%) 
and then MDC1A (8%) with a definitive genetic diagnosis achieved in 24% of cases 
(229).  In 2009, Norwood et al reported  a CMD combined  prevalence of 
0.76/100000 in the Northern England cohort studied with  MDC1A comprising  
0.6/100000 , UCMD 0.13/100000 and BM 0.77/100000 (230). 
 
Here I review the diagnostic outcome of 214 UK patients clinically assessed in our 
department between 2001 and 2008 with a view to describing the general activity of 
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the service and the frequency of the various disorders encountered in our patient 
population. 
 
 
2.2 MATERIALS AND METHODS. 
 
The UK referrals to the Dubowitz Neuromuscular Centre between April 2001 and 
January 2008 as ‘possible CMD’ were retrospectively reviewed. Only patients who 
had been clinically assessed by us at the centre and from whom a muscle biopsy 
was available for the diagnostic studies were included. Patients where biopsy 
sample was unavailable or insufficient for analysis have been excluded. Where 
more than one member of a family was seen, only one member of the family has 
been included for the purpose of analysis (the patient with the most information 
available). 
 
Clinical notes, genetic tests and muscle biopsy reports were reviewed for all 
patients fulfilling the criteria. Diagnostic and biopsy information was gathered firstly 
for all referrals, which however consisted of a considerable number of patients not 
affected by CMD, and then subsequently for patients who fulfilled the tighter 
inclusion criteria for CMD. This included dystrophic or myopathic muscle biopsy with 
no structural features suggestive of alternative diagnosis, presentation before the 
age of 2 years with hypotonia, weakness, contractures, delayed motor milestones, 
elevation of serum CK in several variants, and characteristic eye or brain 
abnormality. Patients in whom a diagnosis of a condition other than CMD was made 
were excluded from this ‘CMD subgroup’ analysis. 
 
Diagnostic standards were as for Dubowitz and Sewry 2007 (CMD and congenital 
myopathy)(4), Godfrey et al 2007 (dystroglycanopathy)(231), Gerenmayeh et al 
2010 (MDC1A)(34), Nadeau et al 2009 (collagen VI)(232) and Kinali et al 2008 
(congenital myasthenia)(233). All biopsy samples from patients referred with 
suspected CMD underwent a panel of routine investigation including histological, 
histochemical and immunohistochemical analysis except for those where sample 
size limited testing. For further information on standard departmental testing 
procedure see 
http://www.ich.ucl.ac.uk/gosh/clinicalservices/neuromuscular_services/. 
 
Genetic testing was directed by biopsy and clinical findings and often supported by 
muscle MRI investigation (40). Molecular genetic analysis of CMD and congenital 
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myopathy genes was provided by Guys and St Thomas' Trust, London (part of CMD 
NCG service), the NCG Referral Centre for LGMD at the Institute of Human 
Genetics at Newcastle University and NCG funded Oxford Congenital Myasthenic 
Syndrome Service. Key references for the listed diseases and their diagnostic 
workup can be found at: http://www.musclegenetable.org/.  
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2.3 RESULTS 
 
2.3.1 Total Cohort Analysis ‘All Referrals’  
 
Muscle biopsy samples were received from 415 patients.  Of these, 218 patients 
were clinically assessed in the Centre. Four siblings were excluded leaving a ‘total 
referral’ number of 214 families included in subsequent analysis. 
 
From these 214 patients, the average age at biopsy assessment was 6.2 years 
(range 1 day - 37.2 years). The referrals represent a very mixed group in terms of 
ethnicity reflecting the London and UK population. Patients were referred from 
throughout the UK;  74/ 214  were referred from the Greater London area and 
140/214 were UK patients referred from outside Greater London with 55/101 non-
Greater London postcodes represented in the sample (Figure 8).  
 
A genetic diagnosis was reached in 83/214 (39%). A further 22 patients (10%) could 
be confidently assigned to a pathological subgroup on the basis of characteristic 
muscle biopsy findings. In total, 105 patients had a diagnosis molecularly confirmed 
or pathologically refined. Of these 105 patients, 64 were affected by a form of CMD 
(Table 3 and 4). There are a further 23 patients in whom a clinical diagnosis is 
strongly suspected but a definitive genetic or pathological diagnosis could not be 
reached.  
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Greater London
 
 
Figure 8: UK postcode map showing regions from which referrals were 
received (shaded areas).  
 
Our referral group is comprised of geographically and ethnically diverse patients 
from most regions of the UK but predominantly England.   
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DIAGNOSIS NUMBER PHENOTYPE NUMBER GENE 
 
Congenital 
Muscular 
Dystrophy 
57 Collagen VI- related 
   (BM =5) 
   (UCMD =17) 
 
Dystroglycanopathy 
 
 
 
 
 
EDMD2* 
 
MDC1A 
 
RSMD1 
 
22 
 
 
 
16 
 
 
 
 
 
4 
 
12 
 
3 
Collagen VI =22 
 
 
 
POMT1 =2 
POMT2 =3 
POMGNT1 =5 
FKRP =5 
LARGE =1 
 
LMNA =4 
 
LAMA2 =12 
 
SEPN1 =3 
 
 
Congenital 
Myopathy 
11 CCD 
 
Myotubular Myopathy 
 
Nemaline Myopathy 
 
CFTD 
 
4 
 
3 
 
3 
 
1 
RYR1 = 4 
 
MTM1 =3 
 
ACTA1 = 3 
 
TPM3 = 1 
Limb Girdle 
Muscular 
Dystrophy 
4 Dystroglycanopathy 4 FKRP = 4 
Congenital 
Myasthenia 
8 Congenital Myasthenia 8 CHRNA1 =2 
COLQ = 1 
DOK7 =3 
RAPSYN =1 
CHRNG =1 
 
Other 3 EDS 
 
RETT Syndrome 
 
Chromosomal 
1 
 
1 
 
1 
Collagen 3a1 =1 
 
MECP2 =1 
 
Chromosomal =1 
TOTAL 83    
 
 
Table 3. Distribution of genetic diagnoses (n=83) in the ‘all referrals’ group 
(n=214). 
 
BM; Bethlem Myopathy, UCMD; Ullrich congenital muscular dystrophy, EDMD2; 
autosomal dominant Emery- Dreifuss muscular dystrophy, MDC1A; merosin 
deficient CMD, RSMD1; rigid spine muscular dystrophy, CCD; central core disease, 
CFTD; congenital fibre type disproportion, EDS; Ehlers- Danlos syndrome. 
*Included in CMD group because of early presentation in these cases. 
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DIAGNOSTIC 
GROUP 
NUMBER PHENOTYPE NUMBER 
 
Congenital Muscular 
Dystrophy 
7 Collagen VI related 
 (BM = 2) 
 (UCMD = 2) 
 
Dystroglycanopathy 
 
4 
 
 
 
3 
Congenital Myopathy 13 Core Myopathy 
 
Centronuclear Myopathy 
 
Myofibrillar Myopathy 
 
Nemaline Myopathy 
 
3 
 
4 
 
1 
 
5 
Other 2 Mitochondrial 
 
Pompe Disease 
1 
 
1 
TOTAL 
 
22   
 
 
Table 4. Distribution of pathological ‘diagnoses’ (n=22) in the ‘all referrals’ 
group (n=214). 
 
BM; Bethlem myopathy, UCMD; Ullrich congenital muscular dystrophy. 
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Congenital Muscular
Dystrophy (30%)
Congenital Myopathy (11%)
Congenital Myasthenia (4%)
Limb Girdle Muscular
Dystrophy (2%)
Other (2%)
Unknown (51%)
 
 Figure 9. Distribution of confirmed diagnoses (molecular or pathological) in 
the ‘all referrals’ group of patients (n=214). 
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Collagen VI 41%
Dystroglycanopathy 30%
MDC1A 21%
EDMD2 6%
RSMD1 5%
  
 
Figure 10. Relative frequency of confirmed CMD diagnoses (n=64) within ‘all 
referrals’ group. 
 
MDC1A; merosin deficient CMD, EDMD2; autosomal dominant Emery- Dreifuss 
muscular dystrophy, RSMD1; rigid spine muscular dystrophy.  
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2.3.2 CMD Subgroup Analysis  
 
For this analysis, patients were chosen from the above 214 who fulfilled the following 
criteria: 
 
1. Dystrophic, myopathic or minimal change muscle biopsy. Patients were 
excluded from this subgroup analysis if biopsy showed additional ‘structural’ 
change (e.g. rods) suggesting an alternative diagnosis. Patients with cores 
were included, as long as RYR1 mutation had been excluded,  as they have 
been reported in patients with RSMD1 and also more rarely in EDMD2 and 
UCMD (CA Sewry and F Muntoni personal communication). 
2. Presentation before 2 years of age with hypotonia, weakness, contractures, 
delayed motor milestones, raised CK or characteristic eye or brain abnormality. 
3. Non CMD diagnoses (or patients in whom alternative diagnosis is strongly 
suspected) excluded. 
 
One hundred and sixteen patients fulfilled all 3 criteria. Average age at biopsy 
assessment was 6.4 years (range 8 days -28.4 years). 37/116 patients were referred 
from Greater London, 79/116 were referred from outside Greater London.  
A molecular diagnosis was reached in 58/116 (46%) patients and a pathological 
subgroup could be assigned to another 5 patients (4%) (Table 5 and Figure 11). 
 
Of the 57 patients in the CMD subgroup with clearly dystrophic biopsies, a molecular 
diagnosis was made in 43 (75%) and a pathological subgroup could be assigned in a 
further 3 patients. 
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Table 5. Distribution of the genetic and pathological diagnoses in the ‘CMD 
subgroup’. 
 
BM; Bethlem Myopathy, UCMD; Ullrich congenital muscular dystrophy, EDMD2; 
autosomal dominant Emery- Dreifuss muscular dystrophy, MDC1A; merosin deficient 
CMD, RSMD1; rigid spine muscular dystrophy. 
 
 
 
 
 
 
 
DIAGNOSIS CMD SUBGROUP NUMBER GENE 
 
Genetic (n=53) Collagen VI related 
  (BM =5) 
  (UCMD =17) 
 
Dystroglycanopathy 
 
 
 
 
 
EDMD2 
 
MDC1A 
 
RSMD1 
 
 
22 
 
 
 
14 
 
 
 
 
 
4 
 
12 
 
1 
Collagen VI =22 
 
 
 
POMT1 =2 
POMT2 =3 
POMGNT1 =4 
FKRP =4 
LARGE =1 
 
LMNA =4 
 
LAMA2 =12 
 
SEPN1 =1 
Pathological (n=5) Collagen VI related 
 
Dystroglycanopathy 
 
2 
 
3 
- 
 
- 
Unknown (n=58) 
 
- 58 - 
Total 
 
 116  
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Figure 11. Graph showing distribution of diagnoses (n=58) in the ‘CMD 
subgroup’. 
 
MDC1A; merosin deficient CMD, EDMD2; autosomal dominant Emery- Dreifuss 
muscular dystrophy,RSMD1; rigid spine muscular dystrophy. 
  
Collagen VI related 21%
Dystroglycanopathy 15%
MDC1A 10%
EDMD2 3%
RSMD1 1%
Unknown 50%
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2.3.3 Skin Biopsies 
 
A CMD diagnosis was also made from analysis of skin biopsy in 5 out of 6 patients in 
whom this was the only biopsy material received. These were all Collagen VI related 
disorders in which the expression of collagen VI was reduced.  
 
2.3.4 Overseas Patients 
 
In addition to the UK patients reported, we also received muscle biopsy samples from 
34 patients from abroad, mostly from the Middle East and Europe. Nineteen of these 
patients were reviewed by the department and a diagnosis was reached in 13/19. In 11 
patients a genetic diagnosis was confirmed, 8 of these were dystroglycanopathy 
patients, 2 had MDC1A and a single patient had a core myopathy. The remaining 2 
patients were diagnosed on the basis of their pathology with a dystroglycanopathy and 
a Collagen VI related disorder.   These patients have been excluded from further 
analysis here as I wanted to present the UK referral data and felt that the overseas 
referrals are overly biased towards our research interests, in particular the 
dystroglycanopathies.  
 
 
2.4 DISCUSSION 
 
 
I present here the diagnostic outcome in a large cohort of UK patients referred to the 
CMD NCG centre for clinical review and muscle biopsy analysis between 2001 and 
2008. The 214 patients reported represent 52% of the UK patients with biopsy samples 
assessed in the NCG Centre during this time. 
 
Examining the ‘all referral’ group, a genetic or pathological diagnosis was made in 49% 
of patients (105/214) referred with ‘possible CMD’. A molecular diagnosis was 
established in 39% of patients (83/214). A total of 64 patients in the “all referral” group 
(30%) had a confirmed (genetic or pathological) diagnosis of CMD.  
 
One hundred and sixteen patients fulfilled the stricter ‘CMD’ inclusion criteria.  A 
diagnosis of CMD was made in 50% of these patients (58/116) and was genetically 
confirmed in 53/116 (46%). Within this group, collagen VI related myopathy was the 
most common diagnosis with 24/116 (21%), followed by dystroglycanopathies with 
17/116 (15%). A diagnosis of MDC1A was made in 12/116 (10%), EDMD2 in 4/116 
(3%) and RSMD1 in 1/116 (1%). Two further genetically proven cases of RSMD1 were 
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excluded from this ‘CMD’ subgroup analysis as they presented after 2 years of age.  I 
found no cases of Integrin α7 deficiency in our population. Diagnoses were not 
determined in 58 cases (50%). It should be noted that we documented a further 5 
cases of collagen VI related disorders confirmed from analysis of skin biopsy alone in 
patients not assessed at our centre and therefore not included in this report,  
reinforcing this as the most prevalent CMD variant in our referral population. 
 
The inclusion of biopsies with cores in the CMD subgroup analysis has almost certainly 
led to the presence of a number of undiagnosed congenital myopathy cases in this 
sample. However, as cores may be observed in RSMD1 and in some cases of EDMD2 
and UCMD, we felt that including these biopsies was appropriate, if RYR1 gene 
mutation had been ruled out. In the CMD subgroup, 6 samples were included with 
myopathic features and cores, only one of these had a confirmed diagnosis (SEPN1 
mutation).   
 
Our results contrast those of a recent Australian study by Peat et al where a specific 
histopathological diagnosis could be allocated in 49% of 101 CMD cases and a 
definitive genetic diagnosis could be made in 24% (229). It should be noted that 
patients with biopsies containing cores were excluded in their study therefore direct 
comparison with our data should be done with care.  Even taking this into account, our 
definitive (genetic) diagnosis rate is almost twice as high (46% v 24%) when comparing 
our data to the Australian CMD cohort. The reasons for the differences in the 
diagnostic pick up rate are most likely a reflection of the fact that all of the patients in 
this study were clinically assessed by the NCG service and that many patients also had 
additional supportive investigations including analysis of collagen VI in fibroblasts and 
muscle MRI imaging to help direct genetic investigations. We have previously reported 
that muscle MRI is a particularly useful diagnostic adjunct in investigating these 
disorders with a high specificity and sensitivity for different subtypes of CMD (40). We 
have found MRI to be especially useful in the case of collagen VI related disorders 
where we have found it to be a more reliable indicator of collagen VI pathology than 
fibroblast analysis. Indeed abnormal production of collagen VI in fibroblast cultures is a 
sensitive indicator but not specific for collagen VI abnormality (Francesco Muntoni- 
unpublished data)  
 
In the Australian study, dystroglycanopathy was found to be the most common group 
representing 25% of cases, with collagen VI abnormalities found in 12% (229). Studies 
from Japan reveal FCMD (a dystroglycanopathy) to be the most prevalent form of CMD 
in the Japanese population (49.2% of CMD cases in one series) but this is due to a 
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FKTN founder mutation. The second most common form of CMD encountered in the 
Japanese population is Collagen VI deficiency with an estimated frequency of 7.2% in 
their CMD cohort. Interestingly, a 2009 paper from the North of England (230) found 
MDC1A to be the most prevalent CMD disorder (0.6/100000) and much more common 
than a CMD presentation of dystroglycanopathy (0.03/100000), UCMD (0.13/100000) 
and RSMD1 (0.13/100000). However, mutations in FKRP are more frequently seen in 
their LGMD cohort (0.43/100000). In addition, BM has an estimated prevalence of 
0.77/100000 in their series but as there is no information about the age of presentation 
of these patients, comparison between the collagen VI related disorders in that study 
and ours is of limited value.  
 
Analysis of our data suggests that MDC1A, in various series of patients reported to be 
the most common form of CMD, is not the most frequent diagnosis in our population, 
as both Collagen VI related disorders and dystroglycanopathy are more prevalent. This 
may be a reflection of improved diagnostic assays and greater awareness of the 
clinical and pathological presentation of other CMD forms; regional variation in the 
prevalence of CMD subtypes may also be implicated. 
 
It is also of interest to note the large number of non CMD diagnoses made in the ‘all 
referrals’ group, reflecting the importance of an integrated approach to the diagnosis of 
these rare and heterogeneous conditions, which includes clinical examination, 
pathological diagnosis and muscle imaging directing the genetic testing. These results 
also confirm our previous observations of conditions resembling CMD, which include 
several congenital myopathies and congenital myasthenias which may show significant 
clinical and pathological overlap with CMD (222). Indeed, the NCG service has now 
expanded to include assessment of congenital myopathy cases as a consequence of 
the diagnostic difficulties presented by these groups of conditions.  
 
Despite our integrated approach, we were unable to reach a diagnosis in just over half 
of the ‘all referrals’ group. These undiagnosed cases are likely to comprise a number of 
non CMD diagnoses, a number who have an as yet undefined form of CMD caused by 
mutations in a novel gene and also some patients with a defined form of CMD in whom 
we are unable to confirm this pathologically or genetically.  Although the sensitivity of 
genetic testing has steadily improved, large heterozygous deletions or duplications are 
likely to be missed using present techniques. In some patients variants of unknown 
significance will have been detected that cannot be proven to be pathogenic using 
current methods. Some of the undiagnosed patients will eventually ‘reveal’ their 
diagnosis as their symptomatology and histopathology evolves.  For example, recent 
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studies highlight the mild initial pathological features in UCMD (234), and the selectivity 
of muscle involvement which characterises many of these conditions (40). In others, a 
diagnosis may be made as a result of new technology, in particular the emergence of 
the NMD chip for block testing neuromuscular disorders in affected individuals. The 
results of the first round of screening for the NMD chip are pending and the first few 
large rearrangements have been detected using this technique. (http://www.nmd-
chip.eu/about). Although the NMD chip as well as recent advances in next generation 
sequencing technologies are very exciting advances in the field of CMD testing, the 
quantity of data generated by such methods and in turn the accurate interpretation of 
results is likely to present its own set of challenges. 
 
With regard to the clinical presentation of the CMDs; although MDC1A is usually seen 
as a classical presentation of severe early weakness, hypotonia and later characteristic 
features on brain MRI, the collagen VI related disorders and dystroglycanopathies are 
frequently more challenging to diagnose due to their often milder phenotypes. In both 
groups and also in EDMD2 and RSMD1, the classification lines between CMD, 
myopathy and LGMD are frequently blurred. This is again reflected in the number of 
cases of LGMD and myopathy seen in our ‘all referrals’ series of patients.  
 
The geographically diverse nature of our referral population unfortunately precludes 
any formal estimation of prevalence or incidence for the different CMD subtypes, none 
the less, the information gathered here I feel is an accurate reflection of clinical activity 
in the CMD NCG service. It is of interest to note that over 50% of patients from outside 
greater London were represented in our patient population highlighting the nationwide 
uptake of services. 
 
In summary, the data presented in this study represents the largest series of UK CMD 
referral data and diagnostic outcome reported. It reveals Collagen VI related to be the 
most common form of CMD in our patient group, accounting for 21% of referrals that 
fulfil the CMD inclusion criteria. Patients with dystroglycanopathy follow closely behind 
accounting for 15% with MDC1A seen in 10%. There remain a large proportion of 
cases (50%) that fulfil the clinical and pathological criteria for CMD, in whom no 
diagnosis can be made. This suggests that further CMD subtypes and genes are yet to 
be discovered. 
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CHAPTER 3:  REFINING THE GENOTYPE-
PHENOTYPE RELATIONSHIP IN A LARGE 
COHORT OF DYSTROGLYCANOPATHY 
PATIENTS. 
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3.1  GENOTYPE PHENOTYPE CORRELATION IN A LARGE COHORT OF 
DYSTROGLYCANOPATHY PATIENTS 
 
 
3.1.1 Introduction 
 
Genotype-phenotype correlation in the dystroglycanopathies: a historical perspective. 
 
Dystroglycanopathy phenotypes have been recognised for many decades, although it 
has only been in recent years that the pathological and molecular basic for these 
disorders has begun to be unravelled. Walker Warburg Syndrome (WWS) is named 
after Walker who first identified the type 2 lissencephaly associated with the condition 
and Warburg who reported several more cases, appreciating the autosomal recessive 
inheritance (235, 236). Eye abnormalities were identified as a concurrent feature by 
Whitley et al. in 1983 and associated the myopathy was identified in 1984 (237, 238). 
WWS had also been reported by a number of other investigators and has historically 
been known by several other names including HARD +/- E (Hydrocephalus, Agyria, 
Retinal Dysplasia +/- Encephalocele) and COD-MD (Cerebro-Oculo-Dysplasia/ 
Muscular Dystrophy)(239, 240).  In 1989, Dobyns and co-workers reported a large 
series of new patients and reviewed the existing literature leading to the establishment 
of diagnostic criteria and the appreciation that many of the previously reported 
conditions were in fact the same disease entity (241). They proposed 4 key diagnostic 
criteria including type 2 lissencephaly (cobblestone complex), retinal abnormality, CMD 
and cerebellar malformation. A number of other clinical features were also reported but 
were not considered essential for diagnosis.  
 
Muscle Eye Brain disease (MEB) was first identified in the Finnish population. The key 
features of CMD, ophthalmic abnormality and hydrocephalus were originally reported in 
1977(242). Subsequent reports, again of Finnish patients, followed in the 1980’s, 
highlighting the extent of the brain abnormality, including cortical migration abnormality 
consistent with type 2 lissencephaly, but not as severe as that seen in WWS(243, 244).  
 
Fukuyama Congenital Muscular Dystrophy (FCMD) was first reported in 1960 by 
Fukuyama et al. who identified 15 cases in Japan with CMD and associated structural 
brain abnormalities (212). By 1981 more than 200 cases had been recognised in Japan 
although it had not been seen outside of this population. Key features seen in FCMD 
include mental retardation, seizures, type 2 lissencephaly, cerebral and cerebellar 
polymicrogyria, hydrocephalus and hypoplasia of the corticospinal tracts (245, 246). 
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Lissencephaly type 2 is a feature common to all 3 disorders. Lissencephaly describes a 
smooth appearance of the cerebral cortex. It is caused by defective neuronal migration 
during development of the cerebral cortex and is found in a variety of disorders. 
Lissencephaly type 2 however, is an unusual finding and is caused by the 
overmigration of neurones through the basal lamina resulting in a nodular ‘cobblestone’ 
appearance to the cerebral surface (247).  This is covered in more detail in section 
4.1.1.  
 
The common finding of type 2 lissencephaly in WWS, MEB and FCMD led researchers 
to consider the relationship between these conditions. Indeed Dobyns et al. postulated 
that WWS and MEB were in fact the same entity, whilst Santavuori et al. thought that 
there were enough differences between the 2 disorders to consider them separate 
disorders (241, 248, 249). In particular, Santavuori considered that MEB tended to 
have milder cerebellar malformations and pachygyria +/- polymicrogyria rather than 
large areas of lissencephaly. The eye abnormalities in MEB were often juvenile onset 
and progressive rather than the congenital abnormalities frequently observed in WWS. 
Both research groups agreed that FCMD, although similar in many aspects, was a 
different condition to both WWS and MEB. In particular, cerebellar and eye 
abnormalities were not a prominent feature and the clinical course was generally less 
severe. A later study by Yoshioka et al. (250) highlighted the differences between 
FCMD and MEB/ WWS but also revealed a clinical overlap between the more severe 
FCMD and the milder WWS/ MEB cases. The lack of genetic and molecular data at this 
time prevented any definitive conclusions being drawn about how these conditions 
related to each other. 
 
The first major advance in understanding the relationship between these three 
conditions came with the identification of the FCMD locus and subsequent reports of 
mutations in the Fukutin (FKTN) gene in 1998 (127, 215). A common founder 
retrotransposal insertion was found in more than 80% of FCMD chromosomes, 
accounting for the high prevalence of FCMD in the Japanese population. This was 
followed in 1999 with the localisation of the MEB locus 1p32-p34 and in 2001 by the 
report of protein O-linked mannose β1,2-N-acetlyglucosaminyltransferase 1 
(POMGnT1) mutations in Finnish and Turkish patients with MEB (129, 209). Cormand 
et al. subsequently analysed a large cohort of MEB and WWS patients and effectively 
excluded linkage to 1p32-p34 from all but 1 patient with diagnostic criteria compatible 
with WWS. Conversely all patients except 1 Swedish girl with features consistent with 
MEB linked to the locus. The first gene identified in patients with WWS was reported a 
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few years later when Protein O-mannosyltransferase (POMT1) was found to be 
mutated in 20% of a WWS patient cohort (130). This provided strong initial evidence for 
the genetic distinction between MEB and WWS although did not provide an explanation 
for the similarity observed between the conditions (206). 
 
 
The recognition of the ‘dystroglycanopathies’ as a specific pathological subgroup 
defined by hypoglycosylation of ADG marked a key turning point and heralded the 
discovery of mutations in three further genes, FKRP, LARGE and POMT2. All were 
good candidate genes because of homology to existing genes or in the case of 
LARGE, involvement in the LargeMyd mouse.  
 
In 2009, after this research was completed, a further gene, Dolichyl-phosphate 
mannosyltransferase polypeptide 3 (DPM3) was identified. Mutations in this gene have 
been shown to give rise to CDG1o, a condition with features overlapping that of a 
dystroglycanopathy and congenital disorder of glycosylation. This gene has been 
excluded from the remaining discussion in this section as its discovery postdates the 
research, hence all references to the ‘6 known genes’ refer to POMT1, POMT2, 
POMGNT1, FKRP, FKTN and LARGE. 
 
As more patients were described with mutations in the 6 known genes, it became 
increasingly apparent that the phenotype associated with mutations in a specific gene 
could be very variable, demonstrated best by the wide spectrum of severity seen in 
patients with mutations in FKRP, where patients may be severely affected by WWS, 
mildly affected by LGMD2I or exhibit a phenotype in between the 2 extremes. In 
addition to the WWS phenotype, POMT1 mutations were subsequently described in 
patients with CMD and microcephaly with mild mental retardation (termed CMD-mental 
retardation) (251) and also in patients with LGMD with microcephaly and mental 
retardation (LGMD2K)(125, 252). FKTN mutations were also isolated in non Japanese 
patients with WWS and then subsequently in patients with a predominant dilated 
cardiomyopathy phenotype with minimal muscular involvement (CMD1X)(32, 207, 
226). 
 
Identifying the molecular genetic basis for the dystroglycanopathy phenotypes, far from 
clarifying the question of whether to lump or split this group of conditions, clouded the 
situation further. In brief, most phenotypes could be caused by more than one gene 
and conversely some genes could cause more than one phenotype.  The phenotypes 
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and associated genes known in 2006, at the start of this work, are summarised in Table 
6. Due to the numerous different names given to the milder phenotypes, for clarity, 
these have been simplified into CMD or LGMD with and without mental retardation, 
with other names referenced as necessary. 
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  Phenotype 
Gene  WWS  MEB  FCMD  CMD‐CRB  CMD ‐ MR  CMD – no 
MR 
LGMD ‐MR  LGMD – no 
MR 
CMD 1X 
POMT1  •(130, 251, 
253) 
      •(130, 251, 
253) 
  •(125, 252)a     
POMT2  •(132)  •(210)               
POMGNT1    •(129, 254)               
FKTN  •(208, 226)    •(127, 255)          •(126)  •(32) 
FKRP  •(207)  •(207)    •(211)  •(211)  •(128)b    •(192)c   
LARGE          •(131)d         
 
Table 6.  Summary of the main dystroglycanopathy phenotypes, associated gene defects and key references prior to 
commencement of our study. The phenotype initially associated with each gene is shaded in grey.   
 
WWS; Walker Warburg Syndrome, MEB; Muscle Eye Brain Disease, FCMD; Fukuyama CMD, CMD-CRB; CMD with cerebellar 
involvement, CMD - MR; CMD with mental retardation, CMD –no MR; CMD without mental retardation, LGMD - MR; LGMD with mental 
retardation, LGMD –no MR; LGMD without mental retardation, CMD1X; dilated cardiomyopathy 1X. 
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a Phenotype also reported in literature as LGMD2K, b Phenotype also reported in literature as MDC1C, c Phenotype also reported in the 
literature as LGMD2I, d Phenotype also reported in the literature as MDC1D. 
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Whilst a lot of information was being published on this group of disorders, the relative 
rarity of these conditions meant that data was not available regarding the extent to 
which molecular and phenotypic overlap occurred and also the proportion of patients 
for which all known genes could be excluded. Our department found itself in the 
fortunate position of being able to address this issue, having accumulated a significant 
number of DNA and muscle biopsy samples from patients with dystroglycanopathies, 
due a to prior research interest in this field.  
 
All previous studies had been conducted on a small number of families or individuals. 
This causes inevitable difficulties in applying mutation detection rates to the general 
population. In addition such reports make it difficult to establish whether the described 
clinical spectrum is truly representative of the phenotypic variability and also how 
common the originally described core phenotypes are for each of these genes. In order 
to address these points, we systematically screened a large population of patients with 
a secondary dystroglycanopathy phenotype for mutations in the associated genes. As 
the spectrum of phenotypes secondary to FKRP involvement has been previously 
reported by us and others, we studied ninety seven patients in whom involvement of 
this gene had been excluded before proceeding with analysis of the 5 remaining genes. 
Patients in whom findings of particular interest were noted, have been investigated 
further with functional studies and are reported in detail.  
 
This comprehensive study redefines the clinical spectrum associated with each of the 
glycosyltransferase genes studied, identifies the frequency of individual gene defects 
and suggests that the majority of patients with a dystroglycanopathy do not have 
mutations in any of the known genes.  
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3.1.2 Patients and Methods  
 
Patients. 
 
The cohort consisted of 92 unrelated individuals including a large group of patients 
from Australia (27 patients) and Turkey (16 patients). The majority of the remaining 
patients were recruited via the Hammersmith Hospital National Commissioning Group 
(NCG) service and included DNA from individuals referred from across the UK and 
Europe with a few samples from further afield. Mutations in FKRP had previously been 
excluded in all cases(128). Criteria for inclusion included hypoglycosylation of ADG at 
the sarcolemma of skeletal muscle demonstrated by immunolabelling (4, 256). Eighty 
patients met these criteria whilst in the remaining 12 cases there was no muscle 
available for ADG studies. In the remaining 12 patients, inclusion in the cohort was 
justified due to their clinical phenotype being highly suggestive of a dystroglycanopathy 
and consisted of children with CMD, elevated serum CK and brain MRI evocative of 
type 2 lissencephaly. Common CMD and LGMD conditions (dystrophinopathy, LGMDs 
such as sarcoglycanopathies, calpainopathy and dysferlinopathy, merosin deficient 
CMD and collagen VI deficiency) were excluded in all patients with available muscle 
biopsy by standard immunocytochemical and/or Western blotting analysis (4). Clinical 
data was collated and patients were divided into defined phenotypic categories. This 
study was approved by Hammersmith Hospital Ethics Committee REC 2000:/5802. 
Control samples were from a cohort of parental bloods of White European ethnicity 
following ethical approval by the Hammersmith and Queen Charlotte’s and Chelsea 
Trust Research Ethics Committee (2001/6029).  
 
Molecular Genetics.  
 
Mutation screening was performed by Caroline Godfrey whilst working at the DNA 
laboratory, GSTS Pathology at Guy’s Hospital.  
 
Genomic DNA was extracted in the referring centre’s laboratory using standard 
protocols. All mutation scanning was performed in the DNA laboratory at Guy’s 
Hospital. The complete coding regions, including intron / exon boundaries of POMT1, 
POMT2, POMGNT1, FKTN and LARGE were amplified by PCR. Single nucleotide 
polymorphisms (SNP) within the primer binding sites were avoided using the 
Diagnostic SNP Check software (ngrl.man.ac.uk/SNPCheck). Amplicons were 
screened for mutations using a combination of uni-directional sequencing using 
standard dideoxynucleotide methodology and heteroduplex analysis as previously 
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described (257). Where available, parental DNA was studied once a sequence 
alteration was identified in the proband. In two families, further segregation analysis 
was carried out to investigate the potential pathogenicity of unclassified variants. In 
families where a de novo mutation was suspected, paternity was confirmed using 11 
STR markers. Mutation nomenclature based on the following GeneBank Accession 
numbers; POMT1; NM_007171.2, POMT2; NM_013382.3, POMGnT1; NM_017739.1, 
FKTN; NM_006731.1 and LARGE; NM_133642.2, with nucleotide number 1 
corresponding to the first base of the translation initiation codon.  
 
3.1.3 Results 
 
Clinical Findings  
 
Patients were classified as having either a CMD or LGMD phenotype and further 
subdivided according to the degree of structural and functional brain involvement. CMD 
was defined as onset of weakness prenatally or within the first 6 months of life. LGMD 
was defined by later onset weakness, specifically after having acquired ambulation. 
The cohort consisted of a total of 64 patients with CMD and 25 patients with LGMD, a 
total of 59 patients had brain involvement. In three patients the clinical information was 
insufficient to be able to assign a phenotypic category. Patients were divided into 1 of 7 
phenotypic categories summarised below; 
 
1) WWS (and WWS-like): Onset prenatally or at birth. Patients assigned to this 
category had severe structural brain abnormalities including complete agyria or severe 
lissencephaly with only rudimentary cortical folding, marked hydrocephalus, severe 
cerebellar involvement and complete or partial absence of the corpus callosum.  Eye 
abnormalities including congenital cataracts, microphthalmia and buphthalmos were 
common. When MRI evidence was not available, death before 1 year of age was taken 
as suggestive of this category if other clinical findings were supportive (206). Motor 
development was typically absent in these patients. Five patients were assigned to this 
group. 
 
2) MEB/ FCMD-like: These categories were merged due to the overlapping phenotypic 
features. Included in this group were CMD with brain abnormality less severe than that 
seen with WWS. MRI findings include pachygyria with preferential frontoparietal 
involvement, polymicrogyria, cerebellar hypoplasia and dysplasia and frequent 
flattening of the pons and brainstem. Eye abnormalities are often seen and include 
congenital glaucoma, progressive myopia, retinal atrophy and juvenile cataracts. 
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Individuals may, rarely, acquire the ability to walk although this is delayed. Rarely 
patients manage to learn a few spoken words. Thirty patients were assigned to this 
group, including one in whom the clinical information was limited.  
 
3) CMD-CRB (CMD with cerebellar involvement): This category included CMD with 
mental retardation and cerebellar involvement on MRI scan as the only structural 
abnormality. Cerebellar abnormalities may include cysts, as described relatively 
frequently in individuals with FKRP gene defects (258) or cerebellar hypoplasia or 
dysplasia. Four patients were assigned to this group. 
 
4) CMD-MR (CMD with mental retardation): CMD with mental retardation and 
structurally normal brain. Patients with isolated microcephaly or minor white matter 
changes on MRI are included in this group. Fifteen patients were assigned to this 
group, including two with limited clinical information. 
 
5) CMD-no MR (CMD with no mental retardation): Several patients within this group 
have not had neuroimaging but had entirely normal intellectual function. Ten patients 
were assigned to this group, one with limited information. 
 
6) LGMD-MR (LGMD with mental retardation): LGMD with mental retardation and 
structurally normal brain. Patients with minor white matter abnormalities and 
microcephaly were included in this group. This category would include patients with a 
phenotype resembling LGMD-2K (125). Five patients were assigned to this group. 
 
7) LGMD-No MR (LGMD with no mental retardation): LGMD with no mental 
retardation. This category would include the LGMD phenotypes resembling LGMD2I 
and 2L (257). Twenty patients were assigned to this group, six with limited clinical 
information. 
 
The division of phenotypes within the cohort is shown in Table 10. Detailed clinical 
information is contained in Table 7 for those patients in whom pathogenic mutations 
were detected. 
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2yr 
N/A N/A U U N/A L N/A WM N/A 
5 LOW LGMD-MR I 4000 W N Y U U N/A L Y Normal N/A 
6 LOW LGMD-MR 3Yr 8000 W  Y N/A U N/A L Y WM- minimal N/A 
7 LOW CMD-MR I 3600 St N Y U U N/A L  Y Normal N/A 
8 LOW CMD-MR 4m 18000 W N/A Y RS N/A N/A L Y WM- minimal Choreic Movement 
disorder 
9 LOW MEB-FCMD N 5500 S Y Y RS, 
Sc 
N/A N/A L Y WM, BS N/A 
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10 LOW MEB-FCMD 4Yr 5200 NW N Y U  N/A L Y Encephalocele N/A 
11 LOW MEB-FCMD 7m N/A NS Y N U Hm N/A  N/A H, WM,CC,  N/A 
12 LOW MEB-FCMD N 3100 NS Y N/A RS  UL>L
L 
L Y WM N/A 
13 N/A MEB-FCMD 8m  W N/A Y U My UL>L
L 
L N WM , CDys, 
CC,PMG 
N/A 
14 LOW MEB-FCMD N 6000 S Y Y Sc CC N/A L Y BS,H,WM SE, RIP age 11yr 
15a N/A CMD-CRB I 4700 W Y Y N/A N/A UL>L
L 
L Y N/A N/A 
15b N/A CMD-CRB I 5200 S N/A N/A N/A N/A N/A L N/A CHy Micropenis and 
cryptorchidism 
16 LOW LGMD-MR 18m 1900 W N Y U N/A N/A L N/A NO MRI RBBB on ECHO 
17 LOW MEB-FCMD N 2000 NS Y Y N/A My UL,L
L 
L Y CHy, H Macroglossia 
18 LOW MEB-FCMD I 780 NW N N N/A CG N/A L N/A BS,CC,WM,H N/A 
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19 LOW MEB-FCMD P 1000 W Y Y U OA, My N/A L N WM,CC SE, feeding 
difficulties 
20 LOW LGMD-no 
MR 
12 Yr 12000 R N Y U My LL>U
L 
NI N  N/A 
21 LOW MEB-FCMD N 1200 NONE N N U RD N/A L N/A H,WM,CC SE, feeding 
difficulties.  
22 LOW  MEB-FCMD 12m 2800 R N N/A U Pt, RA N/A L N/A CHy, CC, WM,H Dyspraxia, feeding 
difficulties, SE 
23 LOW MEB-FCMD N/A N/A N/A N/A N/A N/A N/A N/A N/A N/A H,CC,WM N/A 
24 N/A WWS N 1300 NS N/A N/A U N/A N/A L N/A CC,CHy, WM, H,Lis N/A 
25 LOW WWS P 5700 NONE Y   RDy  L  H,WM,CHy, Lis Feeding difficulties, 
RIP 8 weeks 
26 LOW CMD-no MR 3Yr 3200 S N N U U G NI N/A WM-MILD Hypothyroid 
27 N/A MEB-FCMD I 4000 S N Y U U N/A L N/A CC,WM,H  
28 LOW WWS N 7000 N/A Y Y U RD,Mo N/A  N/A WM,CHy, BS, H Dysmorphic 
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29a LOW LGMD-no 
MR 
4m 10000 W N Y N/A N/A UL>L
L 
NI N N/A Steroid responsive 
29b LOW LGMD-no 
MR 
4m 13000 W N Y U U LL>U
L 
NI N Normal Steroid responsive 
30 LOW LGMD-no 
MR 
10m 60000 W N Y U U LL>U
L 
NI N H-MILD Steroid responsive 
31a LOW LGMD-no 
MR 
4yr 9000 R Y N/A U N/A N/A NI N/A N/A N/A 
 
Table 7.  Clinical Characteristics of 33 individuals from 31 families in whom mutations were detected. 
a WWS; Walker-Warburg Syndrome, MEB/FCMD; Muscle-Eye-Brain/Fukuyama Congenital Muscular Dystrophy, CMD-MR; Congenital 
Muscular Dystrophy with Mental Retardation, CMD-no MR Congenital Muscular Dystrophy with no Mental Retardation, CMD-CRB; 
Congenital Muscular Dystrophy with Cerebellar Involvement, LGMD-MR; Limb Girdle Muscular Dystrophy with Mental Retardation, 
LGMD-no MR; Limb Girdle Muscular Dystrophy with no Mental Retardation. b P; prenatal onset, N; neonatal onset, I; infant onset, Yr; 
years, m; months. c W; walk, S; sit, St; stand, R; run, Prefix N; never. d-e Y; yes, N; no. f RS; rigid spine, Sc; scoliosis, U; unaffected. g CG; 
congenital glaucoma, RD; retinal detachment, RA; Retinal Atrophy, CC; Congenital cataracts, OA; optic atrophy, My; myopia, Mo; 
microphthalmia, Pt; ptosis, U; unaffected, Hm; hypermetropia, RDy; retinal dysplasia. h UL; Upper limbs, LL; lower limbs, G; generalised, i 
NI; normal intelligence, L; low, j Y; yes, N; no, k H; Hydrocephalus, CC; cerebellar cysts, BS; brainstem involvement, WM; white matter 
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abnormality, CHy; cerebellar hypoplasia, Lis; lissencephaly, CDys; cerebellar dysplasia. l SE; seizures, CDH; congenital dislocation of hip, 
RBBB; Right bundle branch block. 
 
 
102 
 
Mutation Analysis 
 
Mutation screening of POMT1, POMT2, POMGNT1, FKTN and LARGE was performed 
on 92 probands in whom FKRP mutations had been previously excluded. Homozygous 
and compound heterozygous mutations were detected in a total of 31 probands (34 
individuals from 31 families). Thirty seven different mutations were identified, 32 of 
which had not been previously reported. Pathogenic mutations are summarized in 
Table 8, the comparative pick up between genes is represented in Figure 12 and their 
locations within each gene are represented In Figure 13. 
 
Without further RNA studies and functional biochemical analysis it is often difficult to 
determine the pathogenicity of unclassified variants within these genes, this is 
exacerbated by the abundance of missense variants. For the purposes of this study, 
nonsense mutations, insertions and deletions, splice site mutations as well as 
previously reported mutations were classified as pathogenic. Both exonic and intronic 
sequence alterations were categorized as polymorphisms if they were present on The 
Single Nucleotide Polymorphism database (http://www.ncbi.nlm.nih.gov), the Leiden 
database (http://www.dmd.nl) or present as an additional change in a patient with two 
proven pathogenic mutations. Amino acid substitutions were classified as pathogenic if 
they were detected in conjunction with a clearly pathogenic mutation or if they have 
been shown to segregate with disease in a large pedigree. In addition, two patients 
with homozygous missense mutations and one patient with compound heterozygous 
missense mutations have been included in Table 8 as they are non-conservative amino 
acid changes that affected an evolutionary conserved amino acid residue (Patient 16, 
Patient 18 and Patient 27). Patients in whom only a single sequence alteration was 
detected are summarised in Table 9. We have been unable to determine whether these 
are rare polymorphisms or pathogenic alterations in patients who harbor a second 
undetectable mutation. These patients have not been included in the 34% of patients 
with mutations. Patient 25 has been included in Tables 7, 8  and 10 as well as Figures  
12 and 13 despite the absence of a second detectable mutation due to the presence of 
a nonsense mutation.  
 
A variety of mutation types were identified; 37 missense mutations; 7 nonsense 
mutations; 9 frameshift mutations; 1 insertion/deletion mutation; 1 deletion and 6 splice 
site mutations, no mutation hot spots were identified. From a total of 37 mutations, 8 
were found to be recurrent within the cohort. The p.Ala200Pro mutation in POMT1, 
previously described as prevalent within the Turkish population (125), was detected in 
three patients, one of whom was of Greek decent (Patient 8). The POMGNT1 donor 
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splice site mutation c.1539+1G>A found to account for the enrichment of MEB within 
the Finnish population was detected in two patients (259). Three further novel 
mutations were detected more than once, specifically the p.Tyr666Cys mutation which 
was found both in the homozygous and heterozygous state in 4 patients. Segregation 
of this novel missense mutation was studied in a large pedigree and was found to 
segregate with the disease (Patient 15). Parental samples where studied for 11 
probands to ensure that compound heterozygous mutations were in trans and that 
apparent homozygous mutations in the proband were not masking undetected 
deletions. Where parental DNA was tested (22 families in total) a single paternal 
mutation was found to occur de novo (p.Phe117Ser, POMT2). A relatively similar 
frequency of patients with mutations were detected in POMT1, POMT2, POMGNT1 
and FKTN (Figure 12). In contrast, only a single patient was found to have a 
pathogenic mutation in LARGE although we were unable to confirm a second 
pathogenic mutation (Patient 25).  
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Patient  Gene Exon/ intron  Nucleotide change Predicted amino acid change Mutation type References
1  POMT1
POMT1 
20 
20 
c.2179_2180delTC
c.2179_2180delTC 
p.Ser727fs 
p.Ser727fs 
Frameshift
Frameshift 
Novel
Novel 
2  POMT1
POMT1 
20 
20 
c.2179_2180delTC
c.2179_2180delTC 
p.Ser727fs 
p.Ser727fs 
Frameshift
Frameshift 
Novel
Novel 
3  POMT1
POMT1 
7 
7 
c.598G>C
c.598G>C 
p.Ala200Pro 
p.Ala200Pro 
Missense
Missense 
Leiden database
Leiden database 
4  POMT1
POMT1 
18 
3 
c.1847_1849delGGT  
c.193G>A 
p.Trp616del   
p.Gly65Arg 
Deletion
Missense 
Novel
Leiden database 
5  POMT1
POMT1 
11 
19 
c.1081C>T
c.2005G>A 
p.Gln361X 
p.Ala669Thr 
Nonsense  
Missense 
Novel 
Novel 
6  POMT1
POMT1 
6 
18 
c.517_523delTTCTTCAinsG
c.1868G>C 
p.Phe173_Asn175delinsAsp
p.Arg623Thr 
Insertion/deletion  
Missense 
Novel 
Novel 
7  POMT1
POMT1 
7 
7 
c.598G>C
c.598G>C 
p.Ala200Pro 
p.Ala200Pro 
Missense
Missense 
Leiden database
Leiden database 
8   POMT1
POMT1 
5 
7 
c.427G>T
c.598G>C 
p.Glu143X 
p.Ala200Pro 
Nonsense  
Missense 
Novel
Leiden database 
9   POMT2
POMT2 
21 
21 
c.2150T>C
c.2177G>A 
p.Phe717Ser 
p.Gly726Glu 
Missense  
Missense 
Novel (de novo)
Leiden database 
10  POMT2
POMT2 
19 
19 
c.1997A>G
c.1997A>G 
p.Tyr666Cys 
p.Tyr666Cys 
Missense
Missense 
Novel
Novel 
11  POMT2
POMT2 
19 
11 
c.1997A>G
c.1238G>C 
p.Tyr666Cys 
p.Arg413Pro 
Missense  
Missense   
Novel
Novel 
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Patient  Gene Exon/ intron  Nucleotide change Predicted amino acid change Mutation type References
12   POMT2
POMT2 
20 
9 
c.2047A>C
c.1051delG 
p.Thr683Pro 
p.Ala351fs 
Missense
Frameshift 
Novel
Novel 
13  POMT2
POMT2 
5 
19 
c.593T>A
c.1997A>G 
p.Ile198Asn 
p.Tyr666Cys 
Missense  
Missense 
Novel
Novel 
14  POMT2
POMT2 
10 
5 
c.1117G>T
c.593T>A 
p.Val373Phe 
p.Ile198Asn 
Missense
Missense 
Novel
Novel 
15a, 15b *  POMT2
POMT2 
19 
19 
c.1997A>G
c.1997A>G 
p.Tyr666Cys 
p.Tyr666Cys 
Missense
Missense 
Novel
Novel 
16  POMT2
POMT2 
5 
21 
c.551C>T
c.2243G>C 
p.Thr184Met 
p.Trp748Ser 
Missense  
Missense 
Novel
Novel 
17  POMT2
POMT2 
9 
21 
c.1057G>A
c.2177G>A 
p.Gly353Ser 
p.Gly726Glu 
Missense  
Missense 
Novel 1
Novel 1 
18  POMGNT1
POMGNT1 
6 
6 
c.526A>C
c.526A>C 
p.Thr176Pro 
p.Thr176Pro 
Missense
Missense 
Novel
Novel 
19  POMGNT1
POMGNT1 
7 
17 
c.652+1G>A  
c.1469G>A   
Donor splice site
p.Cys490Tyr 
Splice site 
Missense 
Novel
Leiden database 
20 *†  POMGNT1
POMGNT1 
20 
20 
c.1666G>A
c.1666G>A 
p.Asp556Asn 
p.Asp556Asn 
Missense
Missense 
Novel 2
Novel 2 
21  POMGNT1
POMGNT1 
17 
17 
c.1539+1G>A
c.1539+1G>A 
Donor splice site
Donor splice site 
Splice site
Splice site 
Leiden database
Leiden database 
22  POMGNT1
POMGNT1 
12 
17 
c.1100G>A
c.1539+1G>A   
p.Arg367His 
Donor splice site 
Missense
Splice site 
Novel
Leiden database 
23  POMGNT1
POMGNT1 
20 
20 
c.1785+2T>G
c.1785+2T>G 
Donor splice site
Donor splice site 
Splice site
Splice site 
Novel
Novel 
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Patient  Gene Exon/ intron  Nucleotide change Predicted amino acid change Mutation type References
24  POMGNT1
POMGNT1 
17 
17 
c.1425G>A
c.1425G>A 
p.Trp475X 
p.Trp475X 
Nonsense
Nonsense 
Novel
Novel 
25  LARGE 13  c.1548C>G p.Trp516X  Nonsense Novel
26  FKTN
FKTN 
8 
8 
c.920G>A
c.920G>A 
p.Arg307Gln 
p.Arg307Gln 
Missense
Missense 
Leiden database
Leiden database 
27  FKTN
FKTN 
8 
8 
c.915G>A
c.915G>A 
p.Trp305Cys 
p.Trp305Cys 
Missense
Missense 
Novel
Novel 
28  FKTN
FKTN 
8 
8 
c.919C>T
c.919C>T 
p.Arg307X 
p.Arg307X 
Nonsense
Nonsense 
Novel
Novel 
29a, 29b   FKTN
FKTN 
8 
9 
c.920G>A
c.1167dupA 
p.Arg307Gln 
p.Phe390fs 
Missense 
Frameshift 
Novel 3
Leiden database 3 
30   FKTN
FKTN 
9 
10 
c.1167dupA
c.1363delG 
p.Phe390fs 
p.Asp455fs 
Frameshift
Frameshift 
Leiden database 3
Novel 3 
31a, 31b  FKTN
FKTN 
4 
7 
c.340G>A
c.859delA 
p.Ala114Thr 
p.Thr286fs 
Missense
Frameshift 
Novel
Novel 
 
Table 8. A summary of pathogenic mutations detected in this study.  
Probands are numbered. Affected siblings are indicated with letters. * Family studies carried out to investigate segregation of the variant 
through the pedigree. † Functional characterisation escribed in section 3.2. The following patients have been reported individually; 1 
Patients previously described in Mercuri et al. 2006. 2 Patients previously described in Clement et al. 2007. 3 Patients previously described 
in Godfrey et al. 2006.  
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Patient  Gene Exon/intron  Nucleotide change Predicted amino acid change Mutation type References
32  POMT1 9  c.905T>G p.Phe302Cys  missense Novel
33  POMT1 19  c.1922C>T p.Ala641Val missense Novel
34  POMT1  20  c.2203C>T p.Arg735Cys  missense Novel
35  POMT1
POMT1 
20 
20 
c.2248+5A>G
c.2248+5A>G 
intronic
intronic 
intronic
intronic 
Novel
Novel 
36  POMT1 20  c.2246G>A synonymous synonymous Novel
37,38,39  POMGNT1 21  c.1867A>G p.Met623Val missense Novel
39  LARGE 4  c.309C>A synonymous synonymous Novel
40  LARGE 12  c.1431C>T synonymous synonymous Novel
41  LARGE 13  c.1640G>A p.Arg547His missense Novel
42,43  LARGE 14  c.1827A>T synonymous synonymous Novel
 
Table 9.  Summary of Unclassified Variants 
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  WWS  MEB/FCMD CMD‐CRB CMD‐MR CMD‐no MR  LGMD‐MR LGMD‐no MR Total
POMT1  1 1 ‐ 3 ‐  3 ‐ 8
POMT2  ‐ 6 2 ‐ ‐  1 ‐ 9
POMGNT1  ‐ 6 ‐ ‐ ‐  ‐ 1 7
FKTN  1 1 ‐ ‐ 1  ‐ 3 6
LARGE  1 ‐ ‐ ‐ ‐  ‐ ‐ 1
Mutation 
detected 
3 (60%)  14 (47%) 2 (50%) 3 (20%) 1 (10%)  4 (80%) 4 (20%) 31 (34%)
Patient total  5 30 4 15 10  5 20 92 *
 
Table 10.  The phenotypic distribution of patients within the cohort, the frequency of mutations in each of the five 
glycosyltransferase genes analysed and the comparative mutation frequencies for individual clinical categories.  
 
WWS; Walker-Warburg syndrome, MEB/FCMD; Muscle-Eye-Brain disease/ Fukuyama Congenital Muscular Dystrophy, CMD-CRB; 
Congenital Muscular Dystrophy with Cerebellar Involvement, CMD-MR; Congenital Muscular Dystrophy with Mental Retardation, CMD-no 
MR; Congenital Muscular Dystrophy with no Mental Retardation, LGMD-MR; Limb Girdle Muscular Dystrophy with Mental Retardation, 
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LGMD-no MR; Limb Girdle Muscular Dystrophy with no Mental Retardation. * Includes three patients not assigned a clinical classification 
due to insufficient clinical information. 
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Figure 12.  Comparative mutation detection rate for different phenotypic categories.  
 
WWS; Walker-Warburg syndrome, MEB/FCMD; Muscle-Eye-Brain syndrome/ Fukuyama Congenital Muscular Dystrophy, CMD-CRB; 
Congenital Muscular Dystrophy with Cerebellar Involvement, CMD-MR; Congenital Muscular Dystrophy with Mental Retardation, CMD-no 
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MR; Congenital Muscular Dystrophy with no Mental Retardation, LGMD-MR; Limb Girdle Muscular Dystrophy with Mental Retardation, 
LGMD-no MR; Limb Girdle Muscular Dystrophy with no Mental Retardation. 
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3.1.4 Discussion 
 
Secondary dystroglycanopathies are a recently defined, common group of muscular 
dystrophies encompassing an extremely wide spectrum of clinical severity and are 
caused by mutations in at least 6 genes encoding putative or demonstrated 
glycosyltransferases. The comparatively small coding region of FKRP has facilitated 
the rapid identification of correlations between genotype and phenotype, allowing the 
discovery of pathogenic mutations in patients with CMD and LGMD, with and without 
structural brain involvement. Specific phenotypes attributed to mutations in FKRP 
include LGMD2I, MDC1C, MEB-like and WWS-like disorders. However, there is no 
information regarding the frequency of involvement in a large and unbiased population, 
or on the genotype-phenotype relationships for the remaining 5 glycosyltransferase 
genes in a large and unbiased population.   
In this study we have systematically screened for mutations in POMT1, POMT2, 
POMGNT1, FKTN and LARGE in a large cohort of patients in whom we had previously 
ruled out FKRP gene involvement. Mutations were detected in 34% of these patients. 
 
POMT1 mutations 
 
Mutations in POMT1 have previously been reported in patients with WWS, CMD-MR 
and LGMD-MR (LGMD-2K). Within our cohort all patients with mutations in POMT1 
had evidence of functional brain involvement, either with no clear associated structural 
brain abnormalities (as in 3 patients with LGMD-MR (LGMD2K), and in 3 patients with 
CMD-MR), or more severe conditions with structural brain defects (one patient with 
WWS, and one individual with a MEB-like phenotype). This suggests that the majority 
of patients with POMT1 mutations have either functional or structural central nervous 
system involvement, including those patients with relatively mild muscle weakness. 
This is in contrast to our findings reported here for patients with FKTN and POMGNT1 
mutations and previously, for FKRP mutations (205).  
 
POMT2 mutations 
 
Similarly, mutations in POMT2 were essentially confined to patients with evidence of 
brain involvement. Of the 9 patients with pathogenic POMT2 mutations, 6 were found 
in individuals with MEB-FCMD. Of the remaining 3 individuals, two have a CMD-
cerebellar phenotype, whilst a single LGMD-MR patient (Patient 16) has learning 
difficulties and remains ambulant at aged 20 having presented at 18 months of age 
with developmental delay. These findings indicate that as for POMT1, the majority, or 
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indeed all patients with mutations in POMT2, do have evidence of central nervous 
system involvement. In addition, we have identified the mildest phenotype associated 
with mutations in POMT2 reported to date in an individual with LGMD-MR. 
 
POMGNT1 mutations 
 
Mutations in POMGNT1 were also associated with a wider than reported spectrum of 
clinical severity, which include a relatively mild form of LGMD. However, of the patients 
in whom POMGNT1 mutations were identified, 5 had a MEB-like disorder, one a WWS-
like disorder with only a single LGMD patient suggesting that POMGNT1 mutations 
more frequently give rise to congenital disorders with associated structural brain 
involvement. Nevertheless, the LGMD patient (Patient 20) has entirely normal 
intellectual function and onset in the second decade of life which dramatically expands 
the phenotypes associated with mutations in POMGNT1. Whilst initial investigations 
supported the pathogenicity of the variant found in this family, subsequent functional 
studies have revealed a more complicated picture which has yet to be fully resolved. 
This patient is reported in more detail in section 3.2(260).  
 
FKTN mutations 
 
Regarding the phenotype initially assigned to mutations in individual genes, our study 
suggests that the original descriptions of several core phenotypes in this group of 
disorders are related to the high prevalence of founder mutations within specific 
populations. Mutations in FKTN, typically associated with FCMD in Japan were, for 
example, found in six patients, none of whom are of Japanese origin. Only 2 of these 
patients had structural brain involvement, one patient affected by WWS (Patient 28) 
and one by a MEB-FCMD phenotype (Patient 27). The remaining patients had no 
structural brain involvement; one case had CMD-no MR (Patient 26) and never 
acquired the ability to walk but has normal IQ and 5 individuals from 3 families have 
entirely normal intellect and a mild LGMD phenotype (LGMD2L) (Patients 29, 30, and 
31). Interestingly in the latter 2 of these families, febrile illness was accompanied by 
acute, dramatic deterioration of motor skills which responded to steroid therapy. The 
muscle biopsy of these patients also contained cellular infiltrate to the extent that 
polymyositis was considered in the differential diagnosis. These three cases have been 
reported by us in detail (257). In striking contrast to what has previously been reported 
in FCMD, none of these 5 patients have evidence of central nervous system 
involvement. Our findings together with the recent description of individuals with FKTN 
mutations presenting with a predominant cardiomyopathy (32), suggest that FKTN 
mutations do not give rise exclusively to FCMD and that the majority of mutations 
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outside Japan give rise to milder conditions that are not usually associated with 
structural brain involvement.  
 
LARGE mutations 
 
Regarding the last gene LARGE, we were only able to identify a single pathogenic 
mutation in a patient with typical WWS phenotype who died in the first few months of 
life (Patient 25). Unfortunately neither sufficient DNA nor frozen muscle from this 
patient was available to investigate the presence of a second, as yet undetected, 
mutation. However, it is highly likely that the nonsense mutation detected is 
pathogenic, especially since no mutations were found in the remaining 
glycosyltransferase genes. This compliments the recent report of an intragenic deletion 
in LARGE giving rise to WWS (261).  
 
Mutation frequencies   
 
Concerning the frequency of involvement of individual gene defects in this cohort, 
mutations in POMT2 were the most prevalent with 9 cases, followed by POMT1 with 8 
cases, POMGnT1 with 7 cases, FKTN with 6 cases and finally LARGE with only a 
single case. We have previously identified FKRP mutations in 79 patients. 
Approximately 75% of these patients have a LGMD2I phenotype (128, 207, 211, 258). 
The relative frequency of FKRP involvement needs to be considered with caution as it 
clearly reflects the genetic origin of patients. For example screening of 79 Australian 
LGMD patients detected only two FKRP mutations (229). However, when 
amalgamating these results, it remains clear that FKRP mutations are the most 
frequently found in this group of conditions. We and others have previously published 
extensively on the spectrum of these mutations (128, 205, 211, 258, 262-271). 
 
Genotype-phenotype correlations 
 
Regarding the broad correlation between phenotype and genotype for POMT1, 
POMT2, POMGnT1, FKTN and LARGE, we detected pathogenic mutations in 3 of 5 
patients with WWS syndrome (60%), 14 of 30 patients with a MEB/FCMD phenotype 
(47%), in 2 of 4 patients with CMD CRB (50%), 3 of 15 patients with CMD-MR (20%), 1 
of 10 patients with CMD-no MR (10%), 4 of 5 patients with LGMD-MR (80%), and 4 of 
20 patients with LGMD-No MR (20%) (Figure 12  and Table 10).  
 
In most instances there was no apparent difference in the pattern of skeletal muscle 
weakness or central nervous system involvement in patients with associated structural 
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brain defects belonging to the severe end of the clinical spectrum. However, 4 LGMD 
patients with associated MR and microcephaly were all found to have mutations either 
in POMT1 or POMT2. Conversely a number of patients with considerably more severe 
muscle weakness compared to brain involvement such as those with CMD-no MR were 
found to have mutations in FKTN, similar to that described in MDC1C (128). A similar 
pattern has frequently been observed in MDC1C associated with FKRP mutations. This 
suggests that there may be a hierarchical involvement of muscle and brain in the 
individual conditions, with POMT1 and POMT2 being associated with significant central 
nervous system involvement even in patients with relatively mild weakness who remain 
ambulant (LGMD2K), while this is not a feature for FKTN or FKRP. These results 
suggest that in some individual categories, defects in certain genes are more likely 
than others, an important consideration when targeting mutation analysis in the 
dystroglycanopathies. 
 
 
The results of this study demonstrate that the phenotypic spectrum of disorders 
associated with mutations in the 6 known glycosyltransferase genes is significantly 
wider than initially suspected. We have also identified restrictions to the clinical 
spectrum associated with each gene. We have expanded the clinical spectrum 
associated with mutations in POMT1, POMT2, POMGnT1, FKTN and LARGE, further 
confirming our previous observation for FKRP that the severity of the clinical picture 
may in fact be dependent on the subsequent degree of hypoglycosylation of ADG 
rather than resulting from a specific gene effect. Finally, this work suggests that more, 
as yet undefined, genes are likely to be implicated in the pathogenesis of the 
secondary dystroglycanopathies. The identification of these other genes may provide 
additional information on the pathway of glycosylation of ADG.  
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3.2 FURTHER INVESTIGATION OF A MILD POMGNT1 MUTATION 
 
3.2.1 Introduction 
 
Patient 20 in the above cohort was found to have a novel homozygous missense 
variant in POMGNT1 (c.1666G>A, p.Asp556Asn). This patient was of particular interest 
due to the very mild phenotype and prompted further investigation to assess the 
pathogenicity of the variant.  
 
3.2.2 Clinical History 
 
This patient is one of 5 children born to healthy non-consanguineous Irish parents. She 
first developed proximal limb muscle weakness at the age of 12 years with difficulty 
rising from sitting and climbing stairs. Her early motor milestones were normal. Her 
weakness progressed quite rapidly and at 14 years she was weak proximally more 
than distally with the neck, hip girdle and shoulder abductors particularly affected. Her 
Gower’s sign was positive. She had hypertrophy of the calves and quadriceps and 
wasting of the hamstrings and deltoids. She had a lordotic stance and a poor heel 
strike because of Achilles tendon tightening. Facial expression was normal. 
Progressive weakness resulted in loss of ambulation at 19 years following a leg 
fracture. Her general health remains excellent. Her eyesight is very myopic (+6); at the 
age of 6 years she underwent corrective surgery for a convergent squint. Her intellect 
is normal and since leaving school she has gone on to university education. Initial 
investigations included: serum CK consistently elevated between 5000-12000 IU/L and 
EMG suggestive of a myopathic process.  
 
3.2.3 Methods and Results 
 
Histology and Immunohistochemistry 
 
The muscle biopsy was dystrophic with abnormal variation in fibre size, necrosis, 
increased endomysial connective tissue and fat, basophilic fibres, some of which were 
granular and had vacuoles (Figure 14 A). Immunolabeling of β-spectrin, dystrophin and 
laminin-2 was normal. Labelling with the IIH6 antibody to the glycosylated epitope of 
ADG was variable between fibres (Figure 14 C). Some fibres showed a mild reduction 
while others were very brightly labelled. Similarly labelling with the core antibody was 
weaker on some small fibres (Figure 14 D). A proportion of these fibres were also 
weaker with the anti BDG antibody and may correspond to basophilic fibres (Fig 14 B).  
 
 
118 
 
Further analysis of the biopsy showed normal Western blot analysis of dystrophin, 
sarcoglycans, laminin-2, caveolin, emerin, calpain 3, dysferlin and telethonin (carried 
out in the diagnostic Limb Girdle Muscular Dystrophies NSCAG centre in Newcastle, 
UK, courtesy of Prof K. Bushby). 
 
Single Section Western blotting and overlay assays 
 
Western blot and overlay analysis of skeletal muscle was performed by Dr Silvia 
Torelli. Western blot showed an expression of ADG similar to the control using an 
antibody which recognises a glycosylated epitope (IIH6; Fig 15 A).  BDG expression 
was normal and demonstrates equal protein loading. The laminin overlay assay 
showed that ADG’s ability to bind laminin was similar to control (Fig 15 B).
  
 
Figure 14
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Mutation Analysis 
 
A homozygous single nucleotide change c.1666G>A, never described before, was 
detected in exon 20 of POMGNT1. This change is predicted to result in the substitution 
of a conserved aspartic acid at amino acid 556 to asparagine (p.Asp556Asn) in the 
POMGNT1 protein. No other sequence variations were detected in the other known 
secondary dystroglycanopathy genes (FKRP, POMT1, POMT2, FKTN or LARGE) and 
linkage to the MDC1B locus on 1q42 was excluded (28). Both parents were found to be 
carriers of the mutation and none of the four unaffected siblings tested were 
homozygous for this change. This alteration was not detected in over 100 disease 
controls. 
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TMD BR            SSRSDCT
1                              37                  59                        300                     catalytic domain                          660        
1666 G>A
aa 556
 
Figure 16. Diagram showing pictorial representation of POMGNT1 and the 
position of the amino acid change.  
 
POMGNT1 is comprised of 660 amino acids and contains a CT; cytoplasmic tail, TMD; 
transmembrane domain, SD; stem domain, and a catalytic domain comprising a 
binding region (BR) and substrate specific region (SSR). The mutation amino acid 
change in patient 20 is at position 556 and substitutes an aspartic acid for asparagine.  
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Kinetic analysis of POMGNT1 enzyme activity 
 
In order to demonstrate the pathogenicity of this sequence variant, we arranged for 
kinetic analysis of POMGNT1 to be carried out by Professor Harry Schachter’s group in 
the department of Structural Biology and Biochemistry in Toronto, Canada.  
 
Kinetic analysis of POMGNT1 activity at 4 different concentrations of UDP-GlcNAc 
(Figure 18 A) shows apparent Km values of 2.2 and 6.1 mM for control and patient 
fibroblasts respectively. The respective apparent Vmax values are 3.4 and 2.5 
nmoles/hr/mg protein; this difference is not statistically significant. It is not possible to 
obtain accurate Km and Vmax values for Man-α-1-O-benzyl with normal POMGNT1 
because these parameters are both so large that a plot of enzyme rate versus acceptor 
concentration shows a straight line through the origin, up to the maximum soluble 
concentration of 60 mM Man-α-1-O-benzyl (272). However, a similar analysis of patient 
fibroblasts (Figure 18 B) shows a qualitative change from a straight line to a classical 
hyperbolic Michaelis-Menten plot (apparent Km and Vmax values of 9 mM and 0.1 
nmoles/hr/mg protein respectively).  
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3.2.4 Discussion 
 
To date, the identification of POMGNT1 mutations has been restricted to patients with 
CMD and brain abnormalities. The majority of these patients have a phenotype 
consistent with MEB, although some more severe cases resembling WWS have also 
been reported(129, 254). 
 
One of the unanswered questions regarding the genotype-phenotype correlation for 
POMGNT1 mutations relates to whether it can cause mild as well as severe 
phenotypes as seen in other secondary dystroglycanopathy genes, most notably FKRP 
(192) (226) but more recently also FKTN (257). 
 
The p.Asp556Asn mutation reported here is predicted to be located in the substrate 
specific region of the catalytic domain. Several lines of evidence indicate that this 
alteration is pathogenic. Firstly the patient’s skeletal muscle biopsy is consistent with a 
muscular dystrophy and suggestive of a dystroglycanopathy. No mutations were 
detected in the five other dystroglycanopathy genes screened. The reduction of ADG 
labelling was subtle on immunocytochemistry and no significant reduction in molecular 
weight was observed on Western blot. This highlights the difficulty in detecting mild 
ADG abnormalities and has been previously observed with mild FKRP mutations in 
LGMD2I(256).  Secondly the mutation segregated with the disease in this relatively 
large family. Thirdly, the mutation causes a reversal of amino acid polarity in the 
substrate specific domain of POMGNT1 which may be expected to have functional 
consequences. In addition, the detailed enzymatic studies offer support for this theory. 
POMGNT1 activity is observed but differs in its kinetics from that of control samples. 
The apparent Km for UDP-GlcNAc is significantly higher and the apparent Vmax for 
Man-α-1-O-benzyl is significantly lower than in the control. Application of the 
POMGNT1 assay conditions that were previously used to analyze MEB patients (1 mM 
UDP-GlcNAc, 62.5 mM Man-α-1-O-benzyl) (219) to the LGMD patient in this study, 
yields a POMGNT1 rate that is significantly higher than the values found in MEB 
patients. Reliable diagnosis of patients such as the one in this study therefore requires 
determination of kinetic parameters.  
 
It is interesting to note that this mutation had no effect on the subcellular localisation or 
expression of a recombinant form of POMGNT1 when overexpressed in C2C12 
myotubes (data not shown, performed by Martin Brockington, Caroline Godfrey and 
Silvia Torelli). However, the p.Asp556Asn mutation introduces a potential N-
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glycosylation site (Asn-X-Ser) into the protein which is predicted to have no other such 
sites. The presence of an N-glycan at this position may cause defective enzyme folding 
that results in an active but inefficient enzyme. 
 
This report significantly expands the spectrum of disorders associated with POMGNT1 
mutations and this patient is the mildest POMGNT1 deficient patient described.  The 
finding of normal POMGNT1 activity on conventional enzymatic assay but the 
identification of altered kinetic properties of the mutant enzyme highlights the 
importance of careful interpretation of functional data especially when studying atypical 
clinical presentations(260). 
 
Since the publication of this data, further information has come to light clouding the 
issue of mutation pathogenicity in this family.  
 
Firstly, although the mutation was excluded from being a common polymorphism on 
the basis that it was not found in 100 disease controls or present in the dbSNP, 
Caroline Godfrey later found the variant in 1 of 150 European disease control 
chromosomes. Secondly, following publication of the data, we were informed that the 
same POMGNT1 substitution had been observed in a French kindred. In this family a 
patient with MEB and her unaffected sibling both harboured the homozygous change. It 
was also reported in 8 out of 218 healthy French control chromosomes (Celin Bouchet, 
personal communication). This analysis was going to be repeated by our colleagues in 
France but we have never been informed about the outcome of the repeated studies. 
Although this evidence throws doubt on the pathogenicity of the change identified, we 
cannot ignore the fact that our patient showed an altered POMGNT1 kinetic profile. It 
may be that this is a secondary effect to a mutation in another glycosyltransferase gene 
or that other moderating factors are implicated in the complex kinetic profile of this 
patient. Although we would have liked to have investigated this situation in more depth, 
to date, further studies have not been undertaken as we are not yet in possession of 
fibroblasts from the French unaffected sibling to assess POMGNT1 function in this 
family.  
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CHAPTER 4: REFINING THE SPECTRUM OF BRAIN 
ABNORMALITIES IN THE DYSTROGLYCANOPATHIES 
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4.1 INTRODUCTION 
 
Brain involvement is a frequent but not consistent feature in patients with 
dystroglycanopathies. At the most severe end of the spectrum, in patients with WWS 
and MEB, patients are affected by cobblestone (type 2) lissencephaly with gross 
structural changes affecting cerebral cortex, brainstem and cerebellum and invariably 
associated with mental retardation. Conversely, patients with milder 
dystroglycanopathy phenotypes such as LGMD2I have no detectable brain abnormality 
on MRI imaging and normal cognitive functioning. As with other phenotypic findings in 
this group of conditions, a complete spectrum exists in between the 2 extremes. Here 
we explore the various brain abnormalities seen in a large cohort of dystroglycanopathy 
patients with proven mutations in either POMT1, POMT2, POMGNT1, FKTN and 
LARGE genes seeking to comprehensively document the findings and outline any 
evident genotype phenotype relationship.  
 
4.1.1 Central Nervous System Development 
 
The central nervous system (CNS) is derived from the dorsal epiblast of the vertebrate 
embryo and is induced by a combination of signals resulting in the formation of a neural 
tube. Anterior posterior and dorsoventral patterning occurs resulting in the formation of 
the prosencephalon (forebrain) which then subdivides into diencephalon and 
telencephalon, the mesencephalon (midbrain) and the rhombencephalon (hindbrain) 
which further divides in to the metencephalon (forming pons and cerebellum) and 
myelencephalon (medulla oblongata)(273) Correct patterning is dependent on the 
interaction of numerous genes including PAX2, PAX6, EN1, EN2, Wnt and sonic 
hedgehog.  
 
 
4.1.1.1 Normal Cortical Development 
 
The development of the human cerebral cortex can be divided into 3 overlapping 
stages. During the first stage, cells proliferate into glial cells in the ventricular and 
subventricular zones lining the cerebral cavity, deep in the forebrain. Postmitotic 
cortical neurones then migrate towards the pial basement membranes on radial glia 
that cover the neuroepithelium, with endfeet attached to the pial surface. Migrating 
neurones split the preplate into the subplate (SP) and marginal zone (MZ), stopping in 
the cortical plate (CP). Each successive generation of neurones passes the previous, 
forming an inside out pattern within the CP. Finally, cortical organisation occurs, 
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regulated by reelin released by Cajal-Retzius cells in the marginal zone, resulting in a 6 
layered cortical plate (Figure 19).  This is a dynamic process, in humans the 
proliferation stage occurs between 5-6 and 16-20 weeks, the migration stage between 
6-7 and 20-14 weeks and organisation begins at week 16 and continues into postnatal 
life.(171, 274, 275). When migration is complete, the six layered cortex comprises 
different types of neurones that form discrete connections within the CNS and perform 
different functions (276).  
 
4.1.1.2 Abnormalities of Cortical Development 
 
A classification system for malformations of cortical development has been devised 
and is based on the three general steps of cortical development. Abnormalities that 
primarily affect proliferation or apoptosis result in abnormal glia and neuronal 
differentiation causing abnormal cell size and morphology. This group would include 
disorders such as megalencephalies and some neoplastic disorders such as 
gangliocytomas. Disorders affecting neuronal migration result in abnormal neuronal 
positioning and include conditions such as periventriuclar nodular heterotopia, 
lissencephaly, and cobblestone complex. Disorders affecting later cortical development 
and organisation are likely to result in abnormalities restricted to the cortex, such as 
polymicrogyria and schizencephaly (277) (275). 
 
 
Neuronal Migration Disorders and Lissencephaly 
 
Many subtypes of neuronal migration disorders have been reported and can broadly be 
classified according the stage of migration at which the defect occurs. In some cases, a 
proportion of migrating neurones may not manage to leave the ventricular zone (VZ). In 
humans this results in periventricular heterotopia (PH) and may be caused by 
mutations in filamin 1 (FLN1). Abnormalities that occur in neurones after they exit the 
VZ may result in the appearance of a smooth cerebral cortex known as type 1 
lissencephaly. In such cases neurones leave the VZ but then arrest, resulting in a 4 
layered cortex that bears little resemblance to the 6 layered cortex seen in the normal 
human brain. Mutations in LIS1 and DCX may result in a type 1 lissencephaly 
phenotype. In other disorders, the defect may be later, with ineffective penetration of 
migrating neurones through the subplate, prior to cortical organisation. In some cases 
(as in the reeler mouse, null for reelin) this leads to inversion of the normal inside out 
pattern of cortical migration and an excess of neurones in the MZ. In patients with type 
2 lissencephaly, the defect is with the expansion of the developing cerebral wall, which 
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results in abnormal neuronal migration. Type 2 lissencephaly, as seen in 
dystroglycanopathy cases, has the appearance of a smooth brain on brain imaging but, 
at the histopathological level, breaches in the pial surface lead to over migration of 
neurones onto the subarachnoid tissue, giving the appearance of verrucose dysplasia 
and characteristic cobblestone appearance. Impaired anchoring of radial glia 
processes may be the primary cause for the migration defect, similar to the 
abnormalities seen in mice null for β1 integrins in the CNS or those with mutations in 
the laminin γ1 chain (Figure 19) (171, 278-280).  
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Polymicrogyria 
 
Polymicrogyria (PMG) is a relatively common malformation of cortical development, 
characterised by multiple small gyri and shallow sulci giving the cortical surface and 
cortical white matter junction a convoluted appearance. It is an aetiologically 
heterogeneous condition although several distinct PMG syndromes are now 
recognised (274). Studies in excitotoxic animal models suggest that PMG results from 
a developmental disorder or insult that affects the neurones towards the end of the 
migration or early cortical organisation phase. Other studies show that in humans, 
cytotoxic insult or hypoperfusion  between weeks 16 and 24 may result in a similar 
picture. Piao et al. examined the expression pattern of GPR56, a gene known to be 
mutated in autosomal recessive bilateral frontoparietal PMG, and proposed that the 
insult may happen earlier, during neuronal proliferation and migration. The weight of 
evidence suggests that PMG is the end point of a number of different aetiological 
processes (281-283). PMG may be focal or diffuse, unilateral or bilateral and can occur 
in isolation or in conjunction with other features. PMG is a frequently observed feature 
in dystroglycanopathy patients (284). 
 
Pathological features of PMG 
 
Microscopically two types of PMG are recognised; 4 layered and unlayered, which 
often coexisit in contiguous areas suggesting that they may not be distinct 
malformations. Four layered PMG is comprised of a molecular layer and 2 layers of 
neurones separated by an intermediate cell-sparse layer containing a few cells and 
myelinated fibres. Unlayered PMG has a continuous molecular layer and a layer of 
neurones without laminar organisation. Unlayered PMG is likely to reflect an early 
disruption of normal neuronal migration with subsequent disordered cortical 
organisation. Four layered PMG probably results from later disruption in neuronal 
migration or cortical organisation(277) (274). 
 
Imaging Features of PMG 
 
The diagnosis of PMG can be made by observing a combination of features on thin 
slice MRI imaging; abnormal gyral pattern, irregularity of the cortical white matter 
junction and in some cases increased cortical thickness. Cortical thickness may be 
altered by myelination and hence increased thickness is not seen on early scans. As 
the brain matures and undergoes myelination of subcortical and intracortical fibres, the 
pattern evolves and increased cortical thickness may then be detected on T2 weighted 
images (Figure 20)(285).  
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4.1.1.3 Developmental Abnormalities of Mid and Hindbrain 
 
A system has recently been proposed by Barkovich et al. that attempts to classify the 
disorders of the midbrain and hindbrain(286). They are a huge, complex and 
heterogenous group of disorders and comprise isolated malformations and those that 
are seen in conjunction with additional brain or other systemic abnormalities. The 
system proposed is based largely on embryology and genetics and in that regard is 
similar to the system proposed for abnormalities of cortical development. Of the 4 
major classification groups, group 2 comprises ‘malformations associated with 
generalized developmental disorders that significantly affect the brainstem and 
cerebellum’. This group is further subdivided and includes ‘malformation of neuronal 
migration that prominently affect the brainstem and cerebellum’ which is again divided 
and includes ‘malformations with basement membrane and neuronal migration defects’ 
which in turn includes the dystroglycanopathies.  
 
A number of different abnormalities have been reported in the dystroglycanopathies 
with varying degrees of severity. These include thinning of the brainstem, midbrain 
kink, enlarged tectum and cerebellar dysplasia, hypoplasia and cysts. The cerebellar 
abnormalities may be caused by disturbances in the external granule layer (287). The 
small pons and midline cleft may result from hypoplasia of the decussating fibres of the 
middle cerebellar peduncles or from impaired tangential migration of pontine nuclear 
neurones as shown in mouse models of LARGE mutations (288). As in the cerebral 
abnormalities, the midbrain-hindbrain disorder appears to be the result of both 
abnormal neuronal migration and abnormal formation of white matter tracts. 
 
4.1.1.4 Dystroglycan in the Brain 
 
Alpha Dystroglycan (ADG) is known to be expressed in the normal brain, where its 
molecular mass is 120kDa, suggesting a different glycosylation profile to that observed 
in muscle where its molecular mass is 200kDa. In mice glycosylated ADG has been 
shown to be particularly prevalent in two CNS locations; firstly in the astrocyte foot 
processes that form the glia limitans at the pial surface of the brain and spinal cord and 
secondly in foot processes surrounding cerebral microvessels (289). It is also found in 
the hippocampus and cerebellar cortex, where it is thought to have a structural role in 
synapses. The pathological changes observed in dystroglycanopathy patients are 
thought largely to be a result of defective basement membrane and the consequential 
disruption of neuronal migration. However, in the dystroglycanopathies, disrupted 
neurological interactions in migrating neurones may also play a part as antibodies 
 
 
136 
 
directed against glycosylated ADG may affect granule neurone migration (290). 
Interestingly dystroglycan, FKTN and POMGNT1 are all expressed in migrating 
cerebellar neurones and also in glial scaffolds used during radial migration. Abnormal 
glycosylation of ADG on the glial scaffolds may in turn affect interaction with ADG 
ligands during migration, suggesting an additional way in which neuronal migration may 
be compromised (287). Glycosylated ADG is also found in several ocular locations; 
extraocular muscle membranes, retina inner limiting membranes, foot processes 
surrounding microvessels and puncta in the outer plexiform layer (163). 
 
Dgnull  mouse 
Mice null for dystroglycan do not develop beyond embryonic day 6.5 due to lack of 
formation of Reicharts basement membrane (161). 
 
Dg-CNS mouse 
Studies by Moore et al. on mice with a dystroglycan-null brain phenotype (GFAP-
Cre/DG null) revealed dramatic abnormalities that mirrored pathological findings in the 
brains of patients with cobblestone complex, associated with the more severe 
dystroglycanopathy phenotypes. Specifically they found that brain selective 
dystroglycan deletion caused microcephaly, aberrant cerebral cortical layering, fusion 
of the cerebral hemispheres and cerebellar folia and abnormal migration of granule 
cells. The dystroglycan null brain also lost high affinity binding to laminin and showed 
discontinuity in the pial surface of the basal lamina, which they hypothesised 
contributed to the neuronal migration abnormality observed (146).  
 
 
MydLARGE mouse 
Further supportive evidence of the central involvement of ADG in the brain 
abnormalities seen in dystroglycanopathy patients came from observations of the 
mydLARGE mouse.  The normal expression pattern of glycosylated ADG is not observed 
in brain tissue from these mice and a pathological phenotype is found that, whilst less 
severe, resembles that seen Dg-CNS.  Abnormalities reported include abnormal neuronal 
migration in the cerebral cortex, cerebellum and hippocampus and disruption of the 
basal lamina. Analysis of the brainstem has revealed ectopic neurones of the pontine 
nuclei, thought to occur as a result of defective tangential neuronal migration (288). 
Interestingly, neuronal layering and radial glia in the retina appear to be normal in the 
myd mouse(163). 
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Pomgnt1null mouse 
Hu et al. studied the neuronal migration abnormalities observed in Pomgnt1null mice 
and demonstrated that the overmigration was secondary to abnormalities in the pial 
basement membrane and disappearance of the glia limitans. They suggested that the 
disappearance of the pia mater in this mouse may be as consequence of weakened 
cell-ECM interactions and subsequent reduced ability to bear mechanical stress 
secondary to hypoglycosylation of ADG(291). 
 
Fktn and Pomt1 mice 
Mice homozygously deleted for Fktn or Pomt1 are embryonically lethal due to defects 
in the basement membrane (292, 293). Chimeric Fktn deficient knockdown mice are 
viable. These mice have brain abnormalities including breaches of neurones through 
the glia limitans into the subarachnoid space. Studies have suggested that the these 
breaches occur as a result of abnormalities in the basement membrane rather than the 
migrating neurones, similar to the conclusions for the Pomgnt1null  mouse(294). 
 
 
4.1.1.5 Dystroglycanopathy Brain Phenotypes 
 
Not all patients with a dystroglycanopathy have brain abnormalities. Severe structural 
and functional brain involvement is however a constant feature of WWS, MEB and 
FCMD. Central to these disorders is the finding of ‘cobblestone cortex’ but they also 
display in varying severity, ventricular dilatation, white matter changes which may be 
transient and abnormalities of the brainstem and cerebellum. These features are 
clearly evident on MRI brain scan.  
 
 
Walker –Warburg Syndrome. 
 
In 1984, Towfighi et al. reported the neuropathology of several cases with Cerebro-
ocular dysplasia- muscular dystrophy, the clinical descriptions of which are consistent 
with WWS. In these cases, the cerebral malformations included lissencephaly, with 
varying degrees of polymicrogyria, hypomyelination of cerebral white matter, diffuse 
leptomenigeal and marginal gliomesodermal proliferation, cerebellar polymicrogyria, 
and hypoplasia or absence of pyramidal tracts. Gross structural abnormalities included 
hydrocephalus and partial fusion of the frontal lobes(240). 
   
Several papers have reported the variety of MRI brain changes in patients with WWS. 
The gross appearance is that of widespread aygria with scattered areas of macrogyria 
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and/or polymicrogyria, giving rise to type 2 lissencephaly, which represents the most 
severe end of the cobblestone complex spectrum. The leptomeninges are thickened 
and may obliterate the interhemispheric fissure, ‘fusing’ the cortex(241).  Brainstem 
abnormalities include thin brainstem, kink at the junction of the midbrain and pons, 
enlarged rounded tectum with fusion of superior and inferior colliculi. The pons is 
hypoplastic with a ventral midline cleft sometimes apparent on axial images.  The 
cerebellum is generally small and highly dysplastic(295). The vermis, especially the 
posterior vermis is always hypoplastic, often associated with enlargement of the fourth 
ventricle and Dandy Walker Malformation. Posterior cephaloceles are also widely 
reported and are seen in 25-50% of cases (241). Ventricular dilatation and 
hydrocephalus is almost universally seen (Figure 21). 
  
 
Figure 21
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Muscle-Eye-Brain Disease. 
 
The first reported neuropathological studies of patients with MEB revealed cortical 
abnormalities including occipital agyria and disorganised cortical lamination and a 
nodular surface consistent with cobblestone cortex (Figure 22) (297). In addition, the 
surface of the cerebellum was devoid of normal folia, the vermis was hypoplastic and 
the pons was flattened. The microscopic cytoarchitectural disorganisation was similar 
to that seen in the cerebral cortex of both WWS and FCMD. 
 
MRI brain changes in MEB include cobblestone cortex, white matter changes, thinning 
and sometimes kinking of the brainstem with small ventral pontine cleft. Cerebellar 
abnormalities include dysplasia, hypoplasia and cysts (Figure 23) (298). 
 
Fukuyama Congenital Muscular Dystrophy. 
 
The findings in FCMD are similar to those in MEB and WWS. Cobblestone complex, 
pachygyria and polymicrogyria are features and dilated ventricles and white matter 
abnormality are also seen. Midbrain hypoplasia is present in some and cerebellar 
polymicrogyria and cysts are also a frequent observation (23 of 25 individuals in one 
study) (Figure 24) (299). 
  
 
Figure 22
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Overlap of Dystroglycanopathy Phenotypes 
 
Several papers reported the overlapping brain pathology seen in WWS, MEB and 
FCMD. Formal attempts to separate the conditions have suggested that WWS is the 
most severe, most often associated with large areas of complete lissencephaly and 
severe structural abnormalities such as encephalocele or fused cortex and profound 
abnormalities of the cerebellum. MEB does not have the severe structural 
abnormalities seen in WWS but often exhibits the remaining features, including 
cobblestone complex, ventricular dilatation, white matter changes, brainstem 
hypoplasia, cerebellar hypoplasia, dysplasia and cysts, but to a lesser degree of 
severity. FCMD is typically viewed as a milder version of MEB/WWS although reports 
of encephalocele and focal cortical fusion in FCMD exist and it is associated with 
breaches of the pial membrane found in cobblestone complex(250).  
 
 
Cobblestone Complex like Variants 
 
Autosomal Recessive Bilateral Frontoparietal Polymicrogyria (BFPP) is caused by 
mutations in GPR56, a G-protein coupled receptor (301). Patients with BFPP typically 
have mild to moderate mental retardation, motor developmental delay, seizures and 
non-progressive cerebellar signs. A neuromuscular phenotype has not been reported. 
MRI brain changes include BFPP, bilateral white matter change and hypoplasia of the 
cerebellum and pons (302). GPR56 has a role in organisation of pial membrane and 
regulation of anchorage of radial glial endfeet (303). The overmigration of neurones 
through the basement membrane in patients with GPR56 mutations results in a 
cobblestone cortex. Similarly in the cerebellum, granule cells show loss of adhesion to 
ECM molecules of the basement membrane (304). Both of these processes resemble 
that seen in the dystroglycanopathies (Figure 20). 
   
Autosomal recessive Debré type cutis laxa (ARCL2) is a rare disorder characterised by 
developmental delay, facial dysmorphism and lax skin with myopia, strabismus and 
seizures reported in some individuals. In addition to the clinical similarities, MRI brain 
findings show some overlap with those seen in dystroglycanopathies, in particular 
cortical malformation involving the posterior frontal, perisylvian and parietal areas, 
partly resembling polymicrogyria. Some patients also have cerebellar hypoplasia. It is 
due to mutations in ATP6V0A2, a gene encoding the a2 subunit of the V-type H+ 
ATPase that has an important role in Golgi function. The mutations result in abnormal 
glycosylation of serum proteins (CDG-II) and result in defective Golgi trafficking in 
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fibroblasts from affected individuals. As highlighted previously (section 1.6.8) in 
reference to DPM3 these findings reiterate the similarity between congenital disorders 
of glycosylation and the dystroglycanopathies (305, 306).  
 
Sprecher et al. described in 2005 a new condition in 7 individuals from 2 
consanguineous Arab families, comprising cerebral dysgenesis, neuropathy, ichthyosis 
and palmoplantar keratoderma (CEDNIK syndrome). It was found to be a result of 
mutations in SNAP29, a gene that encodes a SNARE protein involved in vesicle 
trafficking and fusion. The cerebral abnormalities are similar to those seen in 
dystroglycanopathies and include cortical dysplasia with pachygyria and polymicrogyria 
and various degrees of corpus callosum abnormalities (307). 
 
 
4.1.1.6 Genotype Phenotype Correlations 
 
The MRI brain changes seen in patients with mutations in FKRP has previously been 
reported (258, 264). The spectrum is very wide ranging from normal cognitive 
development and normal brain MRI, as seen in the patients described when the first 
FKRP mutations were identified (128, 205) to severe structural brain abnormality in 
patients with associated learning difficulties. These include a hierarchical pattern of 
changes from isolated cerebellar cysts (211, 308) to more severe structural 
involvement affecting the brainstem and pons and also polymicrogyria and cobblestone 
lissencephalic changes indistinguishable from those found in MEB and WWS, affecting 
fronto-parietal regions more than the occipital and temporal regions(207, 258).  
Ventricular dilatation and white matter abnormalities were also variably present in these 
patients (258, 264, 308). 
 
More recently, it has become obvious that mutations in the other genes encoding 
known or putative glycosyltransferases can also be associated with variable brain 
involvement. Mutations in POMT1 and POMT2, originally associated with  WWS 
phenotype (130, 132), were recently associated with milder brain involvement such as 
in patients with cerebellar hypoplasia (210, 251, 252, 309) or even associated with 
normal brain MRI in patients with microcephaly and mild mental retardation (310). 
Similarly, mutations in FKTN, originally identified in Japanese patients with Fukuyama 
CMD, typically associated with severe structural brain changes including 
polymicrogyria-pachygyria, occasional hemispheric fusion, cerebellar cystic lesions and 
transient dysmyelination (255), have been reported in a few patients with clinical and 
brain imaging features almost identical to those previously identified in WWS (208, 
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226). More recently we and others described several families with milder allelic 
mutations in FKTN associated with normal intelligence and brain MRI (32, 231). In 
contrast, mutations in POMGNT1, originally identified in Finnish and Turkish patients 
with MEB (129), have so far been described in patients with clinical and imaging 
features evocative of a MEB phenotype (254, 259). Mutations in LARGE were initially 
reported in a patient with fronto-parietal pachygyria and brainstem hypoplasia (131), 
and have more recently been associated with WWS-like features (231, 311).  
  
The aim of this study is to report brain MRI findings in 27 patients with muscular 
dystrophy and mutations in POMT1, POMT2 , POMGNT1, FKTN and LARGE in order 
to establish the spectrum of brain involvement associated with each individual gene as 
well as any genotype-phenotype correlations. Scans of patients with mutations in 
FKRP were not included as the range of brain involvement in patients with mutations in 
this gene has previously been documented (258).  
 
4.2 METHODS AND PATIENTS 
 
Twenty-seven patients with mutations in POMT1, POMT2, POMGNT1, FKTN or 
LARGE were selected as they had MRI brain scans available for review. All but 6 of 
these patients are reported in Godfrey et al. (231) and as such were recruited on the 
basis of hypoglycosylation of alpha-dystroglycan (ADG) on muscle biopsy or clinical 
features highly evocative of α-dystroglycanopathy. Four of the remaining 6 patients (13, 
14, 23 and 26) have reduction of ADG evident on skeletal muscle biopsy and the 
remaining 2 patients (18 and 20) have a phenotype suggestive of a dystroglycanopathy 
(Table 11). Details of genetic and pathological methods are as described in Godfrey et 
al.(231). Patients with FKRP mutations were excluded from this study as we have 
previously reported the spectrum of brain involvement, however their findings are 
summarised for completion in Table 13 (258). 
 
All patients had undergone a brain MRI scan by the time the mutations were detected. 
Imaging studies were reviewed by at least two investigators who were blinded to 
clinical information and results of molecular genetic testing. The scans were reviewed 
using a proforma in which the following abnormalities were recorded: Infratentorial: 
cerebellar abnormalities (vermian and/or hemispheric involvement, including presence 
of cerebellar cysts or other signs of cerebellar dysplasia), shape and size of the 
brainstem and pons. Supratentorial: cortical malformation (severity and location), white 
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matter changes and ventriculomegaly. Any additional abnormalities were also 
recorded. 
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Patient Gene Mutations CK Phenotype Microcephaly Mental retardation Eye involvement 
 
1 FKTN p.Arg307Gln 
p.Arg307Gln 
3200 CMD - - - 
2 FKTN p.Ala114Thr 
p.Thr287fs 
9000 LGMD - - - 
3 FKTN p.Arg307Gln 
p.Phe390fs  
13000 LGMD - - - 
4 FKTN p.Phe390fs 
p.Asp455fs 
60000 LGMD - - - 
5 POMT2 p.Thr184Met 
p.Trp748Ser 
1900 LGMD - + - 
6 POMT1 p.Phe173_Asn175delinsAsp 
p.Arg623Thr 
8000 LGMD + + - 
7 POMT1 p.Tyr616del  
p.Gly65Arg 
7800 CMD N/A + - 
8 POMT1 p.Glu143X 
p.Ala200Pro 
18000 CMD + + - 
9 POMT2 p.Gly353Ser 
p.Gly726Glu 
2000 CMD + + Myopia 
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Patient Gene Mutations CK Phenotype Microcephaly Mental retardation Eye involvement 
10 POMT2 p.Phe117Ser 
p.Gly726Glu 
5500 CMD + + - 
11 POMGNT1 c.652+1G>A 
p.Cys490Tyr 
1000 CMD - + Optic atrophy. Myopia 
12 POMT2 p.Thr683Pro 
p.Ala351fs 
3100 CMD + + - 
13 POMT2 p.Trp495Ser 
p.Trp748Arg  
2900 CMD + + - 
14 LARGE p.Glu509Lys 
p.667fs 
4500 CMD - + Nystagmus, abnormal 
ERG 
15 POMT1 p.Ser727fsX 
p.Ser727fsX 
3500 CMD + + Congenital glaucoma 
16 POMT2 p.Tyr666Cys 
p.Arg413Pro 
N/A CMD N/A N/A Hypermetropia 
17 POMT2 p.Ile198Asn 
p.Tyr666Cys 
N/A CMD - + Myopia 
18 LARGE p.Gln87fs 
p.Ser331Phe 
400 CMD - + Myopia 
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Patient Gene Mutations CK Phenotype Microcephaly Mental retardation Eye involvement 
19 POMT2 p.Val373Phe 
p.Ile198Asn 
6000 CMD + + Congenital cataracts 
20 POMGNT1 c.1539+1G>A 
p.Arg580X 
740 CMD - + Myopia, retinal dysplasia 
21 POMGNT1 p.Arg367His 
c.1539+1G>A 
2800 CMD N/A + Ptosis, retinal atrophy 
22 POMGNT1 p.Thr176Pro 
p.Thr176Pro 
780 CMD N/A + Congenital glaucoma 
23 POMGNT1 p.Asp427His 
p.Asp150fsX 
1500 CMD + + Myopia 
24 POMGNT1 c.1539+1G>A 
c.1539+1G>A 
1200 CMD + + Retinal detachment 
25 POMGNT1 p.Trp475X 
p.Trp475X 
1300 CMD N/A + - 
26 POMT2 p.Thr433X 
p.Thr433X 
3200 CMD - + Cataracts, bupthalmus 
27 LARGE p.Trp516X 
- 
5700 CMD N/A + Retinal dysplasia 
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Table 11.  Gene mutations and Clinical Phenotype.  
 
 CMD; congenital muscular dystrophy, LGMD; limb girdle muscular dystrophy, ERG; electroretinogram. 
 
 
 
 
152 
 
 
4.3 RESULTS 
 
Twenty-seven patients fulfilled the inclusion criteria; all but one had 2 allelic mutations 
in one of the genes studied. One patient had a single pathogenic LARGE mutation; she 
had typical WWS phenotype and died in the first few months of life (patient 27) (231) . 
Four patients had FKTN mutations, 4 patients had POMT1 mutations, 9 patients had 
POMT2 mutations, 7 patients had POMGNT1 mutations and 3 patients had LARGE 
mutations. All patients had a CMD phenotype with the exception of 5 patients with an 
LGMD phenotype. The age at brain MRI scan ranged from 3 weeks to 16 years (mean 
age 4.04 years; 11 scans were of patients younger than 2 years of age). Only 4 
patients were reported to have normal cognitive development but this was not always 
formally tested (Table11).  
 
The MRI findings are summarised in Table12. In summary, 8 patients had normal brain 
scans (cases 1-3) or minimal changes (cases 4-8) such as periventricular white matter 
changes and/or mild ventricular dilatation. Two patients (cases 9,10) had evidence of 
cerebellar hypoplasia with no cortical abnormality. Two other patients (cases 11,12) 
had cerebellar cysts or hypoplasia and pontine abnormalities but no obvious cortical 
changes. Two patients (cases 13,14) had fronto-parietal-temporal polymicrogyria but 
no involvement of the cerebellum or brainstem (Figure 25). Three patients (cases 15-
17) had cortical abnormalities with cerebellar dysplasia and posterior concavity 
abnormality of the brainstem (two out of three) but a normal appearance to the pons. 
Eight patients (cases 18-25) showed changes consistent with an MEB phenotype 
(Figure 26, 27 and 28). The remaining 2 patients (cases 26-27) had features consistent 
with a WWS phenotype. 
 
Brainstem abnormalities were seen in a total of 14 patients. A thin brainstem with 
flattening of the pons was common, occurring in 13 of 27 scans including those without 
cortical involvement. In the more abnormal scans the brainstem had an unusual 
concavity to the posterior aspect best seen when viewed in sagittal sections (Figure 
26). In 5 patients there was an abnormally thin brainstem with ventral and dorsal clefts 
of the pons (Figure 26 and 28). This was associated with an abnormal appearance to 
the corticospinal tracts with excessive areas of rounded short T1 and short T2 (Figure 
28). Three of these patients had POMGNT1 mutations (cases 20,21 and 25), 1 patient 
had a POMT2 mutation (case 19) and 1 patient had a LARGE mutation (case 18). 
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Pt Age at 
scan 
Gene VD White matter 
changes 
Cerebellar 
cysts 
Other 
cerebellar 
abnormality 
Brainstem 
abnormality  
Pontine 
abnormality 
Cortical abnormality 
1 
 
5Y FKTN - - - - - - - 
2 10Y 
 
FKTN - - - - - - - 
3 3Y 
 
FKTN - - - - - - - 
4 8Y 
 
FKTN + - - - - - - 
5 6Y 
 
POMT2 + - - - - - - 
6 3Y 
 
POMT1 - PV - - - - - 
7 2Y 
 
POMT1 - PV - - - - - 
8 7Y 
 
POMT1 + PV  - - - - - 
9 3Y 
 
POMT2 - PV - Hypoplastic - - - 
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Pt Age at 
scan 
Gene VD White matter 
changes 
Cerebellar 
cysts 
Other 
cerebellar 
abnormality 
Brainstem 
abnormality  
Pontine 
abnormality 
Cortical abnormality 
10 3Y 
 
POMT2 + PV + Hypoplastic - Hypoplasia - 
11 16Y POMGNT1 + Diffuse 
abnormality 
+ - - Hypoplasia - 
12 9M 
 
POMT2 - PV and FP - Hypoplastic 
vermis 
Posterior 
concavity 
- - 
13 3M 
 
POMT2 - - - - - - FPT PMG 
14 14Y 
 
LARGE - PV, T - - Posterior 
concavity 
Hypoplasia FP pachygyria  
15 3W 
 
POMT1 ++ TO>FP + Dysplastic 
vermis 
Posterior 
concavity 
- TO PMG 
16 1Y POMT2 + FP 
Reduced WM  
+ Dysplastic 
vermis.  
Posterior 
concavity 
- Focal PMG (A>P) 
17 
 
13Y POMT2 - PV + Dysplastic 
vermis 
- - Posterior PMG 
18 
 
1Y LARGE + Abnormal + Dysplastic 
vermis 
 
Posterior 
concavity 
Hypoplasia and 
cleft 
FP PMG  
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Pt Age at 
scan 
Gene VD White matter 
changes 
Cerebellar 
cysts 
Other 
cerebellar 
abnormality 
Brainstem 
abnormality  
Pontine 
abnormality 
Cortical abnormality 
19 3Y POMT2 ++ Diffuse 
abnormality 
+ Cerebellar 
cleft  
Posterior 
concavity 
Hypoplasia, cleft 
and abnormal 
corticospinal tract 
 FP PMG 
20 5M POMGNT1 ++ Abnormal ++ Dysplastic 
vermis 
Posterior 
concavity 
Hypoplasia, cleft 
and abnormal 
corticospinal tract 
Diffuse PMG, slight FP 
gradient 
21 3Y POMGNT1 ++ Abnormal foci + Dysplastic Posterior 
concavity 
Hypoplasia, cleft 
and abnormal 
corticospinal tract 
FP pachygyria,PMG T lobes, 
cobblestone cortex 
22 5M 
 
POMGNT1 ++ Reduced WM + Hypoplastic 
vermis 
Posterior 
concavity 
Hypoplasia Frontal pachygyria, cyst in T 
pole 
23 8M POMGNT1 ++ Diffuse 
abnormality 
++ Dysplastic, 
hypoplastic 
Posterior 
concavity 
Hypoplasia FPT PMG 
24 N/A POMGNT1 ++ Diffuse 
abnormality 
+ Dysplastic Hypoplasia Hypoplasia PMG (A>P) and pachygyria 
25 18M POMGNT1 ++
+ 
Diffuse 
abnormality 
+ Dysplastic, 
hypoplastic 
Anterior 
concavity 
Hypoplasia, cleft 
and abnormal 
corticospinal tract 
Diffuse PMG  
26 5W 
 
POMT2 ++
+ 
  Hypoplastic Hypoplasia Hypoplasia Thin lissencephalic cortical 
mantle 
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Table 12. Brain MRI findings. 
 
Pt; patient, VD; ventricular dilatation, + indicates presence, - indicates absence of abnormality, F; frontal, T; temporal, O; occipital, P; 
parietal, A>P; anterior> posterior, PV; periventricular, WM; white matter, PMG; polymicrogyria. 
Pt Age at 
scan 
Gene VD White matter 
changes 
Cerebellar 
cysts 
Other 
cerebellar 
abnormality 
Brainstem 
abnormality  
Pontine 
abnormality 
Cortical abnormality 
27 4W LARGE ++
+ 
Diffuse 
abnormality 
 Dyplastic, 
hypoplastic  
Posterior 
concavity 
Hypoplasia Posterior lissencephaly, 
cobblestone variant  
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Figure 26. T2-weighted images in transverse and sagittal planes of a 5 month old  
(case 19) with POMGNT1 mutations.  
 
There is widespread polymicrogyria in frontal and parietal lobes and abnormal high 
signal intensity throughout the white matter. There are multiple cysts in the hypoplastic 
cerebellar hemispheres in the transverse view. There are clefts in the dorsal and 
ventral pons. In the sagittal plane the pons is thinned with a concave posterior border.  
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Figure 27. T2-weighted image in the transverse plane of an 8 month old  (case 22) 
with heterozygous POMGNT1 mutations.  
 
There is widespread bilateral polymicrogyria affecting predominantly the frontal and 
parietal lobes. The white matter is reduced in volume with abnormally high signal 
intensity. Areas of lower signal intensity, mainly within the anterior white matter (arrow), 
may represent heterotopic cells that have failed to migrate to the correct location.  
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4.3.1 Genotype Phenotype Correlation.  
 
The 4 patients with FKTN mutations all had a normal MRI or minimal ventricular 
dilatation. Six of 7 patients with POMGNT1 mutations had changes consistent with 
MEB and the remaining patient had cerebellar cysts and a flat pons but no obvious 
signs of cortical dysplasia on a scan performed at 9 months. 
Three of the 4 patients with POMT1 mutations had minimal periventricular white matter 
changes and one had cerebellar cysts and cortical changes but a normal pons. 
The 9 patients with POMT2 mutations had abnormalities which ranged from mild 
ventricular dilatation to isolated cerebellar hypoplasia to generalised cobblestone 
lissencephaly, resembling WWS. 
The 3 patients with LARGE mutations had both diffuse cortical and white matter 
changes; one had cerebellar cysts and features entirely consistent with a MEB-like 
disorder; in one the severity of the lissencephaly was consistent with a WWS 
diagnosis. These results are summarised in Table13.  
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 Normal MRI 
 
 
 
(n=3) 
Normal cortex 
and cerebellum.  
Minimal VD+/- 
PV changes 
(n=5) 
Cerebellar 
hypoplasia no 
cortical 
abnormalities 
(n=2) 
Cerebellar cysts 
or hypoplasia, 
no cortical 
changes 
(n=2) 
WM cortical 
changes. 
Cerebellum 
normal 
(n=2) 
Cortex  and 
cerebellar 
abnormality,   
normal pons 
(n=3) 
MEB-like 
changes 
 
 
(n=8) 
WWS-like 
changes 
 
 
(n=2) 
 Our 
cohort 
Other 
studies
Our 
cohort 
Other 
studies 
Our 
cohort 
Other 
studies 
Our 
cohort 
Other 
studies 
Our 
cohort 
Other 
studies
Our 
cohort 
Other 
studies 
Our 
cohort 
Other 
studies
Our 
cohort 
Other 
studies 
FKTN 
(n=4) 
●●● (126) ● (126)         (300)  (208) 
POMT1 
(n=4) 
 
 (125, 
251, 
252, 
312) 
●●●   (251, 
312) 
   ●  
 
(251)  (130, 
251) 
POMT2 
(n=9) 
 ●  ●● (210, 
309) 
● ●  ●●  ● ● (132) 
POMGNT1 
(n=7) 
     ●     ●●●●●
● 
(129, 
254, 
259) 
  
LARGE 
(n=3) 
      ● (131)   ● ● (311) 
FKRP*  (258)  (258)    (258)  (258)    (258)   
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Table 13. Distribution of MRI brain changes according to gene mutation.  
 
Patients described in the present study are indicated as ●. The shaded areas indicate previously reported phenotypes, with the main 
references shown. 
VD; ventricular dilatation, PV; periventricular, WM; white matter, WWS; Walker Warburg syndrome,  
* FKRP not part of this study, results previously published 
 
 
164 
 
4.4 DISCUSSION 
 
The findings reported in this study expand the spectrum of structural brain involvement 
associated with mutations in several of the genes involved in dystroglycanopathies and 
show that the range of central nervous system involvement due to individual gene 
defects is much wider than originally described.   
 
The cortical abnormalities of patients with dystroglycanopathies has been described in 
multiple pathology reports and chapters.  Three types of gross pathology have been 
described in the cerebral cortex of affected brains(297, 300, 313):   (1) verrucose 
dysplasia in which nodules of cellular cortical tissue protrude through the pial basement 
membrane superficial to normally laminated cortex (chiefly in temporal lobes); (2) 
unlayered polymicrogyria with haphazardly oriented cortical neurons forming irregular 
clusters, separated by gliovascular strands extending from the pia (chiefly in frontal and 
parietal lobes) and (3) agyric regions with four distinctive layers (a-superficial layer 
containing myelinated fibers obscuring the molecular layer, b-thick cellular layer with 
disorganized and occasionally aggregated neurons, c-cell sparse layer of white matter, 
and d-heterotopic nodules of neurons).  The agyric regions are located chiefly in the 
occipital lobes.  Takada et al. noted that small superficial nodules are seen on the 
surface in all regions and suggested that the appearance seen on the surface of what 
are now called dystroglycanopathies is best called “cobblestone” cortex(300). It should 
be noted that both polymicrogyria and agyria are heterogeneous disorders. At least 
four different histological types of agyria have been described by Forman et al. (314, 
315). Of note, these authors do not consider the agyric regions of dystroglycanopathies 
in their classification, instead classifying them separately as “cobblestone 
lissencephaly”.  Here we have followed the nomenclature of Forman et al.  Regarding 
polymicrogyria, while it is possible that many different histological subtypes of 
polymicrogyria can be identified, and some of these subtypes may also be separable 
by their imaging characteristics, such separation was not attempted in this study.  We 
separated the cortical abnormalities identified in our patients into two broad categories, 
based upon the MRI appearance: polymicrogyria and cobblestone lissencephaly. Of 
note verrucose dysplasia cannot be detected by MRI.  Polymicrogyria was diagnosed 
when either multiple microgyri were identified in the cerebral cortex on individual 
images or a slightly thickened (4-7 mm) cortex was seen, with irregularity of the 
cortical-white matter junction (316). Polymicrogyria has different appearances on MRI 
depending upon the state of myelination at the time of the scan(285).  The individual 
microgyri are easily seen in the unmyelinated brain but, as myelination ensues, the 
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cortex begins to appear thick and can superficially resemble pachygyria.  The two 
entities can be differentiated, however, by the lesser thickness (4-7 mm) and 
irregularity of the junction between the cortex and white matter in polymicrogyria (the 
cortex-white matter junction is smooth in pachygyria).  Cobblestone lissencephaly was 
diagnosed when the cortex was thick (> 7 mm), the outer surface of the cortex was 
smooth, the inner surface of the cortex was irregular, and there was a layer of 
irregularly-shaped nodules of grey matter approximately 2 mm deep to the cortex.  In 
many cases, these nodules appeared to be radially oriented immediately below a 
bundle of spindle-shaped grey matter in the cortex.   
 
Three of the 27 patients studied had normal scans and another 5 had only mild 
changes such as minimal ventricular dilatation with periventricular white matter 
changes of long T2. These changes are non-specific and can be observed in low-risk 
full-term infants with normal developmental outcomes (317). The remaining 18 patients 
all had structural brain changes that almost invariably affected infratentorial structures, 
with the exception of one patient in whom only the fronto-parietal-temporal regions 
were polymicrogyric. In 4 of these 18 patients the infratentorial involvement was found 
in isolation, while in the remaining 14 patients it was associated with supratentorial 
cortical and white matter involvement.  In this latter group of patients the supratentorial 
involvement ranged from diffuse periventricular white matter changes with focal areas 
of polymicrogyria to diffuse cortical structural abnormalities including cobblestone 
lissencephaly and an almost absent cortical mantle. In 2 cases, severe  supratentorial 
findings were combined with abnormalities of the posterior fossa, consistent with the 
diagnosis of WWS (241). Infratentorial involvement included hypoplastic or dysplastic 
vermis, cerebellar cysts, a concavity in the brainstem at the floor of the fourth ventricle 
and pontine hypoplasia. 
 
We correlated the results of the scans with the genotype of the patients, and compared 
them with the previously documented changes in FKRP-related dystrophies (207, 211, 
258). Although some of the lesion patterns were more frequently associated with 
individual gene mutations, there was no unique defect which allowed unequivocal 
prediction of the primary gene defect. Florid cerebellar cysts were seen in all patients 
with POMGNT1 mutations, but cysts were also found in 4 of 9 patients with POMT2 
mutations, in 1 of 4 patients with POMT1 mutations and in 1 of 3 with LARGE 
mutations. To the best of our knowledge, cerebellar cysts have not been previously 
associated with any of these genotypes. Interestingly, cerebellar cysts in patients with 
POMGNT1 mutations were also found in the absence of supratentorial white matter or 
cortical involvement, as we have previously reported for patients with FKRP mutations 
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(258), suggesting that the cerebellum is particularly vulnerable to the underlying 
disease process in patients with mutations in these two genes. Targeted screening of 
POMGNT1 and FKRP should therefore be considered where cerebellar cysts are the 
predominant abnormality.  In contrast, none of our patients with FKTN mutations had 
cerebellar cysts. All our patients with FKTN mutations were cognitively normal, in 
contrast to reports of individuals with FCMD where cerebellar polymicrogyria +/- cysts 
were found in 90% of patients (318). Increasingly it is possible to recognise a subgroup 
of FKTN associated phenotypes that are distinct from the classic FCMD reported in 
Japan, where learning difficulties and structural brain involvement are invariable. This 
is not surprising considering that virtually all Japanese patients carry the same founder 
mutation (127) a relatively severe mutation which has not been reported in non-
Japanese patients. In patients with FKTN mutations, the spectrum of brain MRI 
findings, ranging from normal MRI  (32) to the previously reported WWS-like 
changes(208, 226) resemble the spectrum we previously documented in patients with 
FKRP mutations (258).  
 
Mutations in POMT1, POMT2, POMGNT1 and LARGE were not associated with the 
same range of brain MRI findings reported for FKRP, and FKTN. Indeed, with the 
partial exception of POMT2, the other genes showed a relatively narrow range of 
findings; it is, however, of note that the patterns of lesions observed for an individual 
gene defect in this study are often different from those previously reported for the same 
gene. This was particularly evident for patients with POMT2 mutations, originally 
associated with either a WWS or a cerebellar hypoplasia phenotype (132, 210); only 2 
of the 9 cases we studied had these previously reported changes. In the other 7 cases 
the brain changes ranged from isolated mild ventricular dilatation or cerebellar 
dysplasia to various degree of cortical involvement, including isolated fronto-parieto-
temporal polymicrogyria, which has not previously been reported. We also identified 
some patients with POMGNT1, and POMT1 mutations with previously unreported 
findings such as isolated cerebellar cysts in POMGNT1 and relatively mild cortical 
involvement without pons and brainstem abnormalities in POMT1. We also identified a 
patient with novel mutations in the LARGE gene, leading to a MEB-like picture with 
associated cerebellar cysts. It may well be that as further work and patients with 
mutations in these genes are identified, the spectrum of changes found in these three 
genes will also widen.  
 
Other findings of this study were also of interest: in two patients the cortical changes 
affected predominantly the temporal and occipital regions. In one (patient 17, POMT2 
mutation) the posterior cortical changes were associated with normal appearances to 
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the pons and brainstem, whilst in the other (patient 15, POMT1 mutation) the scan was 
performed at 3 weeks at an age when the extent and severity of cortical involvement 
cannot always be fully appreciated. The predominant posterior cortical involvement  is 
at variance with the anterior-posterior gradient described in FKRP mutations (258) and 
POMGNT1 (259, 319). Predominantly posterior cortical malformation is a feature of 
merosin negative CMD (320), while the co-existence of fronto-parietal polymicrogyria 
and occipital agyria, has been reported in FCMD patients (318).  
 
We documented a ventral pontine cleft in 5 cases, 4 with a MEB-like condition 
(secondary to POMGNT1 mutations in three and LARGE in another) and 1 with a more 
severe phenotype falling between the disease spectrum of MEB and WWS, carrying 
POMT2 mutations. Such an abnormal appearance of the pons was reported at a 
similar time by Barkovich et al. in a number of patients with WWS and MEB(295). It is 
most likely caused by the absence of the ventral transverse pontine fibres, at the 
decussation of the middle cerebellar peduncles (295). Indeed these fibres migrate 
tangentially and their migration is impaired in the mydLARGE mouse (288). MR diffusion 
tensor imaging studies may elucidate the exact position of pontine tracts and the 
structural basis for these abnormal imaging appearances (295).  
 
The MRI changes reported here are highly evocative of a “dystroglycanopathy”. There 
is, however, an overlap with other conditions as mentioned previously. Patients with 
GPR56 mutations have bilateral frontoparietal polymicrogyria seen in an 
anteroposterior distribution, bilateral patchy white matter changes and brainstem and 
cerebellar hypoplasia (282).  Whilst the MRI findings are clearly similar to those seen in 
the midgroup of patients reported here (12-23), the polymicrogyria seen in patients with 
GPR56 mutations affects predominantly the fronto-parietal regions and not the 
temporal and occipital areas also seen in patient with a dystroglycanopathy (302). In 
addition cerebellar cysts or scalloped appearance to the back of the brainstem has not 
been reported in patients with GPR56 mutations.  
 
A question that remains to be answered relates to whether or not patients exist with 
brain changes within the spectrum described with mutations in one of the 
dystroglycanopathy genes but with minimal /absent muscle involvement. We are aware 
of one patient with POMGNT1 mutations in whom serum CK was normal, but ADG 
expression reduced on muscle biopsy(321).  There are no systematic studies where 
the analysis of the putative or demonstrated glycosyltransferases mutated in 
dystroglycanopathies has been performed in patients without a skeletal muscle. 
phenotype. 
 
 
168 
 
 
In addition to looking for a correlation between different genes and phenotypes we also 
correlated the type of mutations with the brain MRI findings. Somewhat unsurprisingly 
the 3 scans with the most abnormal appearance (25,26,27) resulted from nonsense 
mutations but in 3 different genes, POMGNT1, POMT2 and LARGE. Interestingly 
however, 2 patients with apparently severe mutations had less brain involvement than 
the 3 above. Patient 15 has a homozygous truncating mutation in POMT1, whilst 
patient 4 with no structural brain lesions was homozygous for two frameshifting 
mutations in FKTN. These findings may be explained by the location of these mutations 
in the most 3’ exon, meaning that the mutant products may not be subject to nonsense 
mediated RNA decay(126).  
 
A limitation of this study relates to the fact that the scans had been performed in 
various centres, at different ages of the patients, and not always optimised with thin 
(i.e. 1.5 mm) slices to detect subtle dysplastic changes, as most scans were 5 mm 
thick. Nevertheless these are the diagnostic scans routinely available in clinical 
settings; hence our findings are of relevance for this group of patients.  
 
The reason for the varied abnormalities of brain involvement seen in patients carrying 
mutations in these different genes is not fully understood. All these gene products have 
so far only been involved in the glycosylation of ADG. The appropriate  glycosylation of 
ADG plays a crucial role for its function as it regulates its binding to extracellular matrix 
proteins such as laminin, neurexin, perlecan and agrin (146).  Although the role of ADG 
in brain development is not fully understood, it has been shown to be important for 
normal basement membrane formation and neuronal migration. As ADG is highly 
expressed in the pial membranes, it is likely that its abnormal glycosylation results in 
reduced integrity and the resulting breaches observed in these CMD variants (171), 
observations supported by the numerous studies performed in knockout mice. (291) 
(294) (146, 178, 291, 312).  
 
In addition to the role of ADG in basement membrane stability, recent studies also 
suggest that it is involved in the process of migration of cerebellar neurons (290).   
 
The difference observed in the pattern of brain involvement in patients carrying 
different gene mutations might suggest that some of these demonstrated or putative 
glycosyltransferases have targets other than ADG in brain, although this has never 
been demonstrated; another possibility is that it might reflect differences in the pattern 
of expression of individual glycosyltransferases in different brain regions. Less likely, it 
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may reflect a mutation specific effect on the ability of these glycosyltransferases to 
differentially bind with interacting proteins. Further work on the relevant animal models 
will help to clarify these issues. 
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CHAPTER 5. CONCLUDING DISCUSSION 
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5.1 THE BROADENING SPECTRUM OF CMD  
 
The term Congenital Muscular Dystrophy encompasses a complex and heterogeneous 
group of disorders. They are broadly defined by an early clinical presentation with 
hypotonia, weakness and developmental delay with dystrophic appearance on muscle 
biopsy. Many have additional clinical features including contractures, brain and eye 
abnormalities, skin defects and raised CK. Although this definition is a good starting 
point, it is clear that many patients with CMD do not adhere to these criteria. Patients 
with genetically proven CMD may show no dystrophic abnormality on muscle biopsy 
and others with mutations in causative CMD genes present later, with features more 
consistent with LGMD. In a number of CMDs CK is normal or only mildly elevated. This 
is indeed somewhat unsatisfactory but in the absence of comprehensive molecular and 
genetic definitions, it remains a useful clinical framework on which to build.   
 
In 2006 when this project started, the molecular and genetic basis for many forms of 
CMD was emerging. This allowed a rudimentary division of CMDs according to the 
cellular location of proteins involved. What is clear is that the majority of CMDs involve 
proteins localised to or interacting with the skeletal muscle ECM, reflecting the 
importance of this structure in prenatal muscle formation and postnatal maintenance of 
muscle integrity. The array of extra skeletal muscle manifestations seen in a number of 
conditions however are a testament to the expression of various CMD proteins in other 
organs and the result of diverse functions of the ECM in these.  
 
The work presented in Chapter 2 reinforces the prevalence of ECM protein 
abnormalities in the UK population of CMD. Among the patients I reviewed fulfilling the 
diagnostic criteria for CMD, 46% had a confirmed molecular defect in a protein of the 
ECM (21% collagen VI related, 15% dystroglycanopathy, 10% MDC1A). Allowing for 
the fact that 50% of patients remained undiagnosed from a genetic perspective, this 
leaves a small proportion of patients with defects in genes of the nuclear envelope 
(EDMD2 3%) or endoplasmic reticulum (1%).  
 
Whilst the ECM seems to be a prime location for proteins defective in CMDs, other 
groups of proteins are also known to be important. Lamin A/C until recently was the 
only nuclear envelope protein known to give rise to a CMD phenotype (although emerin 
mutations are known to give rise to X-linked EDMD). Work over the last few years has 
revealed that nesprin is also implicated in CMD phenotypes. CMD with adducted 
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thumbs(26) is due to mutations in SYNE-1, that encodes nesprin-1(25).  Nesprin-1 
mutations have also been associated with 2 other phenotypes; splice site mutations in 
SYNE-1 that result in loss of the KASH domain of nesprin-1 result in a form of 
autosomal recessive arthrogryposis with myopathic features and mutations in SYNE-1 
have also been found in ARCA1, a late onset autosomal recessive cerebellar 
ataxia(46, 322). Nesprin-1 has been shown to be involved in anchoring specialized 
myonuclei underneath neuromuscular junctions (323). It also binds Lamin A and 
emerin in vitro and in vivo. By binding to lamin and emerin, nesprins link the 
nucleoskeleton and inner nuclear membrane to the outer nuclear membrane and outer 
cytoskeleton (324). Nesprin-1 also belongs to the LINC complex, linking the nuclear 
lamina to the actin cytoskeleton in the cytoplasm, a role that conceivably may be 
important in the pathogenesis of CMD phenotypes(19). Interestingly, given nesprin-1s 
interaction with lamin A, the variable phenotype produced by mutations in the SYNE-1 
is reminiscent, although not as extreme, as the picture seen with LMNA mutations(22, 
30, 115, 118). 
 
This work in Chapter 2 also supports the notion that some subtypes of CMD are rare. 
We observed no cases of integrin α7 deficiency and there remains only 3 cases of this 
reported worldwide. Interestingly, CMD with hyperlaxity (CMDH) reported in the French 
Canadian population is now known to result from mutations in integrin α9 (ITGA9), 
confirming this as the second integrin (after integrin α7) to be implicated in the 
pathogenesis of CMD (26, 29). It remains to be seen whether other integrins may also 
be implicated in CMD.  
 
We found no further cases of MDC1B in out cohort and the total number of reported 
cases of this stands at 6(28). Among the dystroglycanopathies, mutations in LARGE 
remain infrequent.  
 
The work on the frequency of CMD variants also highlights the large number of 
disorders presenting clinically in a similar manner to CMD. Congenital myasthenia and 
CMD overlap in their clinical presentation, highlighted by the number of congenital 
myasthenia patients seen in our CMD referral population (222). Furthermore, it has 
come to light over that last couple of years that the CMD phenotype reported to be 
associated with 4p16.3 (Table 2) is in fact a congenital myasthenia with mutation in 
DOK7 (F Muntoni, personal communication), highlighting just how similar these 
conditions may be (27). The complex interactions of the CMD proteins may go some 
way to explaining the phenotypic overlap with other conditions. DGC ligands in skeletal 
muscle include agrin (mutated in a form of limb girdle myasthenia) and BDG interacts 
 
 
173 
 
with rapsyn (mutated in a form of congenital myasthenia). Dystroglycan also has a role 
in stabilising acetylcholine receptors at the neuromuscular junction(141, 154, 158, 167).  
 
The recent revelation that mutations in DPM3 cause a phenotype with features 
consistent with both a dystroglycanopathy and congenital disorder of glycosylation is 
particularly interesting and has broadened the investigative approach when assessing 
patients with suspected CMD to include studying serum transferrin isoforms (44). 
Interestingly there has been speculation that one of the steps in the mannosylation of 
ADG is catalysed by a β1,4-galactosyltransferase  (B4GalT). Mutations in B4GalT have 
been implicated in congenital disorder of glycosylation type IId (CDG IId; MIM 607091) 
again suggesting that these groups of disorders are more closely linked that previously 
anticipated (325, 326). 
 
The continued progress in understanding the basis of CMD has resulted both in the 
widening spectrum of phenotypes attributed to mutations in many causative genes and 
in some cases the emergence of distinct subclasses of disorder. In 2010 it remains true 
that delineating the underlying aetiology of congenital muscular dystrophy and 
characterising the individual CMD phenotypes is a complex task. 
 
5.2 DYSTROGLYCANOPATHIES 
 
5.2.1 Genotype Phenotype Correlation 
 
Work performed on identifying genotype phenotype correlations in the 
dystroglycanopathies in this thesis (Chapter 3) identified mutations in 34% of the cohort 
studied. Several new phenotypes were also identified including patients with FKTN and 
POMGNT1 mutations without any mental retardation. The paper published 
documenting this work was the first of its kind and confirmed the heterogeneity seen in 
these disorders. Since this work was published (231), 3 further substantial 
dystroglycanopathy cohorts have been reported. In 2009 Mercuri et al. reported a large 
Italian cohort of patients including those with FKRP mutations. Mutations were detected 
in 43/81 (53%) and results confirmed the wide phenotypic spectrum associated with the 
dystroglycanopathies. POMT1, POMT2 and FKRP mutations were the most frequently 
seen dystroglycanopathies in their population and MEB the most prevalent phenotype 
(327). They also reported variations on the classic dystroglycanopathy brain 
phenotypes with patients with isolated ventricular dilatation with no other findings 
reported with mutations in POMT1 and FKRP and also 2 patients with isolated Chiari 
malformation type 1 with mutations in POMT1 and POMT2.  A cohort published by 
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Bouchet et al. reported the genetic mutations associated with foetal type 2 
lissencephaly in the French population. They found mutations in 21/41 (53%) families 
with POMT1 mutations the most prevalent, followed by POMGNT1 and then POMT2. 
They did not find any likely pathogenic FKRP, FKTN or LARGE mutations in their 
patient population. Interestingly they found that POMT1 and POMT2 mutations 
consistently correlated with supra and infratentorial brain involvement whereas the 
patients with POMGNT1 mutations were often more mildly affected (328).  Manzini et 
al. published a study of 43 patients of varied ethnicity and geographical origin with 
WWS and found mutations in 40%. POMT1 mutations were commonly found in 
patients from the Middle East whilst FKTN was a common cause of WWS in the 
patients of European descent. No mutations were found in LARGE or POMGNT1 
(329). Other smaller studies and case reports have also been published supporting our 
findings of FKTN as a frequent cause of LGMD with no mental retardation (227, 330). 
Mutations in POMT2 have been reported in patients with LGMD with no mental 
retardation for the first time (LGMD2N) and also in patients with CMD with mental 
retardation (327, 331, 332) . A FKTN founder mutation has also been identified in the 
Ashkenazi Jewish population that causes WWS. The consistent message throughout 
these studies has been, with the exception of a few founder mutations, genetic and 
phenotypic heterogeneity is extensive in this group of disorders. It is also apparent that 
at least 50% of patients with a dystroglycanopathy phenotype have no mutations in 
POMT1, POMT2, POMGNT1, FKRP, FKTN or LARGE. The recent identification of 
CDG1o as a new dystroglycanopathy phenotype means that DPM3 has not been 
excluded in many patients but it is unlikely to be the only gene contributing to the 
undiagnosed cases. Indeed collaborative studies with the Dutch group which described 
this condition has not identified DPM3 mutations in 20 dystroglycanopathy patients 
from our centre (Francesco Muntoni personal communication). The genotype 
phenotype associations for the dystroglycanopathy genes known in 2010 is 
summarised in Table 14. 
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Gene WWS MEB FCMD CMD-
CRB 
CMD - 
MR 
CMD – 
no MR 
LGMD -
MR 
LGMD – 
no MR 
CMD 1X CDG 1o 
POMT1 (130, 
251, 253) 
(333)  (327) (130, 
251, 
253) 
(327) (125, 252)    
POMT2 (132) (210)  (333) (327, 
331) 
 (333) (334)   
POMGNT1 (254) (129, 
254) 
     (333)   
FKTN (208, 
226, 335) 
(333) (127, 255)   (333)  (126, 227, 
330) 
(32)  
FKRP (207) (207)  (211) (211) (128)  (192) 
 
  
LARGE (311, 
327, 333) 
   (131)      
DPM3          (44) 
 
 
Table14.  The main dystroglycanopathy genotype-phenotype associations in 2010. 
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 Blue shading indicates known associations before our study commenced, red indicates phenotypes identified by our study and green 
indicates subsequently identified phenotypes. Key references are indicated.  
 
WWS; Walker Warburg Syndrome, MEB; Muscle Eye Brain Disease, FCMD; Fukuyama CMD, CMD-CRB;  CMD with cerebellar 
involvement, CMD - MR; CMD with mental retardation, CMD –no MR; CMD without mental retardation, LGMD - MR; LGMD with mental 
retardation, LGMD –no  MR; LGMD without mental retardation, CMD1X; dilated cardiomyopathy 1X, CDG1o; congenital disorder of 
glycosylation type 1o. 
 
.
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5.2.2 Classification of Dystroglycanopathies 
 
‘it is increasingly clear that historical, eponymous classifications may represent an 
unreliable guide to the complex overlap of phenotypes generated by locus and allele 
heterogeneity’  
 
Reproduced with permission Cormand et al. 2001(206). 
 
This quote by Cormand et al. remains true 9 years later. Whilst the advances in the 
understanding of the molecular basis of CMDs has helped in so far as separating the 
main classes of CMD according to the location of the proteins involved, intragroup 
nomenclature, particularly in the dystroglycanopathies is unsatisfactory. The large 
number of individual case reports of phenotypes ascribed by us and others to 
dystroglycanopathy genes has led to many different names for dystroglycanopathy 
phenotypes. At the last count the following phenotypes had been reported: WWS, 
MEB, FCMD, MDC1B, MDC1C, MDC1D, LGMD2I, LGMD2K, LGMD2M, LGMD2N 
(actually assigned initially to 2 different conditions), Italian MEB, CMD with cerebellar 
cysts, CMD with cataracts; CMD with adducted thumbs; CDM1X and CDG1o. This 
does not take into account the various terms initially used to describe WWS.  The 
subtle difference between these conditions and the increasing genetic heterogeneity 
has resulted in confusion among the intermediate phenotypes. With the exception of a 
few founder mutations (FKTN retrotransposal insertion (FCMD), FKRP C286A 
(LGMD2I) and POMT1 A200P (LGMD2K)) it is apparent that a distinctive 
dystroglycanopathy phenotype is rarely going to be exclusively caused by only one 
gene. Our comprehensive genotype phenotype study has reinforced the notion that 
similar phenotypes are caused by more than one gene; FCMD overlaps with MEB 
caused by POMGNT1 and POMT2, LGMD phenotypes with no mental retardation can 
also be caused by mutations in POMGNT1, POMT2 and FKTN.  I found in trying to 
study this collective group of conditions that multiple names, far from being useful often 
caused confusion. Phenotypes described in the literature often needed to be simplified 
to the core essentials in order to be able to apply them to larger studies. I found a large 
benefit to simplifying the core phenotypes to WWS, MEB, FCMD (although in reality 
this was never needed as we had no Japanese patients in any of our studies) and then 
CMD and LGMD with and without mental retardation, a strategy that has continued in 
some of the subsequent departmental papers(38). Account also has to be made for the 
CDG overlap phenotypes and these for the time being should be considered 
separately. Keeping the eponymous names for the severe phenotypes is justified 
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because of the striking features observed in these conditions, making them readily 
discernable from the milder conditions. Simplifying the dystroglycanopathies to core 
phenotypes is a valid strategy in other circumstances. Certainly conveying the range of 
phenotypes to a mass audience less familiar with the conditions is helped enormously 
by adopting this simplified approach which is applicable in everyday clinical practice 
and sufficient for most purposes. The one area in which a stricter definition of 
phenotype is still very important however is for those discreet genetically distinct 
dystroglycanopathy subtypes that are relatively common where long term outcome 
data can be generated with some degree of reliability and the possibility of therapeutic 
intervention is significant. This applies particularly to LGMD2I and FCMD where the 
phenotypes are largely homogenous and common as a result of founder mutations.  In 
terms of whether to ‘lump or split’ this group of conditions, whilst the molecular and 
genetic data are still incomplete I strongly favour lumping except in the specific 
circumstances described above.  
 
Much work following directly from the dystroglycanopathy genotype phenotype study 
was performed by Dr Caroline Godfrey in our laboratory. A natural step on from this 
was to search for new dystroglycanopathy genes. Several good candidate genes have 
been screened for mutations in a cohort of 37 patients many of whom remained 
undiagnosed at the end of the initial study. Genes screened included GYLTL1B, 
β3GNT1, WWP1, GYG1, GYG2, MGAT5B and DAG1 (C. Godfrey personal 
communication).  No clearly pathogenic mutations were detected in any of the genes. 
Whilst this does not exclude their involvement in the pathogenesis of 
dystroglycanopathy, mutations in these genes are clearly not common causes of 
human dystroglycanopathy.  
 
Another departmental study stemming from the genotype phenotype 
dystroglycanopathy paper was led by Dr Jimenez-Mallebrera. Muscle pathology 
findings in 24 patients with dystroglycanopathy were analysed, seeking to establish 
whether or not a correlation existed between ADG depletion on skeletal muscle biopsy 
and clinical severity (336). Such a correlation was observed in patients with mutations 
in POMT1, POMT2 and POMGNT1. This was not however seen in patients with 
mutations in FKTN or FKRP; for example, some patients with mild LGMD phenotypes 
had a severe depletion of ADG epitope staining.  This study concluded that ADG 
depletion could not reliably be used as an indicator of clinical severity. 
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The work described in chapter 3 also formed the basis for the subsequent study of MRI 
brain findings in patients with dystroglycanopathy. In a similar fashion to the work on 
genotype phenotype correlation, this work established the varied MRI appearance in 
patients with confirmed mutations although some consistent and potentially 
diagnostically useful patterns were observed; POMGNT1 mutations were always seen 
in association with florid cerebellar cysts on brain MRI for example, a finding that can 
also be observed in FKRP mutations.  Cerebellar cysts were also seen in some 
patients with POMT1, POMT2 and LARGE mutations but these were typically not as 
extensive. Our results suggest that targeted screening of POMGNT1 and FKRP should 
be considered where cerebellar cysts are the predominant abnormality. In contrast to 
the typical MRI brain changes seen in patients with FCMD, the four MRIs that we 
reviewed with FKTN mutations were either normal or had minimal changes. This 
finding reinforces the concept of a subgroup of FKTN related conditions that are distinct 
from classic FCMD seen in Japan, where almost invariably patients carry a mutation 
unique to that population. We additionally found some patients with isolated temporo 
occipital cortical changes, a distribution more commonly seen in MDC1A.The overlap in 
MRI appearance between patients with GPR56 mutations and bilateral frontoparietal 
polymicrogyria and some of the dystroglycanopathy scans reviewed was also noted. 
This highlights the importance of considering dystroglycanopathy as a differential 
diagnosis in these conditions especially given the wide spectrum of presentation. It will 
be interesting to see whether patients with isolated brain changes and minimal / absent 
muscle involvement are reported in due course as the MRI brain phenotype becomes 
more universally recognisable as representative of a dystroglycanopathy. 
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5.3 FUTURE PERSPECTIVES  
 
5.3.1 Mutation Detection 
 
Although the sensitivity of genetic testing has steadily improved, there are clear 
limitations to the mutation detection methods used in our study. In particular, large 
heterozygous deletions or duplications are likely to be missed using present 
techniques. In some patients variants of unknown significance have been detected that 
cannot be proven to be pathogenic using current methods. In others, a diagnosis may 
eventually be made as a result of new technology, in particular the emergence of the 
NMD chip for block testing neuromuscular disorders in affected individuals. The DNC is 
currently involved in a large European consortium based project aimed at designing, 
producing and validating novel DNA-chips for diagnosing neuromuscular diseases. 
Arrays will be developed with oligonucleotide probes designed to all known 
neuromuscular disease genes as well as a large panel of novel genes including a 
number of the candidate genes screened by Caroline Godfrey as detailed above. The 
results of the first round of screening for the NMD chip are pending and the first few 
large rearrangements have been detected using this technique (http://www.nmd-
chip.eu/about).  
 
 A further advance in mutation detection technology is the advent of next generation 
sequencing. The use of this technology to sequence the entire genome still remains 
prohibitively expensive in most cases yet the use of targeted sequence capture 
approaches followed by parallel DNA sequencing offers a cost effective alternative. 
Either specific genomic regions or the entire exome (constituting approximately 5% of 
the genome) can be captured on microarray and sequenced (337).   DNA from a 
subset of undiagnosed CMD patients will be submitted for exome sequencing as part of 
the UK10K Project at the Wellcome Trust Sanger Institute, Cambridge,  
http://www.uk10k.org/. The UK10K project is expected to uncover many rare genetic 
variants that are important in human disease, CMD included, giving a much deeper 
picture of genetics that can be applied to other studies both in the UK and around the 
world.  
 
Although the NMD chip and other next generation sequencing technologies are very 
exciting advances in the field of CMD testing, the quantity of data generated by such 
methods and in turn the accurate interpretation of results is likely to present its own set 
of challenges.  
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5.3.2 Treatment of CMD and Therapeutic Trials 
 
Until very recently the basis of treatment in CMD was not aimed at a cure but directed 
at symptomatic relief. Despite this, many of the interventions introduced have 
significantly altered the quality of life and natural history of this group of disorders. The 
introduction of non-invasive ventilation has significantly improved life expectancy and 
maximising nutrition has also been important (108, 232, 338). Other therapies including 
physiotherapy and surgery for scoliosis have improved quality of life(339, 340). It has 
only been in recent years with the improved knowledge and understanding of the 
molecular and genetic basis for this group of condition that a shift in direction towards 
trying to treat the underlying biochemical defects rather than physical symptoms has 
been possible.  
 
 
Dystroglycanopathies 
 
One therapeutic strategy considered in the dystroglycanopathies has resulted from 
work by Barresi et al. on adenovirus-mediated forced overexpression of LARGE in 
mydLARGE mice. Such overexpression was shown to result in synthesis of glycan-
enriched ADG with an increased affinity for its extracellular ligands resulting in 
improved skeletal muscle pathology. Importantly, overexpression of LARGE could also 
overcome the hypoglycosylation of ADG resulting from mutations in genes other than 
LARGE.  Adenovirus-mediated LARGE gene transfer in FKTN and POMGNT1 and 
POMT1 deficient patient cell lines resulted in improved glycosylation of ADG and 
enhanced binding of laminin(199, 341). 
 
A separate strategy has considered the up regulation of Galgt2 (cytotoxic T-cell 
GalNAc transferase). Transgenic overexpression of Galgt2 in skeletal muscle 
increased glycosylation of ADG and leads to increased expression of ECM proteins 
including laminin α4 and laminin α5 (342, 343).  
 
More generic approaches to gene therapy, trialled in other disorders may also have an 
application in the dystroglycanopathies. Compounds such as PTC124 (Ataluren), 
currently under assessment in Duchenne muscular dystrophy clinical trials, that allow 
read through of stop codons may be of some use in dystroglycanopathy patients who 
carry a nonsense mutation. Alternatively it may be possible to exploit gene delivery 
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systems using adeno-associated  viral (AAV) vectors as demonstrated in dystrophin 
deficient models(344). 
 
An important point to consider in these cases is what aspects of the disease are likely 
to be improved by any therapeutic strategy.  Most of the work to date has concentrated 
on enhanced  glycosylation of ADG, binding to ligands and improved skeletal muscle 
pathology as a positive outcome measures. What remains to be seen is whether it is 
realistic to expect an improvement in the extraskeletal manifestations of 
dystroglycanopathies. For this reason it may be that prenatal intervention needs to be 
considered as a long term goal.  
 
Collagen VI  Related Disorders 
 
Much of the work looking at therapeutic targets in UCMD has concentrated on the 
finding of myofiber apoptosis as an endpoint in collagen VI dysfunction. This is thought 
to result from premature breakdown of the mitochondrial permeability transition pore 
(mPTP)- controlled potential (345, 346). Cyclosporin A (CsA) inhibits the mPTP and 
has been shown to rescue muscle ultrastructural defects and decrease the number of 
apoptotic nuclei. In a study of 5 patients with collagen VI myopathy, a trial of oral CsA 
largely normalised mitochondrial dysfunction apoptosis and increased muscle 
regeneration (347).  An analogue of CsA, Debio 025, which selectively inhibits 
cyclophilin D (rather than calcineurin and cyclophilins as in the case of CsA) has also 
been tested in col6a1-/-  mice with positive findings including normalisation of 
mitochondrial function in skeletal muscle fibres, significant reduction in ultrastructural 
damage and  decreased incidence of apoptosis in diaphragm muscle fibres(348, 349).    
Testing  of a further compound, Omigapil, that binds to GAPDH and acts as an inhibitor 
of apoptosis has been shown to work effectively in 2 animal models of CMD; col6a1-/-  
(col VI deficiency) but also the dyw/dyw mouse (MDC1A) (350) . 
 
MDC1A 
 
The pathological changes observed in MDC1A have provided researchers with several 
avenues to explore in terms of disease modification. Firstly, in common with UCMD, 
increased apoptosis is a finding in laminin α2 deficient mice and fish. This is thought to 
perhaps be a consequence of membrane instability and decoupling of the muscle from 
the ECM(351, 352). In addition muscle fibrosis is a prominent feature.  
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Strategies looking at overcoming the apoptosis include overexpression of BCL2 (an 
antiapoptotic protein), resulting from crossing laminin α2 deficient mice and transgenic 
mice that overexpress muscle specific BCL2 (353). This resulted in improved lifespan 
and increased growth rate in affected mice. Doxycyclin, another inhibitor of apoptosis, 
has also been shown to improve lifespan and muscle pathology in lama2dy-W mice 
(354).  As described above, Omigapil has also shown to be effective in the MDC1A 
mouse model (350). 
 
Other work had looked at ways to re-establish the connection between ADG and the 
basement membranes which is lost in MDC1A. A minigene derived from Agrin (mini-
agrin), delivered via an AAV vector appears to be able to bridge the muscle to 
basement membrane by binding laminin-511. Trials in MDC1A mice reported an 
ameliorated phenotype with improved motility, lifespan and muscle pathology (355).  
The extensive fibrosis in MDC1A is associated with increased expression of 
transforming growth factor (TGF)-β, the expression of which is promoted by 
Angiotensin II. Angiotensin II type 1 receptor antagonist losartan has recently been 
demonstrated to reduce fibrosis in laminin deficient mice models (356).  
 
Finally, the more dramatic approach of bone marrow transplant has also been tried in 
MDC1A mouse models. This led to an improved life span, skeletal muscle pathology, 
grip strength and respiratory function compared with wild type mice, a finding not seen 
in mdx mice. The reasons for this are not entirely clear but it is thought that it might 
reflect the basal lamina disruption seen in dy mice  skeletal muscle which might be 
rectified by infusion of bone marrow derived cells that restore the laminin – merosin 
networks(357).  
 
SEPN1 Related Disorders 
 
Recent work by Arbogast et al. demonstrates that selenoprotein N plays a key role in 
prevention of oxidative stress damage in cultured muscle cells from patients with 
SEPN1 null mutations(105). Selenoprotein N is also associated  with the ryanodine 
receptor type 1 (RYR1),  a calcium release channel modulated by redox reactions 
(358). In cultured myoblasts null for SEPN1, both intracellular oxidant activity and 
cytosolic calcium were increased (105). The similarity between the clinical and 
pathological phenotypes of RYR1- related central core disease and patients with 
SEPN1 mutations suggest that there may be common disease mechanisms at work 
(359). 
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The susceptibility of SEPN1 null cultured myoblasts to oxidative stress related cell 
death can be ameliorated by treating the cells with N-acetylcysteine (NAC)(105). NAC 
can also reduce protein oxidation in these cells.  NAC may potentially be of therapeutic 
use in patients with SEPN1-related myopathies and clinical trials are planned (360). 
Another potential therapy for SEPN1 related disorders would be AAV virus directed 
gene therapy as SEPN-1 related myopathies result from loss of gene function and the 
gene of a size that would potentially make this feasible (360). 
 
5.4 CONCLUDING COMMENTS 
 
In order to assess the efficacy of any clinical trial or therapeutic intervention, solid 
natural history data is important and much of the clinical data gathered in the process 
of producing this thesis has contributed to the development of clinical databases which 
form the foundation for on-going clinical research. Alongside this I have developed 
disease specific proformas for use in clinics to enable relevant and accurate data to be 
captured to facilitate long term research.  
 
This thesis provides an overview of the classification, clinical and genetic aspects of 
CMD in 2010, with particular emphasis on the expanding field of dystroglycanopathies. 
Whilst much has been learnt over the last decade, further work is needed to refine the 
pathogenic mechanisms underlying these disorders in order to assist in the ultimate 
goal of achieving successful therapeutic intervention or cures for these devastating 
conditions. 
 
  
 
 
185 
 
REFERENCES  
 
1. Mostacciuolo ML, Miorin M, Martinello F, Angelini C, Perini P, Trevisan CP. 
Genetic epidemiology of congenital muscular dystrophy in a sample from north-east 
Italy. Hum Genet 1996;97:277-279. 
2. Muntoni F, Voit T. The congenital muscular dystrophies in 2004: a century of 
exciting progress. Neuromuscul Disord 2004;14:635-649. 
3. Batten F. Three cases of myopathy, infantile type. Brain 1903;26:147-148. 
4. Dubowitz V, Sewry CA. Muscle Biopsy a Practical Approach, Third ed: 
Saunders, 2007. 
5. Dubowitz V. 22nd ENMC sponsored workshop on congenital muscular 
dystrophy held in Baarn, The Netherlands, 14-16 May 1993. Neuromuscul Disord 
1994;4:75-81. 
6. Dubowitz V. 41st ENMC International Workshop on Congenital Muscular 
Dystrophy 8-10 March 1996, Naarden, The Netherlands. Neuromuscul Disord 
1996;6:295-306. 
7. Dubowitz V. 50th ENMC International Workshop: congenital muscular 
dystrophy. 28 February 1997 to 2 March 1997, Naarden, The Netherlands. Neuromuscul 
Disord 1997;7:539-547. 
8. Dubowitz V. 68th ENMC international workshop (5th international workshop): 
On congenital muscular dystrophy, 9-11 April 1999, Naarden, The Netherlands. 
Neuromuscul Disord 1999;9:446-454. 
9. Tome FM, Evangelista T, Leclerc A, et al. Congenital muscular dystrophy with 
merosin deficiency. C R Acad Sci III 1994;317:351-357. 
10. Helbling-Leclerc A, Zhang X, Topaloglu H, et al. Mutations in the laminin alpha 
2-chain gene (LAMA2) cause merosin-deficient congenital muscular dystrophy. Nat 
Genet 1995;11:216-218. 
11. Davies KE, Nowak KJ. Molecular mechanisms of muscular dystrophies: old and 
new players. Nat Rev Mol Cell Biol 2006;7:762-773. 
12. Jimenez-Mallebrera C, Brown SC, Sewry CA, Muntoni F. Congenital muscular 
dystrophy: molecular and cellular aspects. Cell Mol Life Sci 2005;2:809-823. 
13. Sanes JR. The basement membrane/basal lamina of skeletal muscle. J Biol 
Chem 2003;278:12601-12604. 
14. Michele DE, Campbell KP. Dystrophin-glycoprotein complex: post-translational 
processing and dystroglycan function. J Biol Chem 2003;278:15457-15460. 
15. Gruenbaum Y, Margalit A, Goldman RD, Shumaker DK, Wilson KL. The 
nuclear lamina comes of age. Nat Rev Mol Cell Biol 2005;6:21-31. 
16. Burke B, Stewart CL. Life at the edge: the nuclear envelope and human disease. 
Nat Rev Mol Cell Biol 2002;3:575-585. 
17. Gerace L, Blum A, Blobel G. Immunocytochemical localization of the major 
polypeptides of the nuclear pore complex-lamina fraction. Interphase and mitotic 
distribution. J Cell Biol 1978;79:546-566. 
18. Lin F, Worman HJ. Structural organization of the human gene encoding nuclear 
lamin A and nuclear lamin C. J Biol Chem 1993;268:16321-16326. 
19. Crisp M, Liu Q, Roux K, et al. Coupling of the nucleus and cytoplasm: role of 
the LINC complex. J Cell Biol 2006;172:41-53. 
20. Reed UC. Congenital muscular dystrophy. Part I: a review of phenotypical and 
diagnostic aspects. Arq Neuropsiquiatr 2009;67:144-168. 
21. Lisi MT, Cohn RD. Congenital muscular dystrophies: new aspects of an 
expanding group of disorders. Biochim Biophys Acta 2007;1772:159-172. 
 
 
186 
 
22. Mercuri E, Poppe M, Quinlivan R, et al. Extreme variability of phenotype in 
patients with an identical missense mutation in the lamin A/C gene: from congenital 
onset with severe phenotype to milder classic Emery-Dreifuss variant. Arch Neurol 
2004;61:690-694. 
23. Mahjneh I, Bushby K, Anderson L, et al. Merosin-positive congenital muscular 
dystrophy: a large inbred family. Neuropediatrics 1999;30:22-28. 
24. Muntoni F, Taylor J, Sewry CA, Naom I, Dubowitz V. An early onset muscular 
dystrophy with diaphragmatic involvement, early respiratory failure and secondary 
alpha2 laminin deficiency unlinked to the LAMA2 locus on 6q22. Eur J Paediatr Neurol 
1998;2:19-26. 
25. Voit T, Cirak S, Abraham S, et al. Congenital muscular dystrophy with adducted 
thumbs, mental retardation, cerbellar hypoplasia and cataracts is caused by mutation of 
Enaptin (Nesprin-1): The third nucelar envelopathy with muscular dystrophy. 
Neuromuscul Disord 2007;17:833-834. 
26. Tetreault M, Duquette A, Thiffault I, et al. A new form of congenital muscular 
dystrophy with joint hyperlaxity maps to 3p23-21. Brain 2006;129:2077-2084. 
27. Sellick GS, Longman C, Brockington M, et al. Localisation of merosin-positive 
congenital muscular dystrophy to chromosome 4p16.3. Hum Genet 2005;117:207-212. 
28. Brockington M, Sewry CA, Herrmann R, et al. Assignment of a form of 
congenital muscular dystrophy with secondary merosin deficiency to chromosome 
1q42. Am J Hum Genet 2000;66:428-435. 
29. Tetreault M, Thiffault I, Loisel L, et al. Mutations in the Integrin responsible for 
a congenital muscular dystrophy with hyperlaxity and their impact on normal cellular 
adhesion. In: ASHG; 2009; Honolulu, Hawaii, 2009. 
30. Quijano-Roy S, Mbieleu B, Bonnemann CG, et al. De novo LMNA mutations 
cause a new form of congenital muscular dystrophy. Ann Neurol 2008;64:177-186. 
31. D'Amico A, Petrini S, Parisi F, et al. Heart transplantation in a child with 
LGMD2I presenting as isolated dilated cardiomyopathy. Neuromuscul Disord 
2008;18:153-155. 
32. Murakami T, Hayashi YK, Noguchi S, et al. Fukutin gene mutations cause 
dilated cardiomyopathy with minimal muscle weakness. Ann Neurol 2006;60:597-602. 
33. Nakanishi T, Sakauchi M, Kaneda Y, et al. Cardiac involvement in Fukuyama-
type congenital muscular dystrophy. Pediatrics 2006;117:e1187-1192. 
34. Geranmayeh F, Clement E, Feng LH, et al. Genotype-phenotype correlation in a 
large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul 
Disord;20:241-250. 
35. Jones KJ, Morgan G, Johnston H, et al. The expanding phenotype of laminin 
alpha2 chain (merosin) abnormalities: case series and review. J Med Genet 
2001;38:649-657. 
36. Mercuri E, Muntoni F, Berardinelli A, et al. Somatosensory and visual evoked 
potentials in congenital muscular dystrophy: correlation with MRI changes and muscle 
merosin status. Neuropediatrics 1995;26:3-7. 
37. Dubowitz V, Sewry C. Muscle Biopsy: A practical approach, 3 ed: Saunders, 
2006. 
38. Jimenez-Mallebrera C, Maioli MA, Kim J, et al. A comparative analysis of 
collagen VI production in muscle, skin and fibroblasts from 14 Ullrich congenital 
muscular dystrophy patients with dominant and recessive COL6A mutations. 
Neuromuscul Disord 2006;16:571-582. 
39. Mercuri E, Yuva Y, Brown SC, et al. Collagen VI involvement in Ullrich 
syndrome: a clinical, genetic, and immunohistochemical study. Neurology 
2002;58:1354-1359. 
 
 
187 
 
40. Mercuri E, Clements E, Offiah A, et al. Muscle magnetic resonance imaging 
involvement in muscular dystrophies with rigidity of the spine. Ann Neurol;67:201-208. 
41. Astrea G, Schessl J, Clement E, et al. Muscle MRI in FHL1-linked reducing 
body myopathy. Neuromuscul Disord 2009;19:689-691. 
42. Longman C, Mercuri E, Cowan F, et al. Antenatal and postnatal brain magnetic 
resonance imaging in muscle-eye-brain disease. Arch Neurol 2004;61:1301-1306. 
43. Shorer Z, Philpot J, Muntoni F, Sewry C, Dubowitz V. Demyelinating 
peripheral neuropathy in merosin-deficient congenital muscular dystrophy. J Child 
Neurol 1995;10:472-475. 
44. Lefeber DJ, Schonberger J, Morava E, et al. Deficiency of Dol-P-Man synthase 
subunit DPM3 bridges the congenital disorders of glycosylation with the 
dystroglycanopathies. Am J Hum Genet 2009;85:76-86. 
45. Voit T, Parano E, Straub V, et al. Congenital muscular dystrophy with adducted 
thumbs, ptosis, external ophthalmoplegia, mental retardation and cerebellar hypoplasia: 
a novel form of CMD. Neuromuscul Disord 2002;12:623-630. 
46. Attali R, Warwar N, Israel A, et al. Mutation of SYNE-1, encoding an essential 
component of the nuclear lamina, is responsible for autosomal recessive arthrogryposis. 
Hum Mol Genet 2009;18:3462-3469. 
47. Hillaire D, Leclerc A, Faure S, et al. Localization of merosin-negative 
congenital muscular dystrophy to chromosome 6q2 by homozygosity mapping. Hum 
Mol Genet 1994;3:1657-1661. 
48. Hayashi YK, Tezak Z, Momoi T, et al. Massive muscle cell degeneration in the 
early stage of merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 
2001;11:350-359. 
49. Miyagoe-Suzuki Y, Nakagawa M, Takeda S. Merosin and congenital muscular 
dystrophy. Microsc Res Tech 2000;48:181-191. 
50. Colognato H, Yurchenco PD. Form and function: the laminin family of 
heterotrimers. Dev Dyn 2000;218:213-234. 
51. Sewry CA, Uziyel Y, Torelli S, et al. Differential labelling of laminin alpha 2 in 
muscle and neural tissue of dy/dy mice: are there isoforms of the laminin alpha 2 chain? 
Neuropathol Appl Neurobiol 1998;24:66-72. 
52. Philpot J, Sewry C, Pennock J, Dubowitz V. Clinical phenotype in congenital 
muscular dystrophy: correlation with expression of merosin in skeletal muscle. 
Neuromuscul Disord 1995;5:301-305. 
53. Vainzof M, Marie SK, Reed UC, et al. Deficiency of merosin (laminin M or 
alpha 2) in congenital muscular dystrophy associated with cerebral white matter 
alterations. Neuropediatrics 1995;26:293-297. 
54. Dubowitz DJ, Tyszka JM, Sewry CA, Moats RA, Scadeng M, Dubowitz V. 
High resolution magnetic resonance imaging of the brain in the dy/dy mouse with 
merosin-deficient congenital muscular dystrophy. Neuromuscul Disord 2000;10:292-
298. 
55. Matsumura K, Yamada H, Saito F, Sunada Y, Shimizu T. Peripheral nerve 
involvement in merosin-deficient congenital muscular dystrophy and dy mouse. 
Neuromuscul Disord 1997;7:7-12. 
56. Talts JF, Timpl R. Mutation of a basic sequence in the laminin alpha2LG3 
module leads to a lack of proteolytic processing and has different effects on beta1 
integrin-mediated cell adhesion and alpha-dystroglycan binding. FEBS Lett 
1999;458:319-323. 
57. Nissinen M, Helbling-Leclerc A, Zhang X, et al. Substitution of a conserved 
cysteine-996 in a cysteine-rich motif of the laminin alpha2-chain in congenital muscular 
dystrophy with partial deficiency of the protein. Am J Hum Genet 1996;58:1177-1184. 
 
 
188 
 
58. Guicheney P, Vignier N, Zhang X, et al. PCR based mutation screening of the 
laminin alpha2 chain gene (LAMA2): application to prenatal diagnosis and search for 
founder effects in congenital muscular dystrophy. J Med Genet 1998;35:211-217. 
59. Pegoraro E, Marks H, Garcia CA, et al. Laminin alpha2 muscular dystrophy: 
genotype/phenotype studies of 22 patients. Neurology 1998;51:101-110. 
60. Sewry CA, Naom I, D'Alessandro M, et al. Variable clinical phenotype in 
merosin-deficient congenital muscular dystrophy associated with differential 
immunolabelling of two fragments of the laminin alpha 2 chain. Neuromuscul Disord 
1997;7:169-175. 
61. Muntoni F, Guicheney P. 85th ENMC International Workshop on Congenital 
Muscular Dystrophy. 6th International CMD Workshop. 1st Workshop of the Myo-
Cluster Project 'GENRE'. 27-28th October 2000, Naarden, The Netherlands. 
Neuromuscul Disord 2002;12:69-78. 
62. Naom I, D'Alessandro M, Sewry C, et al. The role of immunocytochemistry and 
linkage analysis in the prenatal diagnosis of merosin-deficient congenital muscular 
dystrophy. Hum Genet 1997;99:535-540. 
63. Vainzof M, Richard P, Herrmann R, et al. Prenatal diagnosis in laminin alpha2 
chain (merosin)-deficient congenital muscular dystrophy: a collective experience of five 
international centers. Neuromuscul Disord 2005;15:588-594. 
64. Ullrich O. Kongenitale, atonisch-sklerotische Muskeldystrophie. Monatsschr 
Kinderheilkd 1930:502-510. 
65. Camacho Vanegas O, Bertini E, Zhang RZ, et al. Ullrich scleroatonic muscular 
dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci U S 
A 2001;98:7516-7521. 
66. Hessle H, Engvall E. Type VI collagen. Studies on its localization, structure, and 
biosynthetic form with monoclonal antibodies. J Biol Chem 1984;259:3955-3961. 
67. von der Mark H, Aumailley M, Wick G, Fleischmajer R, Timpl R. 
Immunochemistry, genuine size and tissue localization of collagen VI. Eur J Biochem 
1984;142:493-502. 
68. Bruns RR. Beaded filaments and long-spacing fibrils: relation to type VI 
collagen. J Ultrastruct Res 1984;89:136-145. 
69. Chu ML, Pan TC, Conway D, et al. The structure of type VI collagen. Ann N Y 
Acad Sci 1990;580:55-63. 
70. Chu ML, Mann K, Deutzmann R, et al. Characterization of three constituent 
chains of collagen type VI by peptide sequences and cDNA clones. Eur J Biochem 
1987;168:309-317. 
71. Zhang RZ, Sabatelli P, Pan TC, et al. Effects on collagen VI mRNA stability 
and microfibrillar assembly of three COL6A2 mutations in two families with Ullrich 
congenital muscular dystrophy. J Biol Chem 2002;277:43557-43564. 
72. Engvall E, Hessle H, Klier G. Molecular assembly, secretion, and matrix 
deposition of type VI collagen. J Cell Biol 1986;102:703-710. 
73. Kuo HJ, Maslen CL, Keene DR, Glanville RW. Type VI collagen anchors 
endothelial basement membranes by interacting with type IV collagen. J Biol Chem 
1997;272:26522-26529. 
74. Bruns RR, Press W, Engvall E, Timpl R, Gross J. Type VI collagen in 
extracellular, 100-nm periodic filaments and fibrils: identification by immunoelectron 
microscopy. J Cell Biol 1986;103:393-404. 
75. Keene DR, Engvall E, Glanville RW. Ultrastructure of type VI collagen in 
human skin and cartilage suggests an anchoring function for this filamentous network. J 
Cell Biol 1988;107:1995-2006. 
 
 
189 
 
76. Bidanset DJ, Guidry C, Rosenberg LC, Choi HU, Timpl R, Hook M. Binding of 
the proteoglycan decorin to collagen type VI. J Biol Chem 1992;267:5250-5256. 
77. Bonaldo P, Russo V, Bucciotti F, Doliana R, Colombatti A. Structural and 
functional features of the alpha 3 chain indicate a bridging role for chicken collagen VI 
in connective tissues. Biochemistry 1990;29:1245-1254. 
78. Tillet E, Wiedemann H, Golbik R, et al. Recombinant expression and structural 
and binding properties of alpha 1(VI) and alpha 2(VI) chains of human collagen type 
VI. Eur J Biochem 1994;221:177-185. 
79. Wiberg C, Hedbom E, Khairullina A, et al. Biglycan and decorin bind close to 
the n-terminal region of the collagen VI triple helix. J Biol Chem 2001;276:18947-
18952. 
80. Howell SJ, Doane KJ. Type VI collagen increases cell survival and prevents 
anti-beta 1 integrin-mediated apoptosis. Exp Cell Res 1998;241:230-241. 
81. Ruhl M, Johannsen M, Atkinson J, et al. Soluble collagen VI induces tyrosine 
phosphorylation of paxillin and focal adhesion kinase and activates the MAP kinase 
erk2 in fibroblasts. Exp Cell Res 1999;250:548-557. 
82. Ruhl M, Sahin E, Johannsen M, et al. Soluble collagen VI drives serum-starved 
fibroblasts through S phase and prevents apoptosis via down-regulation of Bax. J Biol 
Chem 1999;274:34361-34368. 
83. Voit T. Congenital muscular dystrophies: 1997 update. Brain Dev 1998;20:65-
74. 
84. Muntoni F, Bertini E, Bonnemann C, et al. 98th ENMC International Workshop 
on Congenital Muscular Dystrophy (CMD), 7th Workshop of the International 
Consortium on CMD, 2nd Workshop of the MYO CLUSTER project GENRE. 26-28th 
October, 2001, Naarden, The Netherlands. Neuromuscul Disord 2002;12:889-896. 
85. Lampe AK, Bushby KM. Collagen VI related muscle disorders. J Med Genet 
2005;42:673-685. 
86. Mercuri E, Lampe A, Allsop J, et al. Muscle MRI in Ullrich congenital muscular 
dystrophy and Bethlem myopathy. Neuromuscul Disord 2005;15:303-310. 
87. Pepe G, Bertini E, Bonaldo P, et al. Bethlem myopathy (BETHLEM) and 
Ullrich scleroatonic muscular dystrophy: 100th ENMC international workshop, 23-24 
November 2001, Naarden, The Netherlands. Neuromuscul Disord 2002;12:984-993. 
88. Haq RU, Speer MC, Chu ML, Tandan R. Respiratory muscle involvement in 
Bethlem myopathy. Neurology 1999;52:174-176. 
89. Mercuri E, Cini C, Counsell S, et al. Muscle MRI findings in a three-generation 
family affected by Bethlem myopathy. Eur J Paediatr Neurol 2002;6:309-314. 
90. Lampe AK, Dunn DM, von Niederhausern AC, et al. Automated genomic 
sequence analysis of the three collagen VI genes: applications to Ullrich congenital 
muscular dystrophy and Bethlem myopathy. J Med Genet 2005;42:108-120. 
91. Lamande SR, Morgelin M, Selan C, Jobsis GJ, Baas F, Bateman JF. Kinked 
collagen VI tetramers and reduced microfibril formation as a result of Bethlem 
myopathy and introduced triple helical glycine mutations. J Biol Chem 2002;277:1949-
1956. 
92. Lamande SR, Shields KA, Kornberg AJ, Shield LK, Bateman JF. Bethlem 
myopathy and engineered collagen VI triple helical deletions prevent intracellular 
multimer assembly and protein secretion. J Biol Chem 1999;274:21817-21822. 
93. Pepe G, Giusti B, Bertini E, et al. A heterozygous splice site mutation in 
COL6A1 leading to an in-frame deletion of the alpha1(VI) collagen chain in an italian 
family affected by bethlem myopathy. Biochem Biophys Res Commun 1999;258:802-
807. 
 
 
190 
 
94. Pan TC, Zhang RZ, Sudano DG, Marie SK, Bonnemann CG, Chu ML. New 
molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-
frame deletion in the COL6A1 gene causes a severe phenotype. Am J Hum Genet 
2003;73:355-369. 
95. Baker NL, Morgelin M, Peat R, et al. Dominant collagen VI mutations are a 
common cause of Ullrich congenital muscular dystrophy. Hum Mol Genet 2005;14:279-
293. 
96. Pepe G, de Visser M, Bertini E, et al. Bethlem myopathy (BETHLEM) 86th 
ENMC international workshop, 10-11 November 2000, Naarden, The Netherlands. 
Neuromuscul Disord 2002;12:296-305. 
97. Higuchi I, Suehara M, Iwaki H, Nakagawa M, Arimura K, Osame M. Collagen 
VI deficiency in Ullrich's disease. Ann Neurol 2001;49:544. 
98. Brockington M, Brown SC, Lampe A, et al. Prenatal diagnosis of Ullrich 
congenital muscular dystrophy using haplotype analysis and collagen VI 
immunocytochemistry. Prenat Diagn 2004;24:440-444. 
99. Clarke NF, Kidson W, Quijano-Roy S, et al. SEPN1: associated with congenital 
fiber-type disproportion and insulin resistance. Ann Neurol 2006;59:546-552. 
100. Ferreiro A, Ceuterick-de Groote C, Marks JJ, et al. Desmin-related myopathy 
with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene. 
Ann Neurol 2004;55:676-686. 
101. Ferreiro A, Quijano-Roy S, Pichereau C, et al. Mutations of the selenoprotein N 
gene, which is implicated in rigid spine muscular dystrophy, cause the classical 
phenotype of multiminicore disease: reassessing the nosology of early-onset 
myopathies. Am J Hum Genet 2002;71:739-749. 
102. Moghadaszadeh B, Petit N, Jaillard C, et al. Mutations in SEPN1 cause 
congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. 
Nat Genet 2001;29:17-18. 
103. Flanigan KM, Kerr L, Bromberg MB, et al. Congenital muscular dystrophy with 
rigid spine syndrome: a clinical, pathological, radiological, and genetic study. Ann 
Neurol 2000;47:152-161. 
104. Petit N, Lescure A, Rederstorff M, et al. Selenoprotein N: an endoplasmic 
reticulum glycoprotein with an early developmental expression pattern. Hum Mol Genet 
2003;12:1045-1053. 
105. Arbogast S, Beuvin M, Fraysse B, Zhou H, Muntoni F, Ferreiro A. Oxidative 
stress in SEPN1-related myopathy: from pathophysiology to treatment. Ann Neurol 
2009;65:677-686. 
106. Dubowitz V. Rigid spine syndrome: a muscle syndrome in search of a name. 
Proc R Soc Med 1973;66:219-220. 
107. D'Amico A, Haliloglu G, Richard P, et al. Two patients with 'Dropped head 
syndrome' due to mutations in LMNA or SEPN1 genes. Neuromuscul Disord 
2005;15:521-524. 
108. Schara U, Kress W, Bonnemann CG, et al. The phenotype and long-term follow-
up in 11 patients with juvenile selenoprotein N1-related myopathy. Eur J Paediatr 
Neurol 2008;12:224-230. 
109. Bonne G, Di Barletta MR, Varnous S, et al. Mutations in the gene encoding 
lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 
1999;21:285-288. 
110. Fisher DZ, Chaudhary N, Blobel G. cDNA sequencing of nuclear lamins A and 
C reveals primary and secondary structural homology to intermediate filament proteins. 
Proc Natl Acad Sci U S A 1986;83:6450-6454. 
 
 
191 
 
111. Dahl KN, Kahn SM, Wilson KL, Discher DE. The nuclear envelope lamina 
network has elasticity and a compressibility limit suggestive of a molecular shock 
absorber. J Cell Sci 2004;117:4779-4786. 
112. Brown SC, Piercy RJ, Muntoni F, Sewry CA. Investigating the pathology of 
Emery-Dreifuss muscular dystrophy. Biochem Soc Trans 2008;36:1335-1338. 
113. Bonne G, Mercuri E, Muchir A, et al. Clinical and molecular genetic spectrum 
of autosomal dominant Emery-Dreifuss muscular dystrophy due to mutations of the 
lamin A/C gene. Ann Neurol 2000;48:170-180. 
114. Bonne G, Yaou RB, Beroud C, et al. 108th ENMC International Workshop, 3rd 
Workshop of the MYO-CLUSTER project: EUROMEN, 7th International Emery-
Dreifuss Muscular Dystrophy (EDMD) Workshop, 13-15 September 2002, Naarden, 
The Netherlands. Neuromuscul Disord 2003;13:508-515. 
115. Vytopil M, Benedetti S, Ricci E, et al. Mutation analysis of the lamin A/C gene 
(LMNA) among patients with different cardiomuscular phenotypes. J Med Genet 
2003;40:e132. 
116. Krimm I, Ostlund C, Gilquin B, et al. The Ig-like structure of the C-terminal 
domain of lamin A/C, mutated in muscular dystrophies, cardiomyopathy, and partial 
lipodystrophy. Structure 2002;10:811-823. 
117. Benedetti S, Menditto I, Degano M, et al. Phenotypic clustering of lamin A/C 
mutations in neuromuscular patients. Neurology 2007;69:1285-1292. 
118. Mercuri E, Brown SC, Nihoyannopoulos P, et al. Extreme variability of skeletal 
and cardiac muscle involvement in patients with mutations in exon 11 of the lamin A/C 
gene. Muscle Nerve 2005;31:602-609. 
119. Fidzianska A, Toniolo D, Hausmanowa-Petrusewicz I. Ultrastructural 
abnormality of sarcolemmal nuclei in Emery-Dreifuss muscular dystrophy (EDMD). J 
Neurol Sci 1998;159:88-93. 
120. Sewry CA, Brown SC, Mercuri E, et al. Skeletal muscle pathology in autosomal 
dominant Emery-Dreifuss muscular dystrophy with lamin A/C mutations. Neuropathol 
Appl Neurobiol 2001;27:281-290. 
121. Fidzianska A, Hausmanowa-Petrusewicz I. Architectural abnormalities in 
muscle nuclei. Ultrastructural differences between X-linked and autosomal dominant 
forms of EDMD. J Neurol Sci 2003;210:47-51. 
122. Hayashi YK, Chou FL, Engvall E, et al. Mutations in the integrin alpha7 gene 
cause congenital myopathy. Nat Genet 1998;19:94-97. 
123. Vachon PH, Xu H, Liu L, et al. Integrins (alpha7beta1) in muscle function and 
survival. Disrupted expression in merosin-deficient congenital muscular dystrophy. J 
Clin Invest 1997;100:1870-1881. 
124. Muntoni F, Brockington M, Torelli S, Brown SC. Defective glycosylation in 
congenital muscular dystrophies. Curr Opin Neurol 2004;17:205-209. 
125. Balci B, Uyanik G, Dincer P, et al. An autosomal recessive limb girdle muscular 
dystrophy (LGMD2) with mild mental retardation is allelic to Walker-Warburg 
syndrome (WWS) caused by a mutation in the POMT1 gene. Neuromuscul Disord 
2005;15:271-275. 
126. Godfrey C, Escolar D, Brockington M, et al. Fukutin gene mutations in steroid-
responsive limb girdle muscular dystrophy. Ann Neurol 2006. 
127. Kobayashi K, Nakahori Y, Miyake M, et al. An ancient retrotransposal insertion 
causes Fukuyama-type congenital muscular dystrophy. Nature 1998;394:388-392. 
128. Brockington M, Blake DJ, Prandini P, et al. Mutations in the fukutin-related 
protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary 
laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J 
Hum Genet 2001;69:1198-1209. 
 
 
192 
 
129. Yoshida A, Kobayashi K, Manya H, et al. Muscular dystrophy and neuronal 
migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 
2001;1:717-724. 
130. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, et al. Mutations in the 
O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder 
Walker-Warburg syndrome. Am J Hum Genet 2002;71:1033-1043. 
131. Longman C, Brockington M, Torelli S, et al. Mutations in the human LARGE 
gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental 
retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 
2003;12:2853-2861. 
132. van Reeuwijk J, Janssen M, van den Elzen C, et al. POMT2 mutations cause 
alpha-dystroglycan hypoglycosylation and Walker-Warburg syndrome. J Med Genet 
2005;42:907-912. 
133. Hoffman EP, Brown RH, Jr., Kunkel LM. Dystrophin: the protein product of the 
Duchenne muscular dystrophy locus. Cell 1987;51:919-928. 
134. Roberds SL, Leturcq F, Allamand V, et al. Missense mutations in the adhalin 
gene linked to autosomal recessive muscular dystrophy. Cell 1994;78:625-633. 
135. Lim LE, Duclos F, Broux O, et al. Beta-sarcoglycan: characterization and role in 
limb-girdle muscular dystrophy linked to 4q12. Nat Genet 1995;11:257-265. 
136. Noguchi S, McNally EM, Ben Othmane K, et al. Mutations in the dystrophin-
associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. Science 
1995;270:819-822. 
137. Nigro V, de Sa Moreira E, Piluso G, et al. Autosomal recessive limb-girdle 
muscular dystrophy, LGMD2F, is caused by a mutation in the delta-sarcoglycan gene. 
Nat Genet 1996;14:195-198. 
138. Ervasti JM, Campbell KP. Membrane organization of the dystrophin-
glycoprotein complex. Cell 1991;66:1121-1131. 
139. Yoshida M, Ozawa E. Glycoprotein complex anchoring dystrophin to 
sarcolemma. J Biochem 1990;108:748-752. 
140. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin 
protects the sarcolemma from stresses developed during muscle contraction. Proc Natl 
Acad Sci U S A 1993;90:3710-3714. 
141. Ibraghimov-Beskrovnaya O, Ervasti JM, Leveille CJ, Slaughter CA, Sernett 
SW, Campbell KP. Primary structure of dystrophin-associated glycoproteins linking 
dystrophin to the extracellular matrix. Nature 1992;355:696-702. 
142. Ibraghimov-Beskrovnaya O, Milatovich A, Ozcelik T, et al. Human 
dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific 
isoforms and chromosomal localization. Hum Mol Genet 1993;2:1651-1657. 
143. Durbeej M, Campbell KP. Biochemical characterization of the epithelial 
dystroglycan complex. J Biol Chem 1999;274:26609-26616. 
144. Langenbach KJ, Rando TA. Inhibition of dystroglycan binding to laminin 
disrupts the PI3K/AKT pathway and survival signaling in muscle cells. Muscle Nerve 
2002;26:644-653. 
145. Spence HJ, Dhillon AS, James M, Winder SJ. Dystroglycan, a scaffold for the 
ERK-MAP kinase cascade. EMBO Rep 2004;5:484-489. 
146. Moore SA, Saito F, Chen J, et al. Deletion of brain dystroglycan recapitulates 
aspects of congenital muscular dystrophy. Nature 2002;418:422-425. 
147. Saito F, Moore SA, Barresi R, et al. Unique role of dystroglycan in peripheral 
nerve myelination, nodal structure, and sodium channel stabilization. Neuron 
2003;38:747-758. 
 
 
193 
 
148. Durbeej M, Ekblom P. Dystroglycan and laminins: glycoconjugates involved in 
branching epithelial morphogenesis. Exp Lung Res 1997;23:109-118. 
149. Jacobson C, Montanaro F, Lindenbaum M, Carbonetto S, Ferns M. alpha-
Dystroglycan functions in acetylcholine receptor aggregation but is not a coreceptor for 
agrin-MuSK signaling. J Neurosci 1998;18:6340-6348. 
150. Montanaro F, Gee SH, Jacobson C, Lindenbaum MH, Froehner SC, Carbonetto 
S. Laminin and alpha-dystroglycan mediate acetylcholine receptor aggregation via a 
MuSK-independent pathway. J Neurosci 1998;18:1250-1260. 
151. Matsumura K, Chiba A, Yamada H, et al. A role of dystroglycan in schwannoma 
cell adhesion to laminin. J Biol Chem 1997;272:13904-13910. 
152. Jung D, Yang B, Meyer J, Chamberlain JS, Campbell KP. Identification and 
characterization of the dystrophin anchoring site on beta-dystroglycan. J Biol Chem 
1995;270:27305-27310. 
153. Chung W, Campanelli JT. WW and EF hand domains of dystrophin-family 
proteins mediate dystroglycan binding. Mol Cell Biol Res Commun 1999;2:162-171. 
154. Henry MD, Campbell KP. Dystroglycan inside and out. Curr Opin Cell Biol 
1999;11:602-607. 
155. Brancaccio A, Schulthess T, Gesemann M, Engel J. The N-terminal region of 
alpha-dystroglycan is an autonomous globular domain. Eur J Biochem 1997;246:166-
172. 
156. Brancaccio A, Ruegg MA, Engel J. Cloning and sequencing of mouse skeletal 
muscle alpha-dystroglycan. Matrix Biol 1995;14:681-685. 
157. Katoh K, Omori Y, Furukawa T. [Extracellular matrix protein, Pikachurin, is 
required for photoreceptor ribbon synapse formation]. Tanpakushitsu Kakusan Koso 
2009;54:1166-1172. 
158. Barresi R, Campbell KP. Dystroglycan: from biosynthesis to pathogenesis of 
human disease. J Cell Sci 2006;119:199-207. 
159. Cao W, Henry MD, Borrow P, et al. Identification of alpha-dystroglycan as a 
receptor for lymphocytic choriomeningitis virus and Lassa fever virus. Science 
1998;282:2079-2081. 
160. Rambukkana A, Yamada H, Zanazzi G, et al. Role of alpha-dystroglycan as a 
Schwann cell receptor for Mycobacterium leprae. Science 1998;282:2076-2079. 
161. Williamson RA, Henry MD, Daniels KJ, et al. Dystroglycan is essential for 
early embryonic development: disruption of Reichert's membrane in Dag1-null mice. 
Hum Mol Genet 1997;6:831-841. 
162. Henry MD, Campbell KP. A role for dystroglycan in basement membrane 
assembly. Cell 1998;95:859-870. 
163. Michele DE, Barresi R, Kanagawa M, et al. Post-translational disruption of 
dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 
2002;418:417-422. 
164. Cote PD, Moukhles H, Lindenbaum M, Carbonetto S. Chimaeric mice deficient 
in dystroglycans develop muscular dystrophy and have disrupted myoneural synapses. 
Nat Genet 1999;23:338-342. 
165. Cohn RD, Henry MD, Michele DE, et al. Disruption of DAG1 in differentiated 
skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell 
2002;110:639-648. 
166. Ayalon G, Davis JQ, Scotland PB, Bennett V. An ankyrin-based mechanism for 
functional organization of dystrophin and dystroglycan. Cell 2008;135:1189-1200. 
167. Cartaud A, Coutant S, Petrucci TC, Cartaud J. Evidence for in situ and in vitro 
association between beta-dystroglycan and the subsynaptic 43K rapsyn protein. 
 
 
194 
 
Consequence for acetylcholine receptor clustering at the synapse. J Biol Chem 
1998;273:11321-11326. 
168. Jacobson C, Cote PD, Rossi SG, Rotundo RL, Carbonetto S. The dystroglycan 
complex is necessary for stabilization of acetylcholine receptor clusters at 
neuromuscular junctions and formation of the synaptic basement membrane. J Cell Biol 
2001;152:435-450. 
169. Moukhles H, Roque R, Carbonetto S. alpha-dystroglycan isoforms are 
differentially distributed in adult rat retina. J Comp Neurol 2000;420:182-194. 
170. Kanagawa M, Omori Y, Sato S, et al. Post-translational maturation of 
dystroglycan is necessary for pikachurin binding and ribbon synaptic localization. J Biol 
Chem;285:31208-31216. 
171. Montanaro F, Carbonetto S. Targeting dystroglycan in the brain. Neuron 
2003;37:193-196. 
172. Durbeej M, Larsson E, Ibraghimov-Beskrovnaya O, Roberds SL, Campbell KP, 
Ekblom P. Non-muscle alpha-dystroglycan is involved in epithelial development. J Cell 
Biol 1995;130:79-91. 
173. Durbeej M, Talts JF, Henry MD, Yurchenco PD, Campbell KP, Ekblom P. 
Dystroglycan binding to laminin alpha1LG4 module influences epithelial 
morphogenesis of salivary gland and lung in vitro. Differentiation 2001;69:121-134. 
174. Hayashi YK, Engvall E, Arikawa-Hirasawa E, et al. Abnormal localization of 
laminin subunits in muscular dystrophies. J Neurol Sci 1993;119:53-64. 
175. Saito Y, Murayama S, Kawai M, Nakano I. Breached cerebral glia limitans-
basal lamina complex in Fukuyama-type congenital muscular dystrophy. Acta 
Neuropathol 1999;98:330-336. 
176. Hayashi YK, Ogawa M, Tagawa K, et al. Selective deficiency of alpha-
dystroglycan in Fukuyama-type congenital muscular dystrophy. Neurology 
2001;57:115-121. 
177. Grewal PK, Holzfeind PJ, Bittner RE, Hewitt JE. Mutant glycosyltransferase 
and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. Nat Genet 
2001;28:151-154. 
178. Holzfeind PJ, Grewal PK, Reitsamer HA, et al. Skeletal, cardiac and tongue 
muscle pathology, defective retinal transmission, and neuronal migration defects in the 
Large(myd) mouse defines a natural model for glycosylation-deficient muscle - eye - 
brain disorders. Hum Mol Genet 2002;11:2673-2687. 
179. Kobata A. Structures and functions of the sugar chains of glycoproteins. Eur J 
Biochem 1992;209:483-501. 
180. Varki A. Biological roles of oligosaccharides: all of the theories are correct. 
Glycobiology 1993;3:97-130. 
181. Freeze HH. Genetic defects in the human glycome. Nat Rev Genet 2006;7:537-
551. 
182. Grunewald S. Congenital disorders of glycosylation: rapidly enlarging group of 
(neuro)metabolic disorders. Early Hum Dev 2007;83:825-830. 
183. Endo T. O-mannosyl glycans in mammals. Biochim Biophys Acta 
1999;1473:237-246. 
184. Yamada H, Chiba A, Endo T, et al. Characterization of dystroglycan-laminin 
interaction in peripheral nerve. J Neurochem 1996;66:1518-1524. 
185. Martin PT. Dystroglycan glycosylation and its role in matrix binding in skeletal 
muscle. Glycobiology 2003;13:55R-66R. 
186. Hoyte K, Kang C, Martin PT. Definition of pre- and postsynaptic forms of the 
CT carbohydrate antigen at the neuromuscular junction: ubiquitous expression of the 
 
 
195 
 
CT antigens and the CT GalNAc transferase in mouse tissues. Brain Res Mol Brain Res 
2002;109:146-160. 
187. Smalheiser NR, Kim E. Purification of cranin, a laminin binding membrane 
protein. Identity with dystroglycan and reassessment of its carbohydrate moieties. J Biol 
Chem 1995;270:15425-15433. 
188. Chiba A, Matsumura K, Yamada H, et al. Structures of sialylated O-linked 
oligosaccharides of bovine peripheral nerve alpha-dystroglycan. The role of a novel O-
mannosyl-type oligosaccharide in the binding of alpha-dystroglycan with laminin. J 
Biol Chem 1997;272:2156-2162. 
189. Jurado LA, Coloma A, Cruces J. Identification of a human homolog of the 
Drosophila rotated abdomen gene (POMT1) encoding a putative protein O-mannosyl-
transferase, and assignment to human chromosome 9q34.1. Genomics 1999;58:171-180. 
190. Manya H, Chiba A, Yoshida A, et al. Demonstration of mammalian protein O-
mannosyltransferase activity: coexpression of POMT1 and POMT2 required for 
enzymatic activity. Proc Natl Acad Sci U S A 2004;101:500-505. 
191. Willer T, Amselgruber W, Deutzmann R, Strahl S. Characterization of POMT2, 
a novel member of the PMT protein O-mannosyltransferase family specifically 
localized to the acrosome of mammalian spermatids. Glycobiology 2002;12:771-783. 
192. Brockington M, Yuva Y, Prandini P, et al. Mutations in the fukutin-related 
protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic 
variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001;10:2851-
2859. 
193. Matsumoto H, Noguchi S, Sugie K, et al. Subcellular localization of fukutin and 
fukutin-related protein in muscle cells. J Biochem 2004;135:709-712. 
194. Keramaris-Vrantsis E, Lu PJ, Doran T, et al. Fukutin-related protein localizes to 
the Golgi apparatus and mutations lead to mislocalization in muscle in vivo. Muscle 
Nerve 2007;36:455-465. 
195. Esapa CT, Benson MA, Schroder JE, et al. Functional requirements for fukutin-
related protein in the Golgi apparatus. Hum Mol Genet 2002;11:3319-3331. 
196. Beedle AM, Nienaber PM, Campbell KP. Fukutin-related protein associates 
with the sarcolemmal dystrophin-glycoprotein complex. J Biol Chem 2007;282:16713-
16717. 
197. Peyrard M, Seroussi E, Sandberg-Nordqvist AC, et al. The human LARGE gene 
from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family. 
Proc Natl Acad Sci U S A 1999;96:598-603. 
198. Grewal PK, McLaughlan JM, Moore CJ, Browning CA, Hewitt JE. 
Characterization of the LARGE family of putative glycosyltransferases associated with 
dystroglycanopathies. Glycobiology 2005;15:912-923. 
199. Kanagawa M, Saito F, Kunz S, et al. Molecular recognition by LARGE is 
essential for expression of functional dystroglycan. Cell 2004;117:953-964. 
200. Brockington M, Torelli S, Prandini P, et al. Localization and functional analysis 
of the LARGE family of glycosyltransferases: significance for muscular dystrophy. 
Hum Mol Genet 2005;14:657-665. 
201. Muntoni F, Torelli S, Brockington M. Muscular dystrophies due to glycosylation 
defects. Neurotherapeutics 2008;5:627-632. 
202. Yoshida-Moriguchi T, Yu L, Stalnaker SH, et al. O-mannosyl phosphorylation 
of alpha-dystroglycan is required for laminin binding. Science;327:88-92. 
203. Henry MD, Cohen MB, Campbell KP. Reduced expression of dystroglycan in 
breast and prostate cancer. Hum Pathol 2001;32:791-795. 
 
 
196 
 
204. Singh J, Itahana Y, Knight-Krajewski S, et al. Proteolytic enzymes and altered 
glycosylation modulate dystroglycan function in carcinoma cells. Cancer Res 
2004;64:6152-6159. 
205. Mercuri E, Brockington M, Straub V, et al. Phenotypic spectrum associated with 
mutations in the fukutin-related protein gene. Ann Neurol 2003;53:537-542. 
206. Cormand B, Pihko H, Bayes M, et al. Clinical and genetic distinction between 
Walker-Warburg syndrome and muscle-eye-brain disease. Neurology 2001;56:1059-
1069. 
207. Beltran-Valero de Bernabe D, Voit T, Longman C, et al. Mutations in the FKRP 
gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J Med Genet 
2004;41:e61. 
208. de Bernabe DB, van Bokhoven H, van Beusekom E, et al. A homozygous 
nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype. J 
Med Genet 2003;40:845-848. 
209. Cormand B, Avela K, Pihko H, et al. Assignment of the muscle-eye-brain 
disease gene to 1p32-p34 by linkage analysis and homozygosity mapping. Am J Hum 
Genet 1999;64:126-135. 
210. Mercuri E, D'Amico A, Tessa A, et al. POMT2 mutation in a patient with 'MEB-
like' phenotype. Neuromuscul Disord 2006;16:446-448. 
211. Topaloglu H, Brockington M, Yuva Y, et al. FKRP gene mutations cause 
congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology 
2003;60:988-992. 
212. Fukuyama Y KM, Haruna H. A perculiar form  of congenital progressive 
muscular dystrophy:report of fifteen cases. Paediat Univ Tokyo 1960;4:5-8. 
213. Clement E, Mercuri E, Godfrey C, et al. Brain involvement in muscular 
dystrophies with defective dystroglycan glycosylation. Ann Neurol 2008;64:573-582. 
214. Toda T, Kobayashi K, Kondo-Iida E, Sasaki J, Nakamura Y. The Fukuyama 
congenital muscular dystrophy story. Neuromuscul Disord 2000;10:153-159. 
215. Toda T, Segawa M, Nomura Y, et al. Localization of a gene for Fukuyama type 
congenital muscular dystrophy to chromosome 9q31-33. Nat Genet 1993;5:283-286. 
216. Mercuri E, Sewry CA, Brown SC, et al. Congenital muscular dystrophy with 
secondary merosin deficiency and normal brain MRI: a novel entity? Neuropediatrics 
2000;31:186-189. 
217. Dincer P, Balci B, Yuva Y, et al. A novel form of recessive limb girdle muscular 
dystrophy with mental retardation and abnormal expression of alpha-dystroglycan. 
Neuromuscul Disord 2003;13:771-778. 
218. Jimenez-Mallebrera C, Torelli S, Feng L, et al. A comparative study of alpha-
dystroglycan glycosylation in dystroglycanopathies suggests that the hypoglycosylation 
of alpha-dystroglycan does not consistently correlate with clinical severity. Brain Pathol 
2009;19:596-611. 
219. Zhang W, Vajsar J, Cao P, et al. Enzymatic diagnostic test for Muscle-Eye-
Brain type congenital muscular dystrophy using commercially available reagents. Clin 
Biochem 2003;36:339-344. 
220. Vajsar J, Zhang W, Dobyns WB, et al. Carriers and patients with muscle-eye-
brain disease can be rapidly diagnosed by enzymatic analysis of fibroblasts and 
lymphoblasts. Neuromuscul Disord 2006;16:132-136. 
221. Mercuri E, Longman C. Congenital muscular dystrophy. Pediatr Ann 
2005;34:560-562, 564-568. 
222. Klein A, Clement E, Mercuri E, Muntoni F. Differential diagnosis of congenital 
muscular dystrophies. Eur J Paediatr Neurol 2008;12:371-377. 
 
 
197 
 
223. Darin N, Kimber E, Kroksmark AK, Tulinius M. Multiple congenital 
contractures: birth prevalence, etiology, and outcome. J Pediatr 2002;140:61-67. 
224. Osawa M SS, Suzuki N, Arai Y, Ikenaka H, Murasugi H, Shishikura K, Suzuki 
H, Saito K, Fukuyama Y. . Fukuyama type congenital muscular dystrophy. In: 
Congenital Muscular Dystrophies: Elsevier Science, 1997. 
225. Toda T. [Fukuyama-type congenital muscular dystrophy]. Rinsho Shinkeigaku 
2000;40:1297-1299. 
226. Silan F, Yoshioka M, Kobayashi K, et al. A new mutation of the fukutin gene in 
a non-Japanese patient. Ann Neurol 2003;53:392-396. 
227. Vuillaumier-Barrot S, Quijano-Roy S, Bouchet-Seraphin C, et al. Four 
Caucasian patients with mutations in the fukutin gene and variable clinical phenotype. 
Neuromuscul Disord 2009;19:182-188. 
228. Okada M, Kawahara G, Noguchi S, et al. Primary collagen VI deficiency is the 
second most common congenital muscular dystrophy in Japan. Neurology 
2007;69:1035-1042. 
229. Peat RA, Smith JM, Compton AG, et al. Diagnosis and etiology of congenital 
muscular dystrophy. Neurology 2008;71:312-321. 
230. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. 
Prevalence of genetic muscle disease in Northern England: in-depth analysis of a 
muscle clinic population. Brain 2009;132:3175-3186. 
231. Godfrey C, Clement E, Mein R, et al. Refining genotype phenotype correlations 
in muscular dystrophies with defective glycosylation of dystroglycan. Brain 
2007;130:2725-2735. 
232. Nadeau A, Kinali M, Main M, et al. Natural history of Ullrich congenital 
muscular dystrophy. Neurology 2009;73:25-31. 
233. Kinali M, Beeson D, Pitt MC, et al. Congenital myasthenic syndromes in 
childhood: diagnostic and management challenges. J Neuroimmunol 2008;201-202:6-
12. 
234. Schessl J, Goemans NM, Magold AI, et al. Predominant fiber atrophy and fiber 
type disproportion in early ullrich disease. Muscle Nerve 2008;38:1184-1191. 
235. Warburg M. Hydrocephaly, congenital retinal nonattachment, and congenital 
falciform fold. Am J Ophthalmol 1978;85:88-94. 
236. Walker AE. Lissencephaly. Arch Neurol Psychiat 1942;48:13-29. 
237. Whitley CB, Thompson TT, Mastri AR, Gorlin RJ. Warburg syndrome: lethal 
neurodysplasia with autosomal recessive inheritance. J Pediatr 1983;102:547-552. 
238. Williams RS, Swisher CN, Jennings M, Ambler M, Caviness VS, Jr. Cerebro-
ocular dysgenesis (Walker-Warburg syndrome): neuropathologic and etiologic analysis. 
Neurology 1984;34:1531-1541. 
239. Pagon RA, Chandler JW, Collie WR, et al. Hydrocephalus, agyria, retinal 
dysplasia, encephalocele (HARD +/- E) syndrome: an autosomal recessive condition. 
Birth Defects Orig Artic Ser 1978;14:233-241. 
240. Towfighi J, Sassani JW, Suzuki K, Ladda RL. Cerebro-ocular dysplasia-
muscular dystrophy (COD-MD) syndrome. Acta Neuropathol 1984;65:110-123. 
241. Dobyns WB, Pagon RA, Armstrong D, et al. Diagnostic criteria for Walker-
Warburg syndrome. Am J Med Genet 1989;32:195-210. 
242. Santavuori P, Leisti J, Kruus S. Muscle, eye and brain disease: a new syndrome. 
Neuropediatrie 1977;8 (suppl):553-558. 
243. Santavuori P, Pihko H, Sainio K, et al. Muscle-eye-brain disease and Walker-
Warburg syndrome. Am J Med Genet 1990;36:371-374. 
244. Santavuori P, Somer H, Sainio K, et al. Muscle-eye-brain disease (MEB). Brain 
Dev 1989;11:147-153. 
 
 
198 
 
245. Yoshioka M, Toda T, Kuroki S, Hamano K. Broader clinical spectrum of 
Fukuyama-type congenital muscular dystrophy manifested by haplotype analysis. J 
Child Neurol 1999;14:711-715. 
246. Fukuyama Y, Osawa M, Suzuki H. Congenital progressive muscular dystrophy 
of the Fukuyama type - clinical, genetic and pathological considerations. Brain Dev 
1981;3:1-29. 
247. Olson EC, Walsh CA. Smooth, rough and upside-down neocortical 
development. Curr Opin Genet Dev 2002;12:320-327. 
248. Santavuori P, Pihko H, Sainio K, et al. Muscle-eye-brain disease and Walker-
Warburg syndrome. (letter). Am J Med Genet 1990;36:371-372. 
249. Dobyns W, Pagon RA, Curry CJ, Greenberg F. Response to Santavuori et al. 
regarding Walker -Warburg syndrome and muscle-eye-brain disease. (letler). Am J Med 
Genet 1990;36:373-374. 
250. Yoshioka M, Kuroki S. Clinical spectrum and genetic studies of Fukuyama 
congenital muscular dystrophy. Am J Med Genet 1994;53:245-250. 
251. van Reeuwijk J, Maugenre S, van den Elzen C, et al. The expanding phenotype 
of POMT1 mutations: from Walker-Warburg syndrome to congenital muscular 
dystrophy, microcephaly, and mental retardation. Hum Mutat 2006;27:453-459. 
252. D'Amico A, Tessa A, Bruno C, et al. Expanding the clinical spectrum of 
POMT1 phenotype. Neurology 2006;66:1564-1567; discussion 1461. 
253. Currier SC, Lee CK, Chang BS, et al. Mutations in POMT1 are found in a 
minority of patients with Walker-Warburg syndrome. Am J Med Genet A 
2005;133A:53-57. 
254. Taniguchi K, Kobayashi K, Saito K, et al. Worldwide distribution and broader 
clinical spectrum of muscle-eye-brain disease. Hum Mol Genet 2003;12:527-534. 
255. Kondo-Iida E, Kobayashi K, Watanabe M, et al. Novel mutations and genotype-
phenotype relationships in 107 families with Fukuyama-type congenital muscular 
dystrophy (FCMD). Hum Mol Genet 1999;8:2303-2309. 
256. Brown SC, Torelli S, Brockington M, et al. Abnormalities in alpha-dystroglycan 
expression in MDC1C and LGMD2I muscular dystrophies. Am J Pathol 2004;164:727-
737. 
257. Godfrey C, Escolar D, Brockington M, et al. Fukutin gene mutations in steroid-
responsive limb girdle muscular dystrophy. Ann Neurol 2006;60:603-610. 
258. Mercuri E, Topaloglu H, Brockington M, et al. Spectrum of brain changes in 
patients with congenital muscular dystrophy and FKRP gene mutations. Arch Neurol 
2006;63:251-257. 
259. Diesen C, Saarinen A, Pihko H, et al. POMGnT1 mutation and phenotypic 
spectrum in muscle-eye-brain disease. J Med Genet 2004;41:e115. 
260. Clement EMG, C.; Tan, J.; et.al.. Mild POMGnT1 mutations underlie a novel 
Limb Girdle Muscular Dystrophy varian. Arch Neurol 2007. 
261. van Reeuwijk J, Grewal PK, Salih MA, et al. Intragenic deletion in the LARGE 
gene causes Walker-Warburg syndrome. Hum Genet 2007. 
262. Matsumoto H, Hayashi YK, Kim DS, et al. Congenital muscular dystrophy with 
glycosylation defects of alpha-dystroglycan in Japan. Neuromuscul Disord 
2005;15:342-348. 
263. Torelli S, Brown SC, Brockington M, et al. Sub-cellular localisation of fukutin 
related protein in different cell lines and in the muscle of patients with MDC1C and 
LGMD2I. Neuromuscul Disord 2005;15:836-843. 
264. Quijano-Roy S, Marti-Carrera I, Makri S, et al. Brain MRI abnormalities in 
muscular dystrophy due to FKRP mutations. Brain Dev 2006;28:232-242. 
 
 
199 
 
265. Harel T, Goldberg Y, Shalev SA, Chervinski I, Ofir R, Birk OS. Limb-girdle 
muscular dystrophy 2I: phenotypic variability within a large consanguineous Bedouin 
family associated with a novel FKRP mutation. Eur J Hum Genet 2004;12:38-43. 
266. Vieira NM, Schlesinger D, de Paula F, Vainzof M, Zatz M. Mutation analysis in 
the FKRP gene provides an explanation for a rare cause of intrafamilial clinical 
variability in LGMD2I. Neuromuscul Disord 2006;16:870-873. 
267. de Paula F, Vieira N, Starling A, et al. Asymptomatic carriers for homozygous 
novel mutations in the FKRP gene: the other end of the spectrum. Eur J Hum Genet 
2003;11:923-930. 
268. Lin YC, Murakami T, Hayashi YK, et al. A novel FKRP gene mutation in a 
Taiwanese patient with limb-girdle muscular dystrophy 2I. Brain Dev 2007;29:234-238. 
269. Boito CA, Melacini P, Vianello A, et al. Clinical and molecular characterization 
of patients with limb-girdle muscular dystrophy type 2I. Arch Neurol 2005;62:1894-
1899. 
270. Frosk P, Greenberg CR, Tennese AA, et al. The most common mutation in 
FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred 
only once and is present in Hutterites and other populations. Hum Mutat 2005;25:38-44. 
271. Bourteel H, Stojkovic T, Cuisset JM, et al. [Phenotypic aspects of FKRP-linked 
muscular dystrophy type 2I in a series of eleven patients.]. Rev Neurol (Paris) 
2007;163:189-196. 
272. Zhang W, Betel D, Schachter H. Cloning and expression of a novel UDP-
GlcNAc:alpha-D-mannoside beta1,2-N-acetylglucosaminyltransferase homologous to 
UDP-GlcNAc:alpha-3-D-mannoside beta1,2-N-acetylglucosaminyltransferase I. 
Biochem J 2002;361:153-162. 
273. Lumsden A, Krumlauf R. Patterning the vertebrate neuraxis. Science 
1996;274:1109-1115. 
274. Jansen A, Andermann E. Genetics of the polymicrogyria syndromes. J Med 
Genet 2005;42:369-378. 
275. Barkovich AJ, Kuzniecky RI, Jackson GD, Guerrini R, Dobyns WB. 
Classification system for malformations of cortical development: update 2001. 
Neurology 2001;57:2168-2178. 
276. Guerrini R, Marini C. Genetic malformations of cortical development. Exp 
Brain Res 2006;173:322-333. 
277. Robain O. Introduction to the pathology of cerebral cortical dysplasia. In: 
Guerrini R, Andermann F, Canapicchi R, Roger J, Zifkin B, Pfanner P, eds. Dysplasias 
of cerebral cortex and epilepsy. Philidelphia: Lippincott-Raven, 1996: 1-9. 
278. Gleeson JG, Walsh CA. Neuronal migration disorders: from genetic diseases to 
developmental mechanisms. Trends Neurosci 2000;23:352-359. 
279. Halfter W, Dong S, Yip YP, Willem M, Mayer U. A critical function of the pial 
basement membrane in cortical histogenesis. J Neurosci 2002;22:6029-6040. 
280. Graus-Porta D, Blaess S, Senften M, et al. Beta1-class integrins regulate the 
development of laminae and folia in the cerebral and cerebellar cortex. Neuron 
2001;31:367-379. 
281. Marret S, Mukendi R, Gadisseux JF, Gressens P, Evrard P. Effect of ibotenate 
on brain development: an excitotoxic mouse model of microgyria and posthypoxic-like 
lesions. J Neuropathol Exp Neurol 1995;54:358-370. 
282. Piao X, Hill RS, Bodell A, et al. G protein-coupled receptor-dependent 
development of human frontal cortex. Science 2004;303:2033-2036. 
283. Barkovich AJ, Rowley H, Bollen A. Correlation of prenatal events with the 
development of polymicrogyria. AJNR Am J Neuroradiol 1995;16:822-827. 
 
 
200 
 
284. Barkovich AJ. Neuroimaging manifestations and classification of congenital 
muscular dystrophies. AJNR Am J Neuroradiol 1998;19:1389-1396. 
285. Takanashi J, Barkovich AJ. The changing MR imaging appearance of 
polymicrogyria: a consequence of myelination. AJNR Am J Neuroradiol 2003;24:788-
793. 
286. Barkovich AJ, Millen KJ, Dobyns WB. A developmental and genetic 
classification for midbrain-hindbrain malformations. Brain 2009;132:3199-3230. 
287. Henion TR, Qu Q, Smith FI. Expression of dystroglycan, fukutin and 
POMGnT1 during mouse cerebellar development. Brain Res Mol Brain Res 
2003;112:177-181. 
288. Qu Q, Crandall JE, Luo T, McCaffery PJ, Smith FI. Defects in tangential 
neuronal migration of pontine nuclei neurons in the Largemyd mouse are associated 
with stalled migration in the ventrolateral hindbrain. Eur J Neurosci 2006;23:2877-
2886. 
289. Zaccaria ML, Di Tommaso F, Brancaccio A, Paggi P, Petrucci TC. 
Dystroglycan distribution in adult mouse brain: a light and electron microscopy study. 
Neuroscience 2001;104:311-324. 
290. Qu Q, Smith FI. Alpha-dystroglycan interactions affect cerebellar granule 
neuron migration. J Neurosci Res 2004;76:771-782. 
291. Hu H, Yang Y, Eade A, Xiong Y, Qi Y. Breaches of the pial basement 
membrane and disappearance of the glia limitans during development underlie the 
cortical lamination defect in the mouse model of muscle-eye-brain disease. J Comp 
Neurol 2007;501:168-183. 
292. Kurahashi H, Taniguchi M, Meno C, et al. Basement membrane fragility 
underlies embryonic lethality in fukutin-null mice. Neurobiol Dis 2005;19:208-217. 
293. Willer T, Prados B, Falcon-Perez JM, et al. Targeted disruption of the Walker-
Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. Proc Natl Acad 
Sci U S A 2004;101:14126-14131. 
294. Chiyonobu T, Sasaki J, Nagai Y, et al. Effects of fukutin deficiency in the 
developing mouse brain. Neuromuscul Disord 2005;15:416-426. 
295. Barkovich AJ, Millen KJ, Dobyns WB. A developmental classification of 
malformations of the brainstem. Ann Neurol 2007. 
296. Jissendi-Tchofo P, Kara S, Barkovich AJ. Midbrain-hindbrain involvement in 
lissencephalies. Neurology 2009;72:410-418. 
297. Haltia M, Leivo I, Somer H, et al. Muscle-eye-brain disease: a neuropathological 
study. Ann Neurol 1997;41:173-180. 
298. Valanne L, Pihko H, Katevuo K, Karttunen P, Somer H, Santavuori P. MRI of 
the brain in muscle-eye-brain (MEB) disease. Neuroradiology 1994;36:473-476. 
299. Aida N, Yagishita A, Takada K, Katsumata Y. Cerebellar MR in Fukuyama 
congenital muscular dystrophy: polymicrogyria with cystic lesions. AJNR Am J 
Neuroradiol 1994;15:1755-1759. 
300. Takada K, Nakamura H, Tanaka J. Cortical dysplasia in congenital muscular 
dystrophy with central nervous system involvement (Fukuyama type). J Neuropathol 
Exp Neurol 1984;43:395-407. 
301. Chang BS, Piao X, Bodell A, et al. Bilateral frontoparietal polymicrogyria: 
clinical and radiological features in 10 families with linkage to chromosome 16. Ann 
Neurol 2003;53:596-606. 
302. Piao X, Chang BS, Bodell A, et al. Genotype-phenotype analysis of human 
frontoparietal polymicrogyria syndromes. Ann Neurol 2005;58:680-687. 
303. Li S, Jin Z, Koirala S, et al. GPR56 regulates pial basement membrane integrity 
and cortical lamination. J Neurosci 2008;28:5817-5826. 
 
 
201 
 
304. Koirala S, Jin Z, Piao X, Corfas G. GPR56-regulated granule cell adhesion is 
essential for rostral cerebellar development. J Neurosci 2009;29:7439-7449. 
305. Kornak U, Reynders E, Dimopoulou A, et al. Impaired glycosylation and cutis 
laxa caused by mutations in the vesicular H+-ATPase subunit ATP6V0A2. Nat Genet 
2008;40:32-34. 
306. Van Maldergem L, Yuksel-Apak M, Kayserili H, et al. Cobblestone-like brain 
dysgenesis and altered glycosylation in congenital cutis laxa, Debre type. Neurology 
2008;71:1602-1608. 
307. Sprecher E, Ishida-Yamamoto A, Mizrahi-Koren M, et al. A mutation in 
SNAP29, coding for a SNARE protein involved in intracellular trafficking, causes a 
novel neurocutaneous syndrome characterized by cerebral dysgenesis, neuropathy, 
ichthyosis, and palmoplantar keratoderma. Am J Hum Genet 2005;77:242-251. 
308. Louhichi N, Triki C, Quijano-Roy S, et al. New FKRP mutations causing 
congenital muscular dystrophy associated with mental retardation and central nervous 
system abnormalities. Identification of a founder mutation in Tunisian families. 
Neurogenetics 2004;5:27-34. 
309. Yanagisawa A, Bouchet C, Van den Bergh PY, et al. New POMT2 mutations 
causing congenital muscular dystrophy. Neurology 2007. 
310. Biancheri R, Bertini E, Falace A, et al. POMGnT1 mutations in congenital 
muscular dystrophy: genotype-phenotype correlation and expanded clinical spectrum. 
Arch Neurol 2006;63:1491-1495. 
311. van Reeuwijk J, Grewal PK, Salih MA, et al. Intragenic deletion in the LARGE 
gene causes Walker-Warburg syndrome. Hum Genet 2007;121:685-690. 
312. Liu J, Ball SL, Yang Y, et al. A genetic model for muscle-eye-brain disease in 
mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). 
Mech Dev 2006;123:228-240. 
313. Friede R. Developmental Neuropathology. Berlin: Springer-Verlag, 1989. 
314. Forman MS, Squier W, Dobyns WB, Golden JA. Genotypically defined 
lissencephalies show distinct pathologies. J Neuropathol Exp Neurol 2005;64:847-857. 
315. Takada K, Nakamura H, Takashima S. Cortical dysplasia in Fukuyama 
congenital muscular dystrophy (FCMD): a Golgi and angioarchitectonic analysis. Acta 
Neuropathol 1988;76:170-178. 
316. Barkovich AJ, Koch TK, Carrol CL. The spectrum of lissencephaly: report of 
ten patients analyzed by magnetic resonance imaging. Ann Neurol 1991;30:139-146. 
317. Mercuri E, Dubowitz L, Brown SP, Cowan F. Incidence of cranial ultrasound 
abnormalities in apparently well neonates on a postnatal ward: correlation with 
antenatal and perinatal factors and neurological status. Arch Dis Child Fetal Neonatal 
Ed 1998;79:F185-189. 
318. Aida N, Tamagawa K, Takada K, et al. Brain MR in Fukuyama congenital 
muscular dystrophy. AJNR Am J Neuroradiol 1996;17:605-613. 
319. Vervoort VS, Holden KR, Ukadike KC, Collins JS, Saul RA, Srivastava AK. 
POMGnT1 gene alterations in a family with neurological abnormalities. Ann Neurol 
2004;56:143-148. 
320. Sunada Y, Edgar TS, Lotz BP, Rust RS, Campbell KP. Merosin-negative 
congenital muscular dystrophy associated with extensive brain abnormalities. 
Neurology 1995;45:2084-2089. 
321. Muntoni F, Guicheney P, Voit T. 158th ENMC international workshop on 
congenital muscular dystrophy (Xth international CMD workshop) 8th-10th February 
2008 Naarden, The Netherlands. Neuromuscul Disord 2009;19:229-234. 
322. Gros-Louis F, Dupre N, Dion P, et al. Mutations in SYNE1 lead to a newly 
discovered form of autosomal recessive cerebellar ataxia. Nat Genet 2007;39:80-85. 
 
 
202 
 
323. Apel ED, Lewis RM, Grady RM, Sanes JR. Syne-1, a dystrophin- and Klarsicht-
related protein associated with synaptic nuclei at the neuromuscular junction. J Biol 
Chem 2000;275:31986-31995. 
324. Mislow JM, Holaska JM, Kim MS, et al. Nesprin-1alpha self-associates and 
binds directly to emerin and lamin A in vitro. FEBS Lett 2002;525:135-140. 
325. Hansske B, Thiel C, Lubke T, et al. Deficiency of UDP-galactose:N-
acetylglucosamine beta-1,4-galactosyltransferase I causes the congenital disorder of 
glycosylation type IId. J Clin Invest 2002;109:725-733. 
326. Peters V, Penzien JM, Reiter G, et al. Congenital disorder of glycosylation IId 
(CDG-IId) -- a new entity: clinical presentation with Dandy-Walker malformation and 
myopathy. Neuropediatrics 2002;33:27-32. 
327. Mercuri E, Messina S, Bruno C, et al. Congenital muscular dystrophies with 
defective glycosylation of dystroglycan: a population study. Neurology 2009;72:1802-
1809. 
328. Bouchet C, Gonzales M, Vuillaumier-Barrot S, et al. Molecular heterogeneity in 
fetal forms of type II lissencephaly. Hum Mutat 2007;28:1020-1027. 
329. Manzini MC, Gleason D, Chang BS, et al. Ethnically diverse causes of Walker-
Warburg syndrome (WWS): FCMD mutations are a more common cause of WWS 
outside of the Middle East. Hum Mutat 2008;29:E231-241. 
330. Puckett RL, Moore SA, Winder TL, et al. Further evidence of Fukutin mutations 
as a cause of childhood onset limb-girdle muscular dystrophy without mental 
retardation. Neuromuscul Disord 2009;19:352-356. 
331. Yanagisawa A, Bouchet C, Quijano-Roy S, et al. POMT2 intragenic deletions 
and splicing abnormalities causing congenital muscular dystrophy with mental 
retardation. Eur J Med Genet 2009;52:201-206. 
332. Yanagisawa A, Bouchet C, Van den Bergh PY, et al. New POMT2 mutations 
causing congenital muscular dystrophy: identification of a founder mutation. Neurology 
2007;69:1254-1260. 
333. Godfrey CC, E.; Mein, R.; Brockington, M.; Smith, J.; Talim, B.; Straub, V.; 
Robb, S.; Quinlivan R.; Feng, L.; Jimenez-Mallebrera, C.; Mercuri, E.; Manzur, A.; 
Kinali, M.; Torelli, S.; Brown, S.; Sewry, C.; Bushby, K.; Topaloglu, H.; North, K.; 
Abbs, S.; Muntoni, F. Refining genotype-phenotype correlations in muscular 
dystrophies with defective glycosylation of dystroglycan. Brain 2007. 
334. Biancheri R, Falace A, Tessa A, et al. POMT2 gene mutation in limb-girdle 
muscular dystrophy with inflammatory changes. Biochem Biophys Res Commun 
2007;363:1033-1037. 
335. Chung W, Winder TL, LeDuc CA, et al. Founder Fukutin mutation causes 
Walker-Warburg syndrome in four Ashkenazi Jewish families. Prenat Diagn 
2009;29:560-569. 
336. Jimenez-Mallebrera C, Torelli S, Feng L, et al. A Comparative Study of alpha-
Dystroglycan Glycosylation in Dystroglycanopathies Suggests that the 
Hypoglycosylation of alpha-Dystroglycan Does Not Consistently Correlate with 
Clinical Severity. Brain Pathol 2008. 
337. Ng SB, Buckingham KJ, Lee C, et al. Exome sequencing identifies the cause of 
a mendelian disorder. Nat Genet;42:30-35. 
338. Ramelli GP, Aloysius A, King C, Davis T, Muntoni F. Gastrostomy placement 
in paediatric patients with neuromuscular disorders: indications and outcome. Dev Med 
Child Neurol 2007;49:367-371. 
339. Merlini L, Bernardi P. Therapy of collagen VI-related myopathies (Bethlem and 
Ullrich). Neurotherapeutics 2008;5:613-618. 
 
 
203 
 
340. Takaso M, Nakazawa T, Imura T, et al. Surgical correction of spinal deformity 
in patients with congenital muscular dystrophy. J Orthop Sci;15:493-501. 
341. Barresi R, Michele DE, Kanagawa M, et al. LARGE can functionally bypass 
alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. 
Nat Med 2004;10:696-703. 
342. Smith PL, Lowe JB. Molecular cloning of a murine N-acetylgalactosamine 
transferase cDNA that determines expression of the T lymphocyte-specific CT 
oligosaccharide differentiation antigen. J Biol Chem 1994;269:15162-15171. 
343. Xia B, Martin PT. Modulation of agrin binding and activity by the CT and 
related carbohydrate antigens. Mol Cell Neurosci 2002;19:539-551. 
344. Blankinship MJ, Gregorevic P, Chamberlain JS. Gene therapy strategies for 
Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. 
Mol Ther 2006;13:241-249. 
345. Angelin A, Tiepolo T, Sabatelli P, et al. Mitochondrial dysfunction in the 
pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with 
cyclosporins. Proc Natl Acad Sci U S A 2007;104:991-996. 
346. Irwin WA, Bergamin N, Sabatelli P, et al. Mitochondrial dysfunction and 
apoptosis in myopathic mice with collagen VI deficiency. Nat Genet 2003;35:367-371. 
347. Merlini L, Angelin A, Tiepolo T, et al. Cyclosporin A corrects mitochondrial 
dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl 
Acad Sci U S A 2008;105:5225-5229. 
348. Hansson MJ, Mattiasson G, Mansson R, et al. The nonimmunosuppressive 
cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on 
permeability transition in brain-derived mitochondria. J Bioenerg Biomembr 
2004;36:407-413. 
349. Tiepolo T, Angelin A, Palma E, et al. The cyclophilin inhibitor Debio 025 
normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in 
Col6a1-/- myopathic mice. Br J Pharmacol 2009;157:1045-1052. 
350. Erb M, Meinen S, Barzaghi P, et al. Omigapil ameliorates the pathology of 
muscle dystrophy caused by laminin-alpha2 deficiency. J Pharmacol Exp Ther 
2009;331:787-795. 
351. Vachon PH, Loechel F, Xu H, Wewer UM, Engvall E. Merosin and laminin in 
myogenesis; specific requirement for merosin in myotube stability and survival. J Cell 
Biol 1996;134:1483-1497. 
352. Hall TE, Bryson-Richardson RJ, Berger S, et al. The zebrafish candyfloss 
mutant implicates extracellular matrix adhesion failure in laminin alpha2-deficient 
congenital muscular dystrophy. Proc Natl Acad Sci U S A 2007;104:7092-7097. 
353. Dominov JA, Kravetz AJ, Ardelt M, Kostek CA, Beermann ML, Miller JB. 
Muscle-specific BCL2 expression ameliorates muscle disease in laminin {alpha}2-
deficient, but not in dystrophin-deficient, mice. Hum Mol Genet 2005;14:1029-1040. 
354. Girgenrath M, Beermann ML, Vishnudas VK, Homma S, Miller JB. Pathology 
is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular 
dystrophy. Ann Neurol 2009;65:47-56. 
355. Qiao C, Li J, Zhu T, et al. Amelioration of laminin-alpha2-deficient congenital 
muscular dystrophy by somatic gene transfer of miniagrin. Proc Natl Acad Sci U S A 
2005;102:11999-12004. 
356. Meinen S, Lin S, Ruegg MA. Treatment approaches in laminin α2 deficient 
congenital muscular dystrophy (MDC1A). . In: Neuromuscul Disord, 2009: 
EM.P.541.504. 
 
 
204 
 
357. Hagiwara H, Ohsawa Y, Asakura S, Murakami T, Teshima T, Sunada Y. Bone 
marrow transplantation improves outcome in a mouse model of congenital muscular 
dystrophy. FEBS Lett 2006;580:4463-4468. 
358. Zissimopoulos S, Lai FA. Redox regulation of the ryanodine receptor/calcium 
release channel. Biochem Soc Trans 2006;34:919-921. 
359. Ferreiro A, Monnier N, Romero NB, et al. A recessive form of central core 
disease, transiently presenting as multi-minicore disease, is associated with a 
homozygous mutation in the ryanodine receptor type 1 gene. Ann Neurol 2002;51:750-
759. 
360. Collins J, Bonnemann CG. Congenital muscular dystrophies: toward molecular 
therapeutic interventions. Curr Neurol Neurosci Rep;10:83-91. 
 
 
 
205 
 
PUBLICATIONS PERTAINING TO THE WORK WITHIN THIS THESIS 
 
 
Permission to include these articles had been granted by the publishers; John Wiley 
and Sons(40, 126, 213, 218), Oxford University Press(231), Elsevier(34, 41, 222), 
Wolters Kluwer Health(232) and  the American Medical Association(260). 
 
  
214 
 
 
  
215 
 
  
 
 
 
216 
 
 
  
217 
 
  
218 
 
 
  
219 
 
  
220 
 
  
221 
 
  
222 
 
  
223 
 
  
 
224 
 
 
 
225 
 
 
Mild POMGNT1 Mutations underlie a Novel Limb-Girdle Muscular Dystrophy 
Variant 
(260) 
 
Can be accessed using the following toll free link 
 
http://archneur.ama-assn.org/cgi/reprint/65/1/137 
